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ABSTRACT 
Cardiovascular diseases are the leading cause of death worldwide followed by cancer. 
Atherosclerosis, the major underlying cause of cardiovascular diseases, is a syndrome 
affecting medium-sized and large arteries. Progressive atherosclerotic disease and the 
development of acute lesion instability are linked with plaque angiogenesis. It is widely 
accepted as an inflammatory disease involving both innate and adaptive immune 
mechanisms. During the development of an atherosclerotic plaque, lesions are infiltrated 
by inflammatory cells and professional antigen presenting cells (APCs). Identifying the 
leukocyte populations and APCs involved during plaque maturation is of great interest 
for understanding the pathogenesis of the disease and providing targets for therapeutic 
interventions aimed at controlling the activation state of culprit cells. 
 
Endothelial dysfunction (ED) is another key event in the initiation and progression of 
atherosclerosis and it serves as a risk factor for the development of cardiovascular 
events. Stimuli that cause oxidative stress, endoplasmic reticulum (ER) stress, metabolic 
stress and genotoxic stress may lead to ED through enhanced endothelial cell (EC) 
injury or death, conditions which are considered essential for plaque rupture. Unfolded 
protein response (UPR) is the front line of defense during ER stress, aiming to re-
establish cellular homeostasis and rescue the cell from apoptosis. Although many steps 
of the ER stress signalling pathway have been elucidated, coordination between 
intracellular ER stress and cell-surface prompted survival signals has been poorly 
investigated. 
 
Paraphrasing the modern version of the medieval sentiment “all roads lead to Rome” to 
“all cellular paths which lead to atherosclerosis”, my dissertation addresses the 
pathophysiology of atherosclerosis from two different aspects. 
 
iNKT cells, inflammation and angiogenesis 
In the present dissertation we provide evidence for the first time for the involvement of 
CD1d-expressing APCs and invariant natural killer T (iNKT) cells in disease progression 
in patients suffering from atherosclerosis. CD1d-expressing APCs are present in 
advanced atherosclerotic plaques and are more abundant in plaques with ectopic 
neovascularization. Patients with active disease have reduced numbers of iNKT cells 
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circulating in blood and the iNKTs present in plaques are more responsive to lipid 
antigens than the ones found in blood. The in vitro data demonstrate that lipid activation 
of plaque-derived iNKTs increases the migration capacity and angiogenic activity of EC 
in an IL-8 dependent manner. Further investigations revealed that the stimulatory effects 
of EC on migration, sprouting and actin reorganization from activated iNKT cells are 
driven through EGFR with selective downstream activation of focal adhesion kinase 
(FAK) and Src. These findings introduce iNKT cells as novel cellular candidates 
promoting plaque neovascularization and destabilization in human atherosclerosis. In 
addition the data demonstrate that EGFR inhibition may represents a novel therapeutic 
modality for the control of inflammation-associated neovascularization within developing 
atherosclerotic plaques. 
 
ER stress and T-cadherin 
T-cadherin is an unusual member of the cadherin superfamily of surface adhesion 
molecules. It is widely expressed in the cardiovascular system and is upregulated during 
proliferative vascular disorders such as atherosclerosis. This dissertation provides 
evidence for the importance of T-cadherin to influence UPR signalling and EC survival 
during ER stress. During UPR T-cadherin levels are significantly elevated. 
Overexpression or silencing of T-cadherin in EC respectively attenuated or amplified the 
ER stress-induced increase in phospho-eIF2alpha, Grp78, CHOP and active caspases.  
Upregulation of T-cadherin expression on EC during ER stress attenuates the activation 
of the proapoptotic PERK (PKR (double-stranded RNA-activated protein kinase)-like ER 
kinase) branch of the UPR cascade and thereby protects EC from ER stress-induced 
apoptosis.  
 
2
1. INTRODUCTION 
1.1 Atherosclerosis-the current view  
Atherosclerosis is the principal cause of death in developed countries and emerging economies 
worldwide. Hypertension, endothelial injury, as well as dyslipidemia, diabetes, 
hyperhomocysteinemia, smoking, aging, and increased body mass index are major risk factors 
for the development of atherosclerosis. It is a disease of medium-sized and large arteries in 
which fatty material and plaque are deposited in the wall of an artery, resulting in narrowing of 
the arterial lumen and eventual impairment of blood flow (Figure 1).  
While the classic concept of atherosclerosis as a 
disorder of lipid metabolism and deposition is 
widely accepted, evolving understanding of the 
biology linking the lipid disorder to vascular 
involvement during atherogenesis and 
subsequent clinical manifestations indicates a far 
more complex pathophysiology than mere lipid 
storage. Atherosclerosis is today recognized as a 
sub-acute inflammatory condition of the vessel 
wall. Inflammation and infiltration of immune cells 
appear crucial in all stages of atherosclerosis, 
from the very initial phases through to the 
progression and finally to the clinical 
complications (Libby, 2008). 
Animal models have been extensively used in order to clarify what causes atherosclerosis, even 
though there are limitations due to significant species differences compared to humans 
(Smithies and Maeda, 1995). Under physiological conditions leukocytes do not adhere to the 
endothelial monolayer. However, in circumstances of endothelial dysfunction adhesion 
molecules and chemotactic factors recruit and bind leukocytes (monocytes, T-cells and mast 
cells) (Figure 2). Vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 
(ICAM-1), integrins, L- P- and E-selectins and cadherins are such adhesion molecules, which 
play an important role for the development of atherosclerosis (Table 1) (Collins et al., 2000; 
Dong et al., 1998; Ivanov et al., 2001; Shih et al., 1999). 
 
 
 
Figure 1. Schematic of arteriosclerosis 
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 Table 1. Adhesion molecules involved in atherosclerosis 
Selectins/ligands Integrins Immunoglobulins Cadherins 
P-selectin Integrin α2β1 ICAM-1 VE-cadherin 
E-selectin Integrin α4β1 ICAM-2 T-cadherin 
L-selectin Integrin αDβ2 ICAM-3 N-cadherin 
P-selectin ligand 1 Integrin αVβ3 VCAM-1  
E-selectin ligand 1 Integrin αVβ5 PECAM-1  
After adherence, chemoattractants prompt the leukocytes to penetrate into the arterial wall, at 
which point M-CSF can stimulate scavenger receptor expression to allow the cells to engulf to 
modified lipoprotein particles and become the foam cells that consist the so called ¨fatty streak¨, 
an aggregation of lipid rich macrophages and T lymphocytes within the innermost layer of the 
artery wall the intima (Figure 3) (Hansson and Libby, 2006) . 
Fatty streaks are not clinically significant, but they are the precursors of the atherosclerotic 
plaques. Lesions consisting of a fibrous cap that encloses a lipid rich core and is the place 
where inflammation, lipid accumulation and cell death takes place (Figure 4). 
 
Plaques mature over time and become extremely complex. Small vessels are prone to grow 
inside the lesion causing haemorrhage, but also calcification and ulceration are observed in 
advanced lesions, processes that make lesions extremely unstable and prone to rupture (Figure 
4) showing that the quality of the plaque is more important than the size (Lusis, 2000). Intimal 
calcification is an active process in which pericyte-like cells secret a matrix scaffold which 
becomes calcified, akin to bone formation. The process is regulated by oxysterols and cytokines 
(Watson et al., 1994). When the plaque ruptures, tissue factor gains contact with the blood to set 
the stage for thrombosis and acute myocardial infarction (Lusis, 2000).
4
  
 
 
Fi
gu
re
 4
. 
Pl
aq
ue
 r
up
tu
re
 a
nd
 t
hr
om
bo
si
s.
 T
he
 
co
re
 o
f t
he
 a
th
er
os
cl
er
ot
ic
 p
la
qu
e 
co
nt
ai
ns
 li
pi
ds
 a
nd
 
de
br
is
 fr
om
 d
ea
d 
ce
lls
. I
m
m
un
e 
ce
lls
 a
re
 p
re
se
nt
 in
 
th
e 
pl
aq
ue
, 
w
hi
ch
 
ca
n 
af
fe
ct
 
in
fla
m
m
at
io
n 
an
d 
va
sc
ul
ar
 
fu
nc
tio
n,
 
by
 
re
le
as
in
g 
pr
o-
in
fla
m
m
at
or
y 
cy
to
ki
ne
s,
 p
ro
te
as
es
, 
pr
o-
th
ro
m
bo
tic
 m
ol
ec
ul
es
 a
nd
 
va
so
ac
tiv
e 
su
bs
ta
nc
es
. 
E
nd
ot
he
liu
m
 
is
 
da
m
ag
ed
 
an
d 
th
e 
w
ea
ke
ne
d 
pl
aq
ue
 r
up
tu
re
s 
an
d 
a 
th
ro
m
bu
s 
is
 fo
rm
ed
. T
he
 n
ec
ro
tic
 c
or
e 
is
 a
 k
ey
 fa
ct
or
 in
 p
la
qu
e 
vu
ln
er
ab
ilit
y.
 
M
ac
ro
ph
ag
e 
de
br
is
 
pr
om
ot
es
 
in
fla
m
m
at
io
n,
 
pl
aq
ue
 
in
st
ab
ili
ty
, 
an
d 
th
ro
m
bo
si
s.
 
Pl
aq
ue
 
ne
cr
os
is
 
ar
is
es
 
fro
m
 
a 
co
m
bi
na
tio
n 
of
 
le
si
on
al
 
m
ac
ro
ph
ag
e 
ap
op
to
si
s 
an
d 
de
fe
ct
iv
e 
cl
ea
ra
nc
e 
of
 t
he
se
 d
ea
d 
ce
lls
, 
a 
pr
oc
es
s 
ca
lle
d 
ef
fe
ro
cy
to
si
s 
(H
an
ss
on
 
an
d 
Li
bb
y,
 
20
06
; 
Ta
ba
s,
 
20
09
). 
 
 Fi
gu
re
 2
. 
A
dh
es
io
n 
an
d 
in
fil
tr
at
io
n 
of
 i
m
m
un
e 
ce
lls
. 
Th
e 
th
re
e 
la
ye
rs
 t
ha
t 
co
m
pr
is
e 
an
 a
rte
ry
 a
re
 
de
pi
ct
ed
 (
fu
ll 
cr
os
s-
se
ct
io
n 
de
pi
ct
ed
 o
n 
th
e 
up
pe
r 
rig
ht
). 
Th
e 
en
do
th
el
iu
m
 l
ie
s 
ov
er
 t
he
 i
nt
im
al
 l
ay
er
. 
Th
e 
in
tim
a 
no
rm
al
ly
 c
on
ta
in
s 
a 
fe
w
 r
es
id
en
t s
m
oo
th
 
m
us
cl
e 
ce
lls
 a
nd
 a
 la
ye
r 
of
 e
xt
ra
ce
llu
la
r 
m
at
rix
. T
he
 
in
te
rn
al
 
el
as
tic
 
la
m
in
a 
pr
ov
id
es
 
th
e 
bo
un
da
ry
 
be
tw
ee
n 
th
e 
in
tim
al
 l
ay
er
 a
nd
 t
he
 t
un
ic
a 
m
ed
ia
, 
no
rm
al
ly
 fi
lle
d 
w
ith
 q
ui
es
ce
nt
 s
m
oo
th
 m
us
cl
e 
ce
lls
 in
 
an
 e
la
st
in
-ri
ch
 e
xt
ra
ce
llu
la
r 
m
at
rix
. 
A
ct
iv
at
in
g 
th
e 
en
do
th
el
iu
m
 
le
ad
s 
to
 
ex
pr
es
si
on
 
of
 
ad
he
si
on
 
m
ol
ec
ul
es
 
fo
r 
le
uk
oc
yt
es
 
an
d 
ch
em
oa
ttr
ac
ta
nt
s,
 
w
hi
ch
 b
rin
g 
th
e 
bo
un
d 
le
uk
oc
yt
es
 i
nt
o 
th
e 
in
tim
al
 
la
ye
r. 
(L
ib
by
, 2
00
8)
. 
 
 
 Fi
gu
re
 
3.
 
Fa
tty
 
st
re
ak
 
fo
rm
at
io
n.
 
M
ac
ro
ph
ag
es
 
ab
so
rb
 
m
od
ifi
ed
 
lip
op
ro
te
in
s 
su
ch
 a
s 
ox
id
iz
ed
 l
ow
-d
en
si
ty
 l
ip
op
ro
te
in
 (
ox
-
LD
L)
 t
hr
ou
gh
 s
ca
ve
ng
er
 r
ec
ep
to
rs
 t
o 
pr
od
uc
e 
fo
am
 c
el
ls
. M
ac
ro
ph
ag
es
 in
 th
e 
le
si
on
s 
re
le
as
e 
ch
em
oa
ttr
ac
ta
nt
 
cy
to
ki
ne
s,
 
pr
oi
nf
la
m
m
at
or
y 
m
ed
ia
to
rs
, 
an
d 
sm
al
l 
lip
id
 m
ol
ec
ul
es
 s
uc
h 
as
 
le
uk
ot
rie
ne
s 
an
d 
pr
os
ta
gl
an
di
ns
. 
A
t 
th
is
 s
ta
ge
 
S
M
C
s 
ar
e 
al
so
 a
ct
iv
at
ed
 (L
ib
by
, 2
00
8)
. 
 
5
 1.2. Endothelial dysfunction in atherosclerosis 
Loss of normal endothelial function (endothelial dysfunction, ED) is a hallmark for vascular 
diseases. ED has long been recognized as an integral component of atherosclerotic vascular 
disease and its presence is a risk factor for the development of clinical events. It is the earliest 
measure of a functional abnormality in the blood vessels and precedes the anatomic lesions in 
the development of atherosclerosis. ED is usually caused by endothelial cell (EC) injury or 
death. In the most extreme case, significant injury leads to EC desquamation from the vessel 
lining. The pathophysiology of ED is very complex, involving several factors which, while 
etiologically distinct, frequently share common mechanisms of action (Pober et al., 2009; Roquer 
et al., 2009). ED should not be confused with endothelial activation which is defined as the 
acquisition of a new endothelial function that benefits the host, and represents the normal 
homeostatic functions of the endothelium. 
 
The endothelium is composed of a thin layer of EC that cover the inner surface of blood vessels 
(Figure 5). It is no longer considered as just a passive barrier which separates the blood vessels 
and the blood. Endothelial tissue is on the contrary a very active and specialized organ. EC are 
quiescent in vivo under physiological conditions, but 
in case of injury or any kind of ED, EC change their 
phenotype and migration and proliferation rates in 
order to heal the lesion and maintain the homeostasis 
(Bachetti and Morbidelli, 2000). Its total weight in a 
healthy adult man is comparable to that of the liver, 
and when extended will cover a surface area of 
several tennis courts. This renders the endothelium 
one of the biggest and most important glands of the 
body (Rubanyi, 1993). Endothelial function is not only 
autocrine, but also paracrine and endocrine (Esper et al., 2006). It is very sensitive organ 
responding to any physical or chemical stimulus. Accordingly it releases the corresponding 
biochemical substances in order to maintain homeostasis. A functional endothelium maintains 
the balance between vasodilation and vasoconstriction, growth inhibition and growth promotion, 
anti-thrombosis and pro-thrombosis, anti-inflammation and pro-inflammation, anti-oxidation and 
pro-oxidation, inter alia (Luscher, 1990; Vallance et al., 1989; Vane et al., 1990; Vanhoutte, 
1989). It has both sensory and executive functions, releasing molecules that regulate all the 
 
 
Figure 5. Monolayer of EC lining on the 
luminal surface of a vessel.
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 biological processes mentioned above. Upsetting this tightly regulated balance leads to ED 
(Ross, 1999).  
The term “endothelial dysfunction” was coined in the eighties by Furchgott and Zawadzki who 
discovered that acetylcholine requires the presence of the EC to relax the underlying vascular 
smooth muscle. The relaxing factor, first termed as endothelium-derived relaxing factor, was 
identified as nitric oxide (NO) (Furchgott and Zawadzki, 1980). NO is a small molecule that can 
easily diffuse across the intima and induce smooth muscle fiber relaxation and finally 
vasodilation (Loscalzo and Welch, 1995). In addition to its potent vasodilator actions, NO also 
reduces tissue oxidation and inflammation, causes inactivation of prothrombotic factors, 
modulates cell growth, proliferation and migration and favors fibrinolysis. Thus NO is considered 
an important anti-atherogenic molecule (Cooke et al., 1992; Cooke and Tsao, 1994; Libby, 2001; 
Marx et al., 2001; Tak and Firestein, 2001).  
ED portrays a disturbance in the physiological protective regulatory balance of the endothelium 
and is manifest as a loss of endothelium-dependent vasodilation because of reduced endothelial 
availability of NO. In addition to loss of physiologic dilation and appearance of inappropriate 
constriction, loss of NO activity results in increased platelet adhesion and aggregation, 
increased leukocyte adhesion and migration into the subendothelial space, formation of lipid-
laden foam cells, and propagation of atherogenesis. While loss of EC generated NO is 
considered as the primary causative event of ED, conditions of sustained injury to the 
endothelium may culminate in cell death (by apoptosis) of insulted cells. EC apoptosis 
represents an irreversible state of EC injury/dysfunction that compromises vessel wall 
permeability to cytokines growth factors, lipids and immune cells, increases coagulation and also 
contributes to further downregulation of vasohomeostatic regulators such as NO, thus further 
propagating progression of atherosclerosis. ED is caused by situations such as the impact of the 
classical atherosclerotic risk factors, genetic alterations, elevated plasma homocysteine 
concentrations, infectious microorganisms (e.g. herpes viruses or Chlamydia pneumoniae) as 
well as the imbalance between the magnitude of injury and the capacity for endothelium repair 
(Pober et al., 2009; Roquer et al., 2009).  
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 ED, which interrupts vascular homeostasis, is characterized by an imbalance between relaxing 
and contracting factors, pro-coagulant and anti-coagulant substances, and between pro-
inflammatory and anti-inflammatory mediators (Figure 6) (Roquer et al., 2009). When ED 
becomes evident, there is vasoconstriction, increased leukocyte adherence, upregulation of 
adhesion molecules, increased chemokine secretion and cell permeability, enhanced LDL 
oxidation, cytokine production, platelet activation, mitogenesis, thrombosis, impaired 
coagulation, vascular inflammation, 
vascular smooth muscle cell 
proliferation and migration, and 
atherosclerosis. ED contributes to the 
initiation and progression of 
atherosclerotic plaque formation as 
well as the triggering of thrombotic 
complications in late stages of the 
disease. The exposure of the 
endothelium to risk factors leads to ED 
with reduced NO bioavailability, 
increased oxidant excess, and the 
expression of adhesion molecules. 
This is followed sequentially by intimal-medial thickening, overt manifestations of 
atherosclerosis, development of arterial stenosis and, ultimately, plaque rupture and 
endovascular thrombosis (Roquer et al., 2009). 
1.3. Mechanisms promoting endothelial dysfunction in atherosclerosis 
Stimuli that can cause endothelial dysfunction include environmental stresses such as oxidative 
stress, endoplasmic reticulum stress, metabolic stress and genotoxic stress, as well as 
pathways of injury mediated by the innate and adaptive immune systems.  
1.3.1. Oxidative stress in endothelial dysfunction 
Oxidative stress is a harmful condition that occurs when there is an excess of free radicals. It 
can be defined as an imbalance between the production of endogenous reactive oxygen species 
(ROS) and the presence of antioxidant molecules that scavenge and metabolize those reactive 
species (Figure 7). Free radicals are formed when oxygen interacts with certain molecules and a 
Vasodilation
Thrombolysis
Platelet disaggregation
Anti-proliferation
Anti-inflammation
Anti-oxidant
Vasoconstriction
Thrombosis
Adhesion molecules
Growth factors
Inflammation
Oxidant activity
 
 
 
Figure 6. Regulatory functions of the endothelium.  
Normal or anti-atherogenic versus dysfunctional or atherogenic 
properties.  
8
 chain reaction starts. The different oxidants can originate principally from cellular and 
extracellular sources, and from enzymatic and nonenzymatic paths (Table 2). Recent studies 
suggest that ED may be caused by accelerated inactivation of NO by ROS (Figure 7) (Victor, 
Rocha et al. 2009). 
  
 
It is believed that inflammation and oxidative process are interconnected since inflamed cells 
produce free radicals, which are involved in cell degradation. Within an inflamed vascular 
setting, LDL becomes oxidized, contributing to atherosclerosis by triggering more inflammation, 
disrupting normal vascular function and resulting in the accumulation of plaque. LDL in its native 
state is not atherogenic. It can be oxidatively modified by all major cells of the arterial wall 
(Keaney 2005; Singh, Devaraj et al. 2005). It can be found in a mildly oxidized form that binds to 
the LDL-receptor and does not lead to foam-cell formation. On the other hand, mildly oxidized 
LDL stimulates the production of monocyte chemotactic protein (MCP-1) which promotes 
monocyte chemotaxis and the production of monocyte colony stimulating factor (M-CSF), 
promoting the differentiation and proliferation of monocytes into macrophages (Singh, Devaraj et 
al. 2005). Extensively oxidized LDL (Ox-LDL) is not recognized by the LDL-receptor and is 
instead ingested by the macrophages via the scavenger receptor, leading to foam-cell formation 
(Rosenfeld, Khoo et al. 1991). Ox-LDL thus importantly contributes to the initiation and 
progression of the atherosclerotic plaque (Figure 8). 
 
Table 2. Sources of oxidative stress 
in vascular wall 
NAD(P)H oxidase  
Nitric oxide synthases 
Myeloperoxidase 
Xanthine oxidase 
Lipoxygenase / cyclooxygenase 
Mitochondrial respiratory chain / 
oxidative phosphorylation 
Sources of ROS
antioxidants
ROS
Oxidative stress
NO. bioavailable
Endothelial DysfunctionRemodeling SMC Growth
Platelet aggregation Loss of Vasodilation Inflammation
 
Figure 7. Oxidative stress-induced endothelial dysfunction in 
cardiovascular diseases. 
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ROS may further contribute to the atherogenic process via the induction of pro-inflammatory 
mediators. Upregulation of cell adhesion molecules such as VCAM-1, intercellular adhesion 
molecule-1, and E-selectin also occur through oxidant-sensitive mechanisms involving 
peroxynitrite-dependent activation of pro-inflammatory transcription factors such as NF-κB, AP-1, 
and egr-1 (Napoli et al., 2001). ROS can impair neurovascular coupling and vasodilation 
mediated by activation of potassium channels, induce vasoconstriction, induce EC apoptosis, 
promote vascular remodeling through enhancement of smooth muscle cell proliferation and 
through upregulation and activation of matrix metalloproteinases (MMPs), which may also 
increase vascular permeability and weaken the thrombus fibrous cap (Touyz, 2006). 
 
Figure 8. The role of lipid oxidation in initiation and progression of atherosclerosis. LDL transits 
into the intima where it undergoes oxidation. Oxidized lipids activate EC which start to express 
adhesion molecules which attract monocytes to adhere and transmigrate into the intima. Monocytes-
derived macrophages ingest oxidized-LDL through scavenger receptors (ScR) and lipid-laden foam 
cells are formed. (Hansson et al., 2006).
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1.3.2. Endoplasmic reticulum stress 
Another type of stress response activated by disturbances in cell function is the endoplasmic 
reticulum (ER) stress response, or unfolded protein response (UPR). The accumulation of 
unfolded proteins in ER represents a stress that is induced by multiple stimuli and pathological 
conditions. Hypoxia, redox changes, glucose deprivation, Ca2+ aberrancies, protein inclusion 
bodies and viral infections can cause accumulation of unfolded proteins in the ER and eventually 
ER stress (Marciniak and Ron, 2006). Upon ER stress, evolutionary conserved signalling events 
are initiated aiming to ameliorate the accumulation of unfolded proteins in the ER. The cellular 
ER stress/UPR signalling cascade falls into three major phases with different effector functions, 
namely adaptation, alarm and apoptosis (Figure 9) (Malhotra and Kaufman, 2007; Ron and 
IRE1ATF6 PERK
Grp78Grp78 Grp78
Grp78 releases Grp78 releases Grp78 releases
Relocates to Golgi,
cleaved by site
1/2 proteases
Cleaved ATF6
Adaptation genes
eIF2α
ATF4 mRNA
translation
ATF4
Alarm genesApoptosis genes
CHOP
Spliced XBP-1 mRNA
XBP-1
TRAF2
other kinases
IKK
IκB
NF-κΒ
Ask1
JNK
c-Jun
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ER lumen
 
 
Figure 9. Tripartite stress signalling from the ER. Upon release of Grp78 from the sensor proteins Ire1 
and PERK oligomerize in ER membrane. Oligomerized Ire1 binds TRAF2, activating Ask1 other 
downstream kinases and eventually p38, c-Jun and NF-κB causing expression of genes associated with 
host defence. The intrinsic ribonuclease activity of Ire1 results in production of XBP-1, a transcription factor 
that induces genes involved in restoring protein folding or removal of unfolded proteins. PERK 
oligomerization induces phosphorylation of eIF2α which attenuates mRNA translation. Paradoxically 
phospho-eIF2α preferentially translates selected mRNAs such as ATF4 mRNA. ATF4 plays a role in 
restoring ER homeostasis. ATF6 translocates to the Golgi apparatus, where the active protein is formed in 
order to express UPR genes. The signalling pathways activated by each of these sensors require unique 
lag times. If ER stress persists a delayed pathway takes over, leading to apoptosis. 
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 Walter, 2007; Wu and Kaufman, 2006; Xu et al., 2005).  
The molecular mechanisms by which ER stress promotes cell protection or death pathways 
have largely been described in cell types other than EC (e.g. epithelial tumor cell lines, 
pancreatic β cells, macrophages) (Boyce and Yuan, 2006; Kim et al., 2008; Lin et al., 2008; 
Malhotra and Kaufman, 2007; Ron and Walter, 2007; Schroder, 2008; Wu and Kaufman, 2006). 
ER stress is triggered by an accumulation of misfolded proteins in the ER which bind to ER 
chaperone Grp78, causing dissociation of Grp78 from the three major ER stress sensors PERK, 
ATF6 and IRE1 and a resultant launching of the UPR (Figure 9). The first response aims at re-
establishing homeostasis and normal ER function. PERK-dependent phosphorylation of eIF2α 
results in translational attenuation reducing the load of new protein synthesis on the ER. IRE1 
induces expression of X-box binding protein XBP-1, while ATF6 is translocated to the Golgi and 
activated by proteolysis. XBP-1 and ATF6 act together with eIF2α-downstream target ATF4 as 
transcription factors activating expression of ER chaperones and components of ER associated 
degradation system (ERAD) eliminating misfolded proteins. In a later phase, immune and anti-
apoptotic responses are activated via the NFκB pathway. When the adaptive mechanisms fail to 
compensate in the face of protracted or excessive ER stress apoptotic cell death is induced to 
protect the organism by eliminating the damaged cells. Several apoptosis pathways are known 
to be involved, the central role being played by the proapoptotic transcription factor CHOP which 
blocks expression of antiapoptotic protein Bcl-2. Transcriptional induction of CHOP mostly 
depends upon activation of PERK/eIF2α; however, IRE1 and ATF6 pathways also stimulate 
CHOP transcription, meaning that CHOP operates at the convergence of all UPR branches. ER 
stress-induced apoptosis can also occur via IRE1-dependent activation of TRAF2/ASK1/JNK 
cascade and via Ca2+-dependent activation of caspase-12.  
Malfunctions of the ER stress response are associated with a variety of diseases, including 
neurodegenerative disorders, diabetes mellitus, ischemic injury, cancers, inflammation, infection, 
and psychotic diseases  (Yoshida, 2007; Zhao and Ackerman, 2006). There is a growing body of 
evidence suggesting that ER stress response also occurs during many processes associated 
with ED and cardiovascular diseases. ER stress and protein misfolding are rapidly induced in 
several cell types including EC and cardiomyocytes by tissue ischemia, hypoxia and reactive 
oxygen species. Upregulation of Grp78, Ask1 and other ER stress-related genes were detected 
in hypoxic cultured myocytes, ischaemic hearts and in a murine model of myocardial infarction 
(Azfer et al., 2006; Szegezdi et al., 2006; Thuerauf et al., 2006), while Ask1-/- mice show reduced 
cardiomyocyte apoptosis rates and better preservation of ventricular function (Yamaguchi et al., 
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 2003). In EC, activation of UPR genes causes a concomitant increase in VEGF and IL-8 
production which lead to stimulation of angiogenesis (Marjon et al., 2004). Accumulation of free 
cholesterol in macrophages causes calcium release, UPR activation and CHOP-induced 
apoptosis (Feng et al., 2003). NF-κB, p38 and JNK are activated through PERK and IRE1 
inducing the expression of inflammatory cytokines (Li et al., 2005). In addition, oxidized lipids 
can result in ER stress and UPR activation in human aortic ECs (Gargalovic et al., 2006). Grp78 
silencing decreases cell tolerance to oxidative stress (Liu et al., 1998), while Grp78 
overexpression inhibits homocysteine-induced ER stress in EC (Werstuck et al., 2001) and 
inhibits procoagulant activity of tissue factor, a membrane glycoprotein essential for initiation of 
the coagulation cascade on the cell surface in response to ROS, homocysteine and other stimuli 
(Watson et al., 2003). Interestingly, there is a cross-talk between ER stress and oxidative stress: 
ER stress may result in accumulation of ROS and initiate expression and activation of oxidation-
related signalling mediators (Cullinan and Diehl, 2006). Importantly, Grp78 protein has been 
detected on the surface of EC and monocyte/macrophage-like cells in atherosclerotic lesions 
(Bhattacharjee et al., 2005), on endothelial-derived procoagulant membrane microparticles 
(Banfi et al., 2005) and in the peripheral circulation of healthy donors (Delpino and Castelli, 
2002).  
1.3.3. Metabolic Stress 
EC supply nutrition and oxygen to tissues and can themselves experience stresses from 
abnormal metabolism (e.g., high glucose and high lipid levels), energy depletion, or hypoxia.  
Insulin resistance, defined as decreased sensitivity and/or responsiveness to metabolic actions 
of insulin that promote glucose disposal, is an important consequence of metabolic stress to EC. 
Insulin resistance is observed in diabetes, glucose intolerance, and dyslipidemias, as well as in 
oxidative stress and inflammation settings. Normal insulin receptor/IGF1 receptor signal 
transduction is well characterized (Saltiel and Kahn, 2001). These receptors have intrinsic 
protein tyrosine kinase activity that is activated by ligand binding. The activated receptors 
phosphorylate several substrates, including insulin receptor substrate 1 (IRS1), which leads to 
activation of phosphatidylinositol-3-kinase (PI3K)-Akt, and Shc, which leads to activation of the 
Ras-Raf-ERK signalling cascades. The PI3K-Akt pathway is the major branch of insulin 
signalling that regulates metabolic function, triggering translocation of glucose transporter 4 
(GLUT4) to the plasma membrane where it mediates glucose uptake in skeletal muscle and 
adipocytes. Thus, impaired IRS-1/Akt activation underlies the molecular mechanism for insulin 
13
 resistance and diabetes. Another important target of Akt in EC is eNOS. Akt phosphorylates 
human eNOS at Ser-1177 and activates the enzyme, leading to NO release (Dimmeler et al., 
1999; Fulton et al., 1999). Mice lacking insulin signalling components (e.g., IRS1) have impaired 
endothelium-dependent vasodilation (Abe et al., 1998). The linkage of IRS1/Akt/eNOS to EC 
function is supported by studies from insulin sensitizers known as thiazolininediones, which have 
been shown to improve EC function and to strongly inhibit the development of atherosclerosis in 
mouse models (Li et al., 2000). In addition to inhibiting eNOS, metabolic stresses such as 
hyperglycemia may induce expression of extracellular matrix and procoagulant proteins, 
increase EC apoptosis, decrease EC proliferation, and inhibit fibrinolysis. Similarly, free fatty 
acids (FFAs) also inhibit EC proliferation and increase EC apoptosis. Mechanistic studies 
suggest that hyperglycemia and FFAs elicit common oxidative stress and proinflammatory 
signalling as well as unique signalling. 
Hypoxia is another source of metabolic stress that has not been extensively studied in EC. 
Recent reports suggest that hypoxia promotes mitochondrial ROS production, paradoxically 
producing oxidative stress (Quintero et al., 2006). 
1.3.4. Genotoxic Stress 
Cells are constantly exposed to both extrinsic and intrinsic DNA damage signals. Irradiation and 
chemical mutagens are the extrinsic sources of damage, while intrinsic damage is self 
generated. Anti-cancer treatments rely in part on ionizing radiation or systemic administration of 
genotoxic chemotherapeutics that promote stress-mediated apoptosis of tumor cells in response 
to DNA damage. ROS may also damage 
DNA, leading to an alternative activation of 
death responses (Norbury and 
Zhivotovsky, 2004). The DNA damage–
dependent response to ROS depends on 
induction of the protein p53, which 
regulates the transcription of many 
different genes involved in DNA repair, 
cell-cycle arrest, senescence, and 
apoptosis (Figure 10) (Riley et al., 2008). 
These pathways have been extensively 
studied in tumor cells, but effects of 
DNA damage
Abnormal 
proliferation Hypoxia
Heat shock
ROS
Nucleotide 
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p53 
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Growth arrest Apoptosis
DNA repair
 
Figure 10. Induction of p53 by diverse genotoxic 
signals leading to growth arrest and apoptosis. 
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 genotoxic stress on EC are less well characterized. Proliferating vascular cells within a tumor 
microenvironment do become exposed to chemotherapeutic agents, which may sensitize EC to 
other agents. In addition, cytokines such as TNF can also cause genetic damage, by generating 
free-radicals, which may eventually cause genomic instability (Pober et al., 2009).  
1.3.5. Inflammatory cells and inflammation 
Inflammation is an essential component of the immune response to pathogens and damaged 
cells. Infectious agents, oxygen radicals, mechanical factors heat shock proteins (HSP) are 
some of the stimuli causing inflammation. It can be classified as either acute or chronic. The 
initial response against the stimuli that is harmful for the tissue is known as acute inflammation, 
and it is achieved by the recruitment of leukocytes from the blood to the injured tissue. Chronic 
inflammation is the prolonged inflammation which leads to a progressive destruction and healing 
of the damaged tissue. Recent epidemiological studies demonstrate a significant link between 
coronary artery disease (CAD) and chronic inflammation (Asanuma et al., 2003; Gelfand et al., 
2006; Nicola et al., 2005).  
In the presence of risk factors (including oxidative, endoplasmic, metabolic and genotoxic 
stresses) abnormal activation of the endothelium begins with mechanisms that signal the onset 
of inflammation. Two examples include the activation of protein kinase C and nuclear 
translocation of nuclear factor-κB (NF-κB) in EC. These lead to their production of mediators that 
amplify inflammation (cytokines, interleukin-1β, tumor necrosis factor-α) and EC membrane 
expression of adhesion molecules that bind monocytes and lymphocytes. This process is 
amplified by the loss of NO release from the activated endothelium. If the inflammatory “insult” to 
the endothelium persists, the state of reduced NO bioavailability cannot be reversed, ED 
becomes aggravated and endothelial apoptosis will ensue (Galkina and Ley, 2009).  
Interaction of EC expressed adhesion molecules with integrins expressed on leukocytes 
facilitates adhesion and extravasation of the leukocytes. Within the lesion, activation of T-cells 
by local antigens (e.g. peptides, lipids), monocyte-to-macrophage transformation with 
subsequent foam cell formation and/or mast cell degranulation lead to an accumulation of 
proinflammatory cytokines and ROS which amplify the local inflammatory response. 
Concomitant production of metalloproteinases eventually weakens the leading edge of plaques, 
facilitating stress-induced fracture (Lessner and Galis, 2004; Newby, 2005).  
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 An important aspect of extravasation concerns the antigen specificities of T cells migrating in the 
early lesions. Several types of leukocytes have an important role during atherogenesis, including 
both pro- and anti-inflammatory subtypes. Those cell types include dendritic cells, mast cells, B 
cells and natural killer cells (NKT) cells 
(Figure 11) (Bobryshev and Lord, 1995; 
Galkina and Ley, 2007; Jonasson et al., 
1986; Kovanen et al., 1995). A series of 
investigations suggest that activated T-
cells are the first inflammatory cells 
observed in the arterial intima (Wick et 
al., 2004; Wick et al., 1995). There is 
evidence in rabbit and mouse models 
that these early infiltrating T cells 
recognize heat-shock protein 60 (HSP-
60) (George et al., 1999; Xu et al., 
1993). Studies have not been 
conducted in early human lesions, but 
data obtained in late lesions confirm the 
presence of T cells with these 
specificities, albeit at low frequencies. It 
is not yet clear whether there is local 
expansion of T cells specific for other 
antigens accumulating in the lesions. 
Candidate antigens stimulating these T 
cells are oxidized lipoproteins, microbial 
antigens released after infection and 
locally accumulated modified lipids. 
Identification of the antigen specificities of plaque-infiltrating T cells is important for 
understanding this key aspect of plaque evolution. Knowledge of antigen specificities can be 
used to perform appropriately targeted vaccination, which is a new emerging concept in 
preventing tissue lesions in atherosclerosis (Hansson, 2002). 
 
 
 
Figure 11. Leukocyte diversity in atherosclerosis 
(Klingenberg and Hansson, 2009) 
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 NKT cells are a distinct subtype of T lymphocytes, which express markers of natural killer cells 
as well therefore function as a ‘bridge’ between innate and adaptive immunity. Their major 
difference from T cells is that they posses the unique ability to respond to lipid antigens. In order 
to get activated the lipids have to be presented to them by antigen presenting cells that express 
CD1d molecules. CD1d molecule is a member of the CD1 family of glycoproteins and they are 
related to the class I major 
histocompatibility complex (MHC) 
molecules (Figure 12). Lipids are 
recognized through the semi-
invariant T-cell receptor (TCR) 
Vα24Jα18/Vβ11 in humans 
(Vα14Jα18/Vβ8 in mice) 
(Kronenberg, 2005). 
It is only relatively recent that NKT cells have been implicated in pathological conditions and 
more specifically in atherosclerosis. NKT cells were demonstrated to localize in advanced 
lesions and specifically in the rupture-prone shoulders of atherosclerotic plaques and in plaque 
in patients with abdominal aortic aneurysm (Bobryshev and Lord, 2005; Chan et al., 2005). 
Several studies in murine models demonstrate that NKT cell activation has the potential to 
accelerate the atherogenic process. It has been shown that α-Galactosylceramide (αGalCer), a 
glycolipid antigen and potent activator of iNKT cells, accelerates atherosclerotic lesion formation 
in apoE-/- and Ldlr-/- mice and in C57B1/6 mice that are on an atherogenic diet; CD1d-deficient 
and TCR Vα14-deficient mice, which both lack iNKT cells, are protected from development of 
atherosclerosis (Major et al., 2004; Nakai et al., 2004; Tupin et al., 2004). Moreover, adoptive 
transfer of iNKT cells markedly increases plaque burden (VanderLaan et al., 2007). Taken 
together, these animal studies provide strong evidence to suggest that iNKT cells are involved in 
atherosclerotic plaque development. However, no detailed investigations were performed yet on 
iNKT cells in human atherosclerosis. Although CD1d protein is expressed in human 
atherosclerotic lesions (Melian et al., 1999) it remains unknown whether CD1d expression 
correlates with lesion severity or disease activity.  
 
 
 
 
Figure 12. iNKT cell activation via uptake of exogenous lipid 
antigens by antigen presenting cells (APCs). A CD1d-restricted 
antigen-presentation mechanism (Van Kaer, 2007) 
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 1.4. The role of neovascularization in atherogenesis and development of the 
vulnerable plaque  
Angiogenesis is defined as the formation of new vessels. The angiogenic process is either 
physiological (e.g. wound healing) or pathophysiological (e.g. neoplasia, inflammation) and it is 
the most dynamic process of the endothelium.  
Angiogenesis is today a recognized feature of the atherogenic process. Angiogenesis in the 
developing lesion serves primarily to provide nutrients to the developing and expanding intima 
and therefore, may prevent cellular death and contribute to plaque growth and stabilization. 
However, angiogenesis in the setting of the vulnerable plaque is a double-edged sword and 
underlies many of the clinical complications associated with atherosclerosis (Doyle and Caplice, 
2007; Herrmann et al., 2001; Khurana et al., 2005; Mause and Weber, 2009). Cardiovascular 
events complicating atherosclerosis are most commonly the result of sudden arterial thrombosis 
in the heart, brain, legs, and other organs. Causes of the acute arterial thrombosis are plaque 
rupture and erosion, and atherosclerotic plaques which are prone to precipitate acute thrombotic 
occlusions are unstable, vulnerable plaques. Intraplaque neovascularization significantly 
contributes to plaque instability. 
In the absence of disease, adventitial blood vessels originating from the vasa vasorum (Vv) 
penetrate into the vessel wall. Those microvessels provide vessel wall nutrients to the tunica 
media, while the intima is fed by oxygen diffusion from the lumen. Microvessels are not usually 
present in the normal human intimal layers (Ritman and Lerman, 2007). The Vv remains in a 
dormant state probably due to the expression and synthesis of anti-angiogenic factors e.g. 
thrombospondin and endostatin which more than counterbalance the presence of low quantities 
of pro-angiogenic factors in the micro-environment. However during intimal plaque development, 
and initially triggered by tissue hypoxia and insufficiency of nutritional supply, the balance 
between the angiogenic and anti-angiogenic factors becomes altered with increased production 
of growth factors and cytokines together with a reduction in negative modulators. Hence the 
angiogenic switch shifts to “on”, resulting in adventitial vessel angiogenesis at the site proximal 
to internal vascular damage and plaque growth (Slevin M., 2009).  
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 Neovascularization of the atherosclerotic plaque (Figure 13) has important clinical 
consequences. The new microvessels are immature and prone to leak and serve as a port of 
entry for inflammatory cells, from the systemic circulation to the nascent atherosclerotic lesion 
(Moulton, 2001; Moulton et al., 2003) (Figure 13). Microfocal accumulations of blood vessels 
potentiate inflammatory 
reactions and encourage 
matrix remodelling which is 
in many ways analogous to 
wound healing (Ross, 1993; 
Ross, 1999). However, 
despite the contribution of 
angiogenesis to reparative 
processes, the excessive 
neovascularization of such 
vulnerable plaque regions as the shoulder and fibrous cap contributes to local plaque 
destabilization and rupture. Neoformed microvessels in the plaque are devoid of basement 
membrane and easily leak lipids, proteins, and blood cells in the surrounding interstitium. They 
are inherently weak, and prone to disruption especially in response to the haemodynamic forces 
of the vessel lumen (Folkman, 1995; McCarthy et al., 1999; Mofidi et al., 2001). The ensuing 
intraplaque haemorrhage predisposes the plaque to rupture, thereby causing local thrombosis 
and subsequent ischemic clinical manifestations such as stroke, unstable angina or myocardial 
infarction (Barger and Beeuwkes, 1990; Folkman, 1995; McCarthy et al., 1999; Mofidi et al., 
2001; Moulton, 2001). The presence of adventitial Vv, intimal angiogenesis and plaque 
neovascularization are increasingly considered as predictors of instability in atheromatous 
lesions of cerebrovascular and cardiovascular patients. 
The mechanisms of microvessel formation in atheroma probably resemble those common to 
other sites of angiogenesis. Tissue hypoxia and insufficiency of nutritional supply are well known 
triggers. The correlation of focal collections of inflammatory cells with areas of intraplaque 
neovascularization and haemorrhage, suggests that release of growth factors and cytokines by 
macrophages and leukocytes may also have a key role in modulating the vascularization 
process. Inflammatory protagonists and mechanisms underlying intraplaque neovascularization 
are not well understood. The inflammatory triggers of the early phases of atherogenesis are 
relatively well known, but few direct mediators of angiogenesis have been identified and 
Lesion No lesion 
C DA B 
Atherosclerotic vessel 
Figure 13. Neovascularization within the atherosclerotic lesion. A,B –
Staining for endothelial cells in a section from lesional tissue. C, Strong 
inflammatory infiltrate is present in neovascularized lesional tissue. D, non-
lesional tissue 
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 associated with plaque instability in vivo. Oxidized lipids (e.g. 1-palmitoyl-2-arachidonoyl-sn-
glycero-3-phosphorylcholine) that are prevalent in atherosclerotic plaque have been shown to 
stimulate EC proliferation and migration and angiogenesis in vitro (Ross, 1999). Inflammatory 
cells residing in the plaque, including macrophages, can also produce a number of pro-
angiogenic cytokines and chemokines (e.g. IL-1α, IL-6, IL-8, bFGF, VEGF). In vivo studies have 
shown that blocking blood vessel formation can significantly reduce plaque size (Stefanadis et 
al., 2007). Pharmacological inhibition of angiogenesis and therefore inhibition of plaque 
development can be achieved by targeting key molecules and cells. Key molecules involved in 
initiation and maintenance of the angiogenic process involve the angiopoietin signalling 
pathways. Ang-1 induces formation of stable blood vessels, whereas Ang-2 destabilizes the 
interaction between EC and their support cells. Ang-2 is also correlated with the activity of matrix 
metalloproteinase-2 (MMP-2) expression suggesting a role in development of unstable plaque 
microvessels. Furthermore Ang-1 is an anti-inflammatory cytokine which can reduce neovessel 
leakage and vascular permeability (Slevin M., 2009).  
1.5. Cell adhesion molecules in atherosclerosis 
A wide variety of cell-cell interactions take place during inflammation. These interactions include 
leukocyte-leukocyte, leukocyte-endothelium, leukocyte-vascular smooth muscle cell, leukocyte-
extracellular matrix and leukocyte-interstitial cell interaction. The proteins mediating these 
interactions are the adhesion molecules. Cell adhesion molecules play numerous crucial 
functions at the interface of a cell and its environment, whether this environment is another cell, 
from a similar or different cell type, the extracellular matrix or even sometimes soluble elements. 
Adhesion molecules are widely distributed and virtually every cell expresses cellular adhesion 
molecules. There are four major families of cell adhesion molecules, namely the selectins (and 
selectin ligands), the immunoglobulins, the integrins and the cadherins.  
Several lines of evidence support a role for cell adhesion molecules in atherogenesis. A major 
function of these adhesion molecules is to promote leukocyte recruitment from the vasculature 
into the tissue. Increased expression of adhesion molecules was detected on established 
lesions in animal models of atherosclerosis and more importantly in humans. In human coronary 
atherosclerotic plaques, expression of adhesion molecules on plaque neovasculature was two 
fold higher than on an arterial luminal endothelium. Increased leukocyte infiltration on plaque 
sites is correlated with expression of specific adhesion molecules (Huo and Ley, 2001). Levels of 
soluble adhesion molecules have been postulated to be useful risk predictors of cardiovascular 
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 events in healthy populations and various settings of disease, even though their pathological 
role remains uncertain. 
1.5.1. The role of cell adhesion molecules in mediating leukocyte recruitment and 
extravasation  
The recruitment of leukocytes from the circulation and their subsequent influx into surrounding 
tissues at sites of inflammation or injury requires multistep adhesive and signalling events, 
including selectin-mediated capture and rolling, leukocyte activation, integrin-mediated firm 
adhesion and their subsequent transendothelial migration (Figure 14) (Blankenberg et al., 2003).  
 
1.5.1.1. Selectins and their ligands 
Selectins are a family of three C-type lectins sharing a conserved structure and are expressed 
exclusively by bone-marrow-derived cells and EC. The three members of the selectin family are 
named according to their main expression site: L-selectin is expressed in leukocytes, E-selectin 
is specific to EC and P-selectin is mainly found on platelets but is also expressed on EC. They 
are carbohydrate-binding proteins and the extracellular domain of each consists of a 
 
 
Figure 14. Adhesion molecules promote leukocyte recruitment through a series of events. 
Leukocyte rolling, firm adhesion, activation and extravasation into the tissue are the main events and 
are controlled by adhesion molecules. 
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 carbohydrate recognition motif, an epidermal growth factor (EGF)-like motif, and varying 
numbers of a short repeated domain related to complement-regulatory proteins (CRP).  
The main physiological function of all selectins is in mediating leukocyte adhesion under flow, 
but both selectins and their ligands have signalling functions (Ley and Kansas, 2004). The 
selectins have each a specific pattern of expression. L-selectin is present in almost all 
leukocytes, on some T and B cells and some NK cells depending on their activation state, and is 
constitutive. P-selectin is found in secretory granules of platelets and is expressed on the 
platelet surface after activation. It is also inducible expressed by inflamed EC in many diseases 
including atherosclerosis. In human atherosclerotic lesions, strong expression of P-selectin was 
detected on the endothelium overlying active atherosclerotic plaques but not on normal arterial 
endothelium or on endothelium overlying inactive fibrous plaques (Johnson-Tidey et al., 1994; 
Ley, 2003). This availability of P-selectin molecules at the cell surface is achieved within a few 
minutes. E-selectin is expressed by acutely inflamed EC in most organs and in non-inflammed 
skin microvessels. The NF-κB transcription factor seems crucial in the activation of this gene. 
This induction takes a few hours and decreases rapidly after a peak.  
The mechanisms by which these molecules are downregulated after activation are important: it 
is necessary to clear them from the cell surface after activation in order to limit/stop the 
inflammatory process. Over-expression or maintenance of these molecules may have critical 
consequences on inflammation and on the integrity of the vascular wall. After cell activation, 
selectin molecules are rapidly removed from the cell surface, by a mechanism of internalization 
and lysosomal targeting (P- and E-selectin) or by shedding/proteolytic cleavage (L-, E-selectin). 
Soluble isoforms of E- and L-selectins, measurable in blood, are the results of this latter process 
(Hafezi-Moghadam et al., 2001). A soluble isoform of P-selectin is also observed, and is the 
product of an alternatively spliced messenger lacking the transmembrane domain (Ishiwata et 
al., 1994). Shedding, although not confirmed, might also contribute to a shorter soluble isoform 
of P-selectin (Berger et al., 1998). These soluble molecules are not only degradation products: 
they can have their own function, potentially as competitors interacting with their normal counter-
receptors without triggering cell recruitment, as inhibitors or as agonists. All selectins participate 
in different, albeit overlapping, ways to the early steps of leukocyte recruitment at the endothelial 
surface under shear forces: leukocyte rolling and tethering (Figure 14). By interactions with their 
ligands, selectins create weak bonds between activated EC (E- and P-selectin) and leukocytes 
(L-selectin). P-selectin/PSGL-1 binding triggers leukocyte activation, integrin mobilization and 
induces inflammation and thrombosis (Blankenberg et al., 2003).  
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 1.5.1.2. Immunoglobulin (Ig) adhesion molecules  
The immunoglobulin (Ig) –like large family of adhesion molecules are membrane glycoprotein 
receptors. Ig superfamily cell adhesion molecules have an extracellular domain, which contains 
a variable number of Ig-like intrachain disulfide-bonded loops with conserved cysteine residues, 
a transmembrane domain, and an intracellular domain that interacts with the cytoskeleton 
(Blankenberg et al., 2003). Members of the Ig superfamily include the intercellular adhesion 
molecules (ICAMs), vascular-cell adhesion molecule (VCAM-1), platelet-endothelial-cell 
adhesion molecule (PECAM-1), and neural-cell adhesion molecule (NCAM). ICAM-1 is widely 
expressed at a basal level and can be up-regulated by pro-inflammatory cytokines in leukocytes 
and EC (Manka et al., 1999), whereas ICAM-2 is present on leukocytes, platelets and 
endothelium but is rather down-regulated by inflammatory mediators. ICAM-3 is detected in EC 
and leukocytes and is the only ICAM molecule on neutrophils. Soluble forms of ICAM-1 and 
ICAM-3 have been shown to result from shedding (Fiore et al., 2002). VCAM-1 is 
transcriptionally induced on activated EC but can also be expressed by other cell types like 
macrophages, myoblasts, dendritic cells (Blankenberg et al., 2003). VCAM-1 participates to the 
recruitment of blood cells by allowing them to firmly adhere on activated EC. PECAM-1 is 
expressed by leukocytes, platelets and EC. It is mainly found at adherent junctions of EC where 
it participates in homophilic binding between adjacent cells (Newton et al., 1997). In humans, 
plaque neovasculature shows increased levels of ICAM-1 and VCAM-1 expression. In addition 
macrophages and T-lymphocytes are efficiently recruited in plaques when ICAM-1 and VCAM-1 
are expressed, suggesting that inflammatory cell recruitment through activation of intimal 
neovasculature may participate in the pathogenesis of atherosclerosis (Huo and Ley, 2001).  
1.5.1.3. Integrins 
Integrins are heterodimeric transmembrane glycoproteins resulting from the non-covalent 
association of an α chain and a β chain. Eighteen different α chains and 8 β chains have been 
described, whereas only 24 different heterodimers have been observed. Alternative splicing is 
common in this family and increases the complexity/specificity of associations (Armulik, 2002). 
Both the α and β subunits contain two separate tails, both of which penetrate the plasma 
membrane and possess small cytoplasmic domains. Soluble forms of integrins have not yet 
been reported. Most integrins function as receptors for ECM proteins, however some family 
members mediate heterotypic cell-cell adhesion. Integrins are expressed in a large variety of 
cells and have various conformational states. In resting cells, they are usually non-adhesive, 
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 present on the cell surface but in a conformation that provides low affinity for ligands. The 
mechanism by which a cell regulates the affinity state of its integrin receptor is called “inside-out” 
signalling. It involves the propagation of conformational changes from the cytoplasmic domains 
of integrins to the extracellular binding sites in response to intracellular signalling events. 
“Outside-in” signals are delivered within the cell after ligation between an integrin and its ligand 
(Abram and Lowell, 2009; Hughes and Pfaff, 1998; Qin et al., 2004). Integrin-mediated cellular 
interactions initiate signalling pathways that regulate a plethora of responses including cell 
morphology, differentiation, survival, proliferation, migration, and invasion. Integrin mediated 
anchorage is also a key regulator of anoikis, a programmed cell death (apoptosis) caused by 
loss of anchorage. Normal cells are dependent on anchorage not only for growth, but also for 
survival. 
In atherosclerosis, integrins have distinct roles in inflammatory cell recruitment to the damaged 
vessel wall. β2 integrins are strictly expressed in leukocytes, the α chains giving more subtle 
patterns of expression to the functional dimeric protein. For example, αLβ2 is expressed in 
almost all leukocytes whereas αXβ2 is more restricted to monocytes/ macrophages (Lopez-
Rodriguez et al., 1995). This class of integrins interacts with molecules of the ICAM subfamily; 
after cell activation, they become themselves activated and interact with ICAMs to induce a firm 
arrest at the surface of the activated endothelium (Lynam et al., 1998). Cells can then change 
their shape and migrate upon the surface of the endothelium to reach a junction. The interaction 
VCAM-1/integrin α4β1 is also important for this step (Rose et al., 2001). Integrins from the β3 
family are expressed in platelets: α2bβ3, also known as glycoprotein (GP) IIb/IIIa, is specific for 
this cell type and plays a role in fibrin formation, whereas αVβ3 is more widely expressed and is 
involved in cell survival, migration and proliferation (Desgrosellier and Cheresh; Schwartz et al., 
1999).  
A subset of integrins contributes to the regulation of angiogenesis. In atherosclerotic plaques, 
αvβ3 is highly expressed by medial and intimal SMCs and by EC of angiogenic microvessels 
(Hoshiga et al., 1995). In a rabbit model of atherosclerosis, targeting of EC expressed αvβ3 with 
nanoparticles containing antiangiogenic fumagillin was shown to markedly reduce plaque 
neovascularization (Winter et al., 2006). In addition selective αvβ3 blockage, limited macrophage 
infiltration and neovascularization in the vessel wall (Bishop et al., 2001). Integrin α7 expression 
was shown to be enhanced in a rat model of atherosclerosis (Chao et al., 2004). Experimental 
studies have demonstrated that engagement of α5β1, α1β1, α2β1 and αvβ5 integrins promote 
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 tumor growth and angiogenesis (Avraamides et al., 2008). However, their precise roles in the 
context of plaque neovascularization are not yet understood.  
1.5.2. The role of cadherins in regulating endothelial function 
Cadherins play an important role in endothelial cell integrity and growth and vascular 
morphogenesis. The large cadherin superfamily includes calcium dependent cell adhesion 
molecules responsible for cell-cell recognition and adhesion (Figure 15).  
Besides their adhesive 
properties, cadherins may 
act by transferring 
intracellular signals though 
interactions with complex 
network of cytoskeleton and 
signalling molecules. They 
are expressed in several 
types of tissues with some 
specificity. EC express VE-
cadherin, N-cadherin and 
T-cadherin. VE-cadherin is 
unique to EC and is the 
cadherin present in the 
adherens junctions of EC 
(Dejana, 2004). A specific 
feature of VE-cadherin as 
compared with all other 
classical cadherins is that it may also behave as a desmosomal-like cadherin, whereby through 
plakoglobin VE-cadherin can recruit desmosomal proteins desmoplakin and vimentin at the 
membrane. This desmosomal-like structure (complexus adhaerentes) is specific for EC (Bazzoni 
and Dejana, 2004). N-cadherin is excluded from adherens junctions in EC and is diffusely 
distributed on the cell membrane (Navarro et al., 1998; Resink et al., 2009; Salomon et al., 
1992). It is also expressed at contact zones between pericytes and EC (Gerhardt et al., 1999). 
T-cadherin in EC is globally distributed on the cell surface with only very minor enrichment at 
cell-cell borders and polarizes to the leading edge of migrating EC (Philippova et al., 2003). 
Figure 15. Schematic overview of basic structural features of the 
cadherin superfamily members. Cadherins are mainly single pass 
transmembrane proteins characterized by the presence of extracellular 
cadherin repeats (EC domains) (Resink et al., 2009).
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 Regulation of EC adhesive and signalling functions by VE-cadherin has been the subject of 
intensive study for decades. N-cadherin and T-cadherin are relative newcomers to investigations 
on EC biology and their roles in vascular diseases are poorly defined.  
1.5.2.1. VE-cadherin 
A wealth of in vitro and in vivo studies have established that VE-cadherin plays essential roles in 
controlling vascular permeability, integrity, and remodeling, leukocyte transmigration, 
vasculogenesis and angiogenesis (Bazzoni and Dejana, 2004; Carmeliet and Collen, 2000; 
Cavallaro et al., 2006; Dejana, 2004; Dejana et al., 2008; Lampugnani and Dejana, 2007; 
Vestweber, 2007; Vestweber, 2008; Wallez and Huber, 2008; Wallez et al., 2006). Not 
surprisingly therefore, alterations in VE-cadherin expression and distribution contribute to 
atherogenesis. In the mouse has been shown that VE-cadherin is very important during 
angiogenesis, and inactivation of the corresponding gene leads to a lethal phenotype. Although 
the EC that do not express VE-cadherin are able to form vascular networks, indicating that it is 
not essential for this process, vascular remodelling is affected. EC tend to detach from one 
another and vessels regressed and collapsed leading to early embryonic lethality in mice, a 
consequence of vascular insufficiency (Carmeliet et al., 1999; Gory-Faure et al., 1999). Different 
mechanisms may account for the role of VE-cadherin in angiogenesis. Apart from its adhesive 
properties it is suggested that it is also implicated in intracellular signalling. VE-cadherin 
associates to VEGF-R2 and modulates its signalling pathway, leading to alterations of vascular 
development with aberrant lumen, hemorrhages and eventually vascular regression (Grazia 
Lampugnani et al., 2003). Additionally VE-cadherin has a key role in vascular permeability when 
is associated with β-catenin (Ukropec et al., 2000). In the intima of healthy human arteries VE-
cadherin is not expressed (Bobryshev et al., 1999). However during atherosclerosis it is found 
within the intima with a frequency and intensity that increases in advanced lesions and reflects 
the level of neovascularization (Bobryshev et al., 1999; Sigala et al., 2003). In vivo, VE-cadherin 
expression at cell-cell junctions is weaker in atherosclerosis-susceptible sites (Miao et al., 2005). 
The expression of VE-cadherin was associated with plaque instability, degree of stenosis and 
clinical events (Sigala et al., 2003). Neovessels surrounded by inflammatory cells had irregular 
or reduced levels of VE-cadherin in association a breakdown of endothelial integrity, favouring 
further infiltration of inflammatory cells into plaque tissue (Bobryshev et al., 1999). “Soluble” VE-
cadherin can be detected in human plasma (Koga et al., 2005; Soeki et al., 2004). Plasma levels 
of VE-cadherin were correlated with the degree of coronary atherosclerosis, independently of 
classical atherosclerotic risk factors (Soeki et al., 2004). 
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 1.5.2.2. N-cadherin 
Expression of N-cadherin on EC has not yet been studied in human atherosclerosis or 
experimental restenosis and its role has remained largely elusive. However, its pro-angiogenic 
properties suggest that it is likely that an increase might be detected in association with 
neovascularization. In contrast with the typical localization of VE-cadherin at cell-cell junctions, 
N-cadherin is distributed over the whole cell surface of cultured EC (Navarro et al., 1998). N-
cadherin has been shown to play a critical role in angiogenesis, although its function differs from 
that of VE-cadherin. Whereas VE-cadherin mostly promotes the homotypic interaction between 
EC, N-cadherin is responsible for the formation of heterotypic ablumenal adherens junctions 
between EC and pericytes (Gerhardt et al., 1999; Gerhardt et al., 2000; Liebner et al., 2000) or 
myoendothelial junctions between EC and underlying VSMC (Isakson et al., 2008; Paik et al., 
2004). N-cadherin-dependent pericyte coverage is critical for stabilization and of maturation of 
newly-formed endothelial sprouts. N-cadherin blockage in vivo results in defective pericyte 
adhesion accompanied by vascular dysmorphogenesis and hemorrhage (Gerhardt and 
Betsholtz, 2003; Gerhardt et al., 2000). Recent data suggest that N-cadherin may also influence 
angiogenesis by directly regulating EC function and influencing VE-cadherin expression levels. 
Knockdown of N-cadherin in vivo and in vitro caused a significant decrease in VE-cadherin (Luo 
and Radice, 2005). A synthetic peptide capable of antagonizing N-cadherin-mediated adhesion 
disrupted angiogenesis in vitro (Devemy and Blaschuk, 2008). Furthermore, neutralization of N-
cadherin with a cyclic peptide containing the HAV motif was shown to induce apoptosis through 
inhibition of cadherin-mediated activation of FGFR signalling (Erez et al., 2004). Soluble N-
cadherin (consisting of the extracellular domain) stimulated angiogenesis in vivo and migration in 
vitro (Derycke et al., 2006). Soluble N-cadherin did not affect intercellular adhesion, and its 
effects on EC migration are mediated through complex formation with fibroblast growth factor 
receptor (FGFR), which has been implicated as an important partner of N-cadherin in a number 
of cell types, including EC (Derycke et al., 2006). Possibly metalloproteinase-mediated shedding 
of soluble N-cadherin from VSMC during proliferation may have a knock-on pro-angiogenic 
effect (Uglow et al., 2003).  
1.5.2.3. T-cadherin 
T-cadherin is an atypical cadherin. It is the only one member of the cadherin superfamily which 
lacks both the transmembrane and cytoplasmic regions, but it is instead anchored to the 
membrane via a glycosylphosphatidylinositol (GPI) anchor (Figure15)(Philippova et al., 2009). 
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 Therefore it cannot interact with the classical intracellular partners and with the cytoskeleton. T-
cadherin on EC is globally distributed on the cell surface with only very minor enrichment at cell-
cell borders, and it polarizes to the leading edge of migrating EC (Philippova et al., 2003). It is 
suggested that T-cadherin is rather involved in cell signalling and it is suggested that perhaps it 
role is in sensing neighbouring cells and informing its host cell of the microenvironment, thus 
functioning as a guidance receptor (Ivanov et al., 2004b; Joshi et al., 2007). In vitro T-cadherin is 
upregulated on proliferating EC (Ivanov et al., 2004a) or EC exposed to oxidative stress (Joshi 
et al., 2005). T-cadherin overexpression on EC in vitro induces proliferation and motility (Ivanov 
et al., 2004b) and protects EC from oxidative stress-induced apoptosis (Joshi et al., 2005; 
Philippova et al., 2008). Together the data suggest that T-cadherin is both a marker of EC 
activation/stress and an inducer of an activated EC phenotype. Anti-adhesive/repulsive functions 
for T-cadherin in the vasculature emerged from studies showing that homophilic ligation in EC is 
rapidly followed by the acquisition of a less-adhesive, motile or pro-migratory, pro-angiogenic 
phenotype (Ivanov et al., 2004b; Philippova et al., 2005). These functions of T-cadherin require 
the activity of the small GTPases RhoA and Rac1 (Philippova et al., 2005). GPI-anchored T-
cadherin lacks transmembrane and cytosolic domains, and thus its effects on EC behaviour 
require association with molecular adaptors to mediate inward signalling. A number of 
membrane adaptors including integrin β3, Grp78/Bip and integrin linked kinase have been 
identified (Joshi et al., 2007; Philippova et al., 2008). In vivo T-cadherin is up-regulated in 
atherosclerotic lesions (Ivanov et al., 2001), during restenosis (Kudrjashova et al., 2002) and on 
EC from tumour vasculature (Wyder et al., 2000). Proangiogenic properties for T-cadherin have 
been demonstrated using in vitro models of angiogenesis (Philippova et al., 2006). Using a 
model of myoblast-mediated gene transfer to mouse skeletal muscle delivery of soluble T-
cadherin potentiated VEGF effects on neovascularization in a manner that involved an increase 
in vessel caliber (Philippova et al., 2006). Another study using the Matrigel implant model 
reported that ectopic delivery of T-cadherin inhibited neovascularization (Rubina et al., 2007). 
However, specific confirmation of proangiogenic functions for T-cadherin was recently provided 
through use of T-cadherin null mice whereby T-cadherin deficiency was found to limit angiogenic 
responses (Hebbard et al., 2008).  
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2. AIMS 
2.1. Inflammation and angiogenesis in plaque instability  
Increasing evidence has suggested that the extent of intraplaque neovascularization is directly 
related to the infiltration of inflammatory cells into the vessel wall, the stage of plaque 
development, the risk of plaque rupture, and subsequently, the presence of symptomatic 
disease, the timing of ischemic neurological events and myocardial/cerebral infarction. We aim 
to identify relevant inflammatory cells and pro-angiogenic soluble factors released by 
inflammatory cells that might contribute to development of unstable atherosclerotic plaque by 
activation of intraplaque angiogenesis.  
The first objective (Project 1) was to investigate CD1d+ APC and iNKT cells in human 
atherosclerotic lesions, correlate them with disease severity and activity, and elucidate potential 
mechanisms by which these cells might be involved in plaque formation and/or destabilization. 
The second objective (Project 2) was to identify key signal transduction mechanisms for 
the angiogenic response elicited in response to iNKT cell activation. 
 
2.2. Regulating endoplasmic reticulum stress in endothelial cells: the role of T-
cadherin 
Accumulating data suggest some relationship between T-cadherin and ER stress. T-cadherin is 
both a marker of EC activation/stress and facilitates acquisition of an activated, proangiogenic 
EC phenotype. In EC, activation of UPR genes causes a concomitant increase in VEGF and IL-8 
production which lead to stimulation of angiogenesis. Overexpression and ligation of T-cadherin 
on the EC surface activate cell survival and proliferation signalling pathways (PI3-kinase, Akt, 
GSK-3β) common to those activated by chaperon Grp78, a crucial regulator of UPR signalling 
during ER stress. We aimed (Project 3) to identify the relationship between T-cadherin 
expression and ER stress response in EC. Here we investigate the ability of T-cadherin to 
influence UPR signalling and endothelial cell survival during ER stress. 
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Project 1 
The role of lipid activated inflammatory cells in the pathogenesis of atherosclerosis  
The results of this project have been published. 
Invariant NKT cells: Linking inflammation and neovascularization in human 
atherosclerosis. 
 
European Journal of Immunology, September 2010, DOI:10.1002/eji.201040619 
(The paper is appended) 
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Summary 
Atherosclerosis, a chronic inflammatory lipid storage disease of large arteries, is complicated 
by cardiovascular events usually precipitated by plaque rupture or erosion. Inflammation 
participates in lesion progression and plaque rupture. Identification of leukocyte populations 
involved in plaque destabilization is important for effective prevention of cardiovascular 
events. This study investigates CD1d-expressing cells and invariant natural killer T (iNKT) 
cells in human arterial tissue, their correlation with disease severity and symptoms, and 
potential mechanisms for their involvement in plaque formation and/or destabilization. CD1d-
expressing cells were present in advanced plaques in patients who suffered from 
cardiovascular events in the past and were most abundant in plaques with ectopic 
neovascularization. Confocal microscopy detected iNKT cells in plaques, and plaque-derived 
iNKT cell lines promptly produced proinflammatory cytokines when stimulated by CD1d-
expressing APC presenting α-galactosylceramide lipid antigen. Furthermore, iNKT cells were 
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diminished in the circulating blood of patients with symptomatic atherosclerosis. Activated 
iNKT cell-derived culture supernatants showed angiogenic activity in an endothelial cell (EC)-
spheroid model of in vitro angiogenesis and strongly activated EC migration. This functional 
activity was ascribed to IL-8 released by iNKT cells upon lipid recognition. These findings 
introduce iNKT cells as novel cellular candidates promoting plaque neovascularization and 
destabilization in human atherosclerosis. 
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Introduction  
Atherosclerosis is complicated by cardiovascular (CV) events, which usually occur when 
plaques rupture or erode. Vulnerable plaques prone to rupture are characterized by 
inflammation, plaque hemorrhage and abnormal apoptosis [1, 2], three processes that are 
spatially and temporally interconnected. Both innate and acquired immune responses can 
modulate atherosclerotic plaque development [3]. Macrophages and T lymphocytes 
infiltrating the arterial wall during atherosclerosis [2, 4] produce proinflammatory cytokines, 
chemokines, metalloproteinases and mesenchymal growth factors that are all potentially 
involved in plaque growth and rupture but might also contribute to plaque remodeling and 
stabilization. A histopathological quantitative analysis has suggested that macrophages in 
the arterial wall seem to be protective in the early, but deleterious in the late stages of 
disease [5]. T-cell populations with different functional capacities have been identified within 
atherosclerotic lesions [4] and contribute to the pathogenic complexity of the inflammatory 
process [6]. In addition to inflammation, other mechanisms such as lipid retention [7], 
neovascularization [1, 5, 8] and tissue remodeling [9, 10] support plaque growth. How 
different leukocyte populations contribute to or are affected by these additional mechanisms 
remains elusive. T cells recognizing protein or lipid antigens within plaques are likely 
involved. Invariant natural killer T cells (iNKT) cells, which express a semi-invariant TCR 
made by Vα24 and Vβ11 chains, have attracted attention as lipid-responsive cells [11]. 
These cells recognize lipid antigens presented by CD1d, a member of the CD1 family of 
antigen-presenting molecules [12]. α-Galactosylceramide (αGalCer), a glycolipid antigen and 
potent activator of iNKT cells, accelerates atherosclerotic lesion formation in the ApoE-/- 
mouse model [13-15]. CD1d-deficient and TCR Vα14-deficient mice, both lacking iNKT cells, 
are protected in this model of atherosclerosis [15-17]. Moreover, in this model adoptive 
transfer of iNKT cells markedly increases plaque burden [18]. In contrast, in the LDL 
receptor-/- mouse model an atheroprotective role for iNKT cells has been described [19]. 
Taken together, these animal studies provide strong evidence that iNKT cells are involved in 
atherosclerotic plaque development and progression.  
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No detailed investigations on iNKT cells in human atherosclerosis have yet been 
performed. Although CD1d protein is expressed in human atherosclerotic lesions [20] it 
remains unknown whether CD1d expression correlates with lesion severity or disease 
activity. This study examines CD1d-expressing cells and iNKT cells in human atherosclerotic 
lesions, their correlation with disease severity and activity, and potential mechanisms for their 
involvement in plaque formation, progression and/or destabilization. 
 
Results 
 
CD1d+ cells in human atherosclerotic lesions are a sign of arterial vulnerability 
We quantified intimal macrophages and CD1d+ cells in arterial tissue obtained from 
asymptomatic (ASA) patients who never experienced CV events previously (n = 21) and 
patients with symptomatic (SA) atherosclerosis who developed CV events in the past (n = 
15) using human arterial tissue microarrays (Fig. 1). Definition of CV events is given under 
Materials and Methods. This approach permits correlation of histomorphological findings with 
disease activity and lesion severity. We analyzed a total of 108 arterial sectors obtained 
systematically from three different vascular beds (carotid, renal and iliac artery) of 36 patients 
(clinical characteristics shown in Table.1). Plaque type according to the American Heart 
Association (AHA) classification [21], and numbers of CD1d-expressing cells, CD68+ 
macrophages and vWF-positive microvessels per intima area were determined in serial 
histopathological sections. In a per sector analysis, both CD68+ macrophages and CD1d+ 
cells were found more commonly in advanced lesions than at early plaque stages (Fig. 1A; 
Supporting Information Fig. 1 for CD1d+ staining controls). In a per patient analysis, i.e. when 
the three observations in the iliac, renal and carotid artery for each patient were averaged, 
the density (number of cells per mm2) of CD68+ or CD1d+ cells did not differ between ASA 
and SA patients (Fig. 1B). On the contrary, when signs of ectopic neovascularization were 
also considered as a variable, SA patients had on average the highest numbers of CD1d+ 
cells (P < 0.05) (Fig. 1B). It is remarkable that CD1d+ cells were virtually absent from lesions 
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without signs of ectopic neovascularization (early lesions) and low in asymptomatic patients. 
For the tissue microarray analysis, arterial rings were harvested on average 24h after death. 
We tested whether the number of detectable CD1d+ cells would fade with time after death but 
found no such correlation (data not shown).  
 
iNKT cells are found in atherosclerotic lesions 
The presence of CD1d-expressing cells in advanced, unstable atherosclerotic lesions 
prompted a search for iNKT cells. Due to the predicted scarcity of these cells, different 
approaches were applied to investigate their presence in atherosclerotic plaques. Lesional 
arterial intima from 5 SA patients was examined by confocal microscopy. We demonstrated 
the presence of CD3+/Vα24+ and CD3+/Vβ11+ cells, which represented up to 3% of total 
infiltrating CD3+ T cells in all lesions analyzed (Fig. 2A and Table 2). These findings suggest 
but do not prove the presence of iNKT cells. We therefore prepared cell suspensions from 
thrombendarterectomy specimens and performed co-staining with anti-Vα24 and anti-Vβ11 
mAb ex vivo (Fig. 2B). The identification of Vα24/Vβ11 double-positive cells with fluorescent 
microscopy provided evidence that iNKT cells are present in the diseased arterial wall.  
Next we performed dual fluorescence confocal microscopy of lesional tissue from 8 
SA patients using anti-CD1d and anti-TCR Vα24-Jα18 (6B11) mAb, which recognizes the 
iNKT-specific invariant TCR Vα chain [22, 23]. Representative micrographs unequivocally 
demonstrating the presence of iNKT cells in atherosclerotic lesions are presented in Fig. 3. In 
some instances there was evidence of co-localization of the iNKT TCR with CD1d and even 
iNKT TCR and CD1d polarization towards each other. These findings could indicate an 
ongoing activation of iNKT cells within the atherosclerotic tissue.  
To confirm and formally prove that iNKT cells reside in atherosclerotic lesions we 
isolated and expanded iNKT cells from thrombendarterectomy specimens obtained from SA 
patients and performed phenotypic and functional studies. We stimulated plaque-derived T 
cells with αGalCer and CD1d-expressing cells to facilitate the selective expansion of iNKT 
cells and succeeded in establishing 6 bulk T cell lines. Flow cytometry analysis using 5 color 
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staining showed that 60-90% of CD3+ cells were co-expressing TCR Vα24 and Vβ11 chains 
(Fig. 4A). In all lines, Vα24+Vβ11+ cells were also stained with αGalCer-loaded soluble 
human CD1d dimers, thus confirming the lipid specificity and CD1d restriction of their TCR. 
Five of the 6 iNKT cell isolates were CD4 positive (representative shown in Fig. 4A) and all 6 
were CD8 negative. Plaque-derived iNKT cells stimulated with αGalCer produced large 
amounts of IL-4, TNF-α, IFN-γ and GM-CSF (Fig. 4B). We compared the 6 plaque-derived 
iNKT cell lines and 66 blood-derived iNKT cell clones with respect to their responsiveness to 
αGalCer. The ED50 was calculated after measurement of IFN-γ (Fig. 4C), TNF-α, IL-4, and 
GM-CSF (data not shown) release. For all cytokines plaque-derived iNKT cells exhibited 
ED50 values at least 10-fold lower than peripheral blood-derived iNKT cells. Taken together, 
these results prove that the iNKT cells present within atherosclerotic lesions have phenotypic 
and functional features of bona fide iNKT cells [24] and react to αGalCer with unusual high 
efficiency. 
 
Circulating iNKT cell numbers are reduced in patients with symptomatic 
atherosclerosis 
Next we investigated iNKT cells in the blood from three groups of donors, namely SA 
patients, age-matched control patients free of CV events in the past (i.e. ASA) and young 
healthy individuals. iNKT cells were detected in PBMC with 4 color immunofluorescence 
analysis using anti-CD3ε, anti-TCR Vα24, anti-TCR Vβ11 mAb and αGalCer-loaded CD1d 
dimers. We detected a significant (P ≤ 0.001) reduction of circulating iNKT cells in SA 
patients compared with either ASA patients or young healthy individuals (Fig. 5). A reduction 
was also observed in the ASA patients as compared with the young healthy individuals (P < 
0.01), possibly reflecting an age-related effect on this lymphocyte subset [25]. These findings 
raise interesting issues regarding the fate of iNKT cells in peripheral blood of symptomatic 
atherosclerotic patients: are they reduced because of lack of proliferative responsiveness to 
stimulatory lipids, increased apoptosis or increased extravasation into tissues? 
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Characterization of proatherosclerotic activity of iNKT cells 
The presence of CD1d+ cells and iNKT cells within advanced atherosclerotic lesions, 
particularly in patients with symptomatic disease, led us to investigate whether this T 
lymphocyte population has a role in key processes of plaque formation and destabilization. 
Following αGalCer stimulation plaque-derived iNKT cells release proinflammatory and 
potential angiogenic modulators (Supporting Information Fig. 2). Both plaque- and blood-
derived iNKT cells secreted the same type of cytokines (data not shown). 
Since neovascularized arterial sectors had the highest numbers of CD1d+ cells, 
subsequent investigations focused on effects of iNKT activation on angiogenic behavior of 
EC. We examined angiogenic potential of conditioned medium (CM) derived from iNKT cell 
cultures stimulated with (CM+) or without (CM-) αGalCer using the EC-spheroid model of in 
vitro microvascular sprout formation as a global functional test for angiogenesis. Visualization 
of spheroids indicated that CM+ induced greater sprout outgrowth than CM- (Fig. 6A). 
Morphometric analysis showed a significant increase in both the number (Fig. 6B) and length 
(Fig. 6C) of sprouts. CM collected from cultures containing αGalCer but lacking either CD1d+-
APC or iNKT cells, or both, failed to enhance sprout outgrowth (Supporting Information Fig. 
3). Taken together, these data confirm that antigen-stimulated iNKT cells can promote 
angiogenesis in vitro. 
 
Soluble factors released by iNKT cells promote endothelial cell migration  
Angiogenesis is a complex process and both proliferation and migration of EC contribute to 
this phenomenon [8, 26]. To identify which of these activities is modulated in response to 
iNKT cell activation, we compared effects of CM on proliferation and migration of EC in 
monolayer cultures. CM+ derived from different iNKT cells did not activate EC proliferation 
(Supporting Information Fig. 4) but did induce cell migration. Two methods were used to 
evaluate migration. In the first, confluent EC monolayers were scrape-wounded and 
migration into the wound was recorded over a 12h period by time-lapse videomicroscopy. 
This wound-healing assay showed more rapid migration for EC cultured in the presence of 
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CM+ (Fig. 7A and B, and Supporting Information Fig. 5). Representative videos showing EC 
motility in the presence of CM- (Supporting Information Fig5video1-CM-.avi) and CM+ 
(Supporting Information Fig5video2-CM+.avi) are given in the Supporting Information. The 
second assay quantified transmigration of EC in a Boyden-chamber and also demonstrated 
enhanced migration of EC toward CM+ (Fig. 7C). These data suggest a chemokine-like 
effect on EC angiogenic behavior. 
 
IL-8 is produced by iNKT cells and induces endothelial cell migration  
IL-8, a pleiotropic chemokine with known angiogenic activity in vitro and in vivo [27, 28], was 
amongst numerous factors released by activated iNKT cells (Supporting Information Fig. 2). 
iNKT cells isolated from plaques (Fig. 8A) and peripheral blood (Supporting Information Fig. 
6) showed strong intracellular staining for IL-8 when stimulated with αGalCer proving that 
they readily produce this chemokine. To determine the contribution of iNKT cell-released IL-8 
to the angiogenic potential of CM+, wound-healing assays were conducted in the presence of 
anti-IL-8 blocking antibodies or using CM which had been immunodepleted of IL-8 prior to 
assay. Both treatments completely abrogated the enhanced EC migration (Fig. 8B). Basal 
EC migration was not affected by inclusion of anti-IL-8 antibodies or IL-8-depletion, excluding 
non-specific inhibitory effects of the antibodies. Therefore, the enhanced migration response 
of EC to CM+ is dependent upon IL-8 released by activated iNKT cells. 
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Discussion 
Our study investigated iNKT cells in human atherosclerosis. We found that cells expressing 
CD1d are present in advanced atherosclerotic plaques and lesions from patients with active, 
symptomatic disease. In patients with symptomatic atherosclerosis, vascularized plaques 
had the highest number of CD1d+ cells. We identified the presence of iNKT cells in 
atherosclerotic lesions and characterized their function after isolation from plaques. iNKT 
cells from plaques show a high reactivity to the αGalCer antigen and may promote 
neovascularization in an IL-8-dependent manner. Our study suggests that iNKT cells 
contribute to the predisposition of atherosclerotic plaques to rupture. 
In order to perform quantitative immunohistochemical analysis of inflammatory cells in 
atherosclerotic plaques, we took advantage of the arterial tissue microarray technique which 
permitted us to compare serial sections of 108 arterial sectors from 36 patients. Our 
approach, recently reproduced [29], facilitated evaluation of associations between the 
presence of CD68+ macrophages and CD1d+ cells and disease activity, lesion severity (i.e. 
plaque stage) and plaque neovascularization. CD68+ macrophages were found in all samples 
analyzed, even in those without lesions, as reported [5], and were slightly increased in very 
advanced plaques. In contrast, CD1d+ cells were virtually absent from the normal arterial 
intima or in early plaque stages, whereas they were increased in advanced lesions 
particularly in the presence of neovessels. Expression of CD1d in human atherosclerotic 
plaques has been reported in two studies [20, 30]. However, sample numbers were small 
and no correlations were made with clinical stage, disease activity or histological hallmarks, 
leaving open the question of whether CD1d expression correlates with lesion grade. In our 
study, a substantial number of CD1d+ cells was observed in advanced lesions (AHA type 
>IV) and particularly in lesions with signs of neovascularization, thus demonstrating a close 
correlation with advanced disease. The preferential localization of CD1d+ cells in areas with 
neovascularization could be explained by their efficient recruitment into vascularized plaques 
[31] and/or by their capacity to promote plaque neovascularization. Our data are in 
accordance with the concept that CD1d may present lipid antigens locally to specific T cells, 
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including iNKT cells, which in turn may release angiogenic factors and contribute to 
neovascularization. 
In the diseased arterial wall we found T cells expressing Vα24 or Vβ11 TCR chains, 
which are used by iNKT cells. Flow cytometric analysis of freshly isolated iNKT cells was not 
possible due to small biopsy size and the minute number of resident iNKT cells. This 
technical limitation prevented exact quantification of iNKT cells and analysis of expressed 
activation markers. Therefore, the activation status of iNKT cells within lesions remains 
unknown. However, we could identify iNKT cells in lesional tissue by several methodological 
approaches, namely i) detection of TCR Vα24-Jα18 with the 6B11 mAb; ii) detection of Vα24 
and Vβ11 co-expressing T cells freshly isolated from lesions, and iii) expansion and 
functional characterization of iNKT cell lines from plaques. We observed an intraplaque 
infiltration of iNKT cells and a significant reduction of iNKT cells in circulating blood in 
symptomatic patients. This relative accumulation in plaques could be caused by homing and 
retention following local activation and/or proliferation upon antigen recognition. 
The presence of iNKT cells in lesions has been inferred in mouse atherosclerosis 
models by molecular investigations and not cellular isolation. In a pioneering study on ApoE-
deficient mice under high cholesterol diet, the presence of iNKT cells was suggested by RT-
PCR studies [13, 14, 32]. However, to date iNKT cells have neither been isolated from 
plaques nor functionally characterized. In one study, CD3+CD161+ cells were histologically 
detected in carotid specimens and appeared with a frequency of 0.3-2% among plaque 
infiltrating T cells [30]. CD161 is expressed by a variety of T lymphocytes and therefore is not 
a specific marker for iNKT cells. In a second study, all CD3+ cells expanded from aortic 
aneurysms expressed the CD161 marker [33], suggesting an abnormal proliferation of this 
cell type in vitro. Since the expression of semi-invariant TCR Vα24/Vβ11 was not 
investigated the presence of iNKT cells was not confirmed. We isolated plaque-infiltrating 
iNKT cells, which were Vα24+Vβ11+. They also bound αGalCer-loaded CD1d dimers, 
providing clear evidence that they are classical iNKT cells, and were efficiently activated by 
αGalCer-loaded CD1d-expressing APC to release IL-4, IFN-γ, GM-CSF and TNF-α. Thus, in 
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atherosclerotic plaques there is accumulation of cells expressing phenotypic and functional 
features of bona fide iNKT cells. 
Importantly, the iNKT cell lines isolated from plaques all showed an extremely low 
threshold of activation when stimulated with αGalCer. The same low threshold was found 
only in a minor fraction of iNKT cell clones isolated from peripheral blood. These findings 
might suggest that due to antigen recognition and expansion in plaques, there is a 
preferential accumulation of iNKT cells expressing TCR with high responsiveness to αGalCer 
in vitro. Whether high reactivity to αGalCer reflects high reactivity to lipids accumulating 
within plaques is unknown since endogenous self-lipid antigens stimulating iNKT cells remain 
poorly characterized. An additional and non-mutually exclusive possibility is that plaque-
derived iNKT cells lack NK inhibitory receptors and therefore are activated by very low doses 
of antigen. Intriguingly, in a model of atherosclerosis in ApoE-deficient mice iNKT cells with 
low expression of the inhibitory Ly49 receptors showed proatherogenic activity which was 
more pronounced than that of Ly49-positive iNKT cells [34]. The high reactivity of plaque-
derived human iNKT cells deserves further investigations, since it remains unclear whether 
the entire plaque infiltrating iNKT cell population shows this unusual behavior. 
How iNKT cell activation exerts proatherogenic effects remains an open issue. One 
potential mechanism relates to inflammation, which in human atherosclerosis is 
characteristically progressive. Since human iNKT cells isolated from plaques do release 
proinflammatory cytokines, their chronic in situ activation by lipid antigens might lead to 
lesion progression. This hypothesis is in line with many studies conducted in mice. Injection 
of αGalCer increases size and number of plaques in a mouse atherosclerosis model [15]. 
This experimental iNKT cell activation elicits massive release of Th1 and Th2 cytokines and 
elevation in plasma levels of IL-6 and monocyte chemoattractant protein 1, which have been 
proposed to enhance local inflammation [11, 15]. In humans atherosclerosis is a slowly 
progressive disease and there is as yet no evidence of massive inflammation in the arterial 
wall in early lesions. Instead a chronic inflammatory reaction may apply, probably together 
with other disease-promoting mechanisms. 
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A second pathogenic mechanism concerns neovascularization. The significant 
association of CD1d+ cells with neovascularization in plaques suggests that iNKT cells may 
be involved in angiogenic processes. Our findings revealed that iNKT cell activation by 
antigen has proangiogenic effects as shown by enhanced microvascular sprout formation in 
an in vitro assay of angiogenesis. This effect was associated with EC migration as 
demonstrated by enhanced EC motility in both wound-healing and transmigration Boyden 
chamber assays.  
Amongst the multiple cytokines that were produced by activated iNKT cells, IL-8 was 
the most promising candidate to further investigate. IL-8 was detected previously in the 
supernatant from lipid-stimulated blood-derived iNKT cells [35]. We found that plaque-
derived iNKT cells produce IL-8 as shown by intracellular staining. Further, the enhanced EC 
migration was dependent on release of IL-8 from iNKT cells since the migration response 
was abrogated by IL-8-blockade or IL-8 immunodepletion. The participation of IL-8 in 
atherosclerotic lesion progression is suggested by several studies [36]. IL-8 has been 
detected in atheromatous tissue [28, 37, 38] and can be induced in monocytes by oxidized 
LDL and cholesterol [37, 39]. Functionally, IL-8 contributes to intimal macrophage 
accumulation [40], to endothelial adhesiveness for monocytes [41], has mitogenic and 
chemoattractant effects on smooth muscle cells [42] and may also facilitate plaque 
recruitment of CD8+ effector T cells with high cytotoxic potential [43]. IL-8 has been proposed 
as an important mediator of angiogenesis in CV lesions contributing to plaque growth [28]. It 
is tempting to speculate that iNKT cells, when chronically activated by lipid antigens in the 
arterial wall, exert both promigratory and proinflammatory functions which become important 
for plaque neovascularization and destabilization. These functions might be shared with 
resident monocytes and other T cells recognizing specific antigens in plaques.  
In conclusion, our studies have revealed CD1d+ cells in advanced, vascularized 
atherosclerotic lesions from patients with active disease. We have identified the presence of 
iNKT cells within plaques, isolated plaque iNKT cells and demonstrated their high sensitivity 
to antigen stimulation and their proinflammatory and proangiogenic potential in vitro. By 
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these mechanisms, iNKT cells might participate in plaque growth and destabilization. 
Gathering evidence suggests that atherosclerosis is an autoimmune disease treatable with 
immunotherapeutic approaches [44]. Our observations invoke iNKT cells and CD1d-
expressing cells as additional potential candidate targets for immunopreventative 
interventions.  
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Materials and methods 
 
Patients and arterial tissues 
All investigations with human subjects and tissues were approved by the regional ethical 
review board and performed in accordance with institutional guidelines. The arterial tissue 
microarrays have been described previously [5]. In brief, 0.5 cm long arterial ring segments 
were obtained systematically during autopsy from 36 deceased patients who were treated for 
a broad variety of medical conditions at the Department of General Medicine of an academic 
medical center (Cantonal Hospital Bruderholz). The arterial rings were removed always at 
the same anatomical site regardless of the local lesion severity: 2 cm before the bifurcation 
for the left common carotid, 2 cm after branching from the aorta for the left renal and 2 cm 
after the aortic bifurcation for the left iliac artery. The deceased patients entering this study 
were not selected but were by intention prospectively included in order to circumvent any 
relevant selection bias. Clinical characteristics are given in Table 1. Fifteen of these patients 
were known to have symptomatic, active atherosclerosis and to have suffered from CV 
events, defined as as myocardial infarction, angina pectoris with signs of myocardial 
ischemia, cerebrovascular ischemic stroke, transient ischemic attack, peripheral arterial 
occlusive disease, symptomatic aortic aneurysm, or any arterial revascularization procedure 
to treat atherosclerosis [5].  
 PBMC were obtained from a second cohort of 269 in-patients hospitalized for any 
reason and who, with written informed consent, participated in a cross-sectional 
observational study of atherosclerosis [45]. Twenty-eight of this second cohort had previous 
CV events in more than 1 organ system; among these SA patients, the 10 oldest individuals 
(median age: 78, range 76-83 years) were selected for the analysis of the number of 
circulating iNKT cells (Supporting Information Table 1). From this second cohort, 110 of 269 
patients never reported any CV events in the past; among them, the 10 oldest subjects 
(median age: 79, range 78-83 years) were selected as an age-matched ASA group. The age 
of these patients matches that of SA and ASA patients from whom tissue microarrays were 
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generated. As an additional control group, 10 healthy young individuals free of any clinical 
evidence for atherosclerosis (median age 29, range 26-33 years) were included. PBMC from 
whole blood were isolated and processed as described [46]. Multicolor FACS was used to 
characterize iNKT cells in total PBMC as described in Supporting Information. 
 
Analysis of iNKT cells in arterial tissue 
Fresh-frozen, OCT embedded arterial rings obtained at autopsy from 13 symptomatic 
patients with advanced grade atherosclerotic plaques (AHA grade IV, V or VI) were variously 
used for the identification of TCR Vα24+ or TCR Vβ11+ T cells (n = 5) and of TCR Vα24-
Jα18+ T cells (n = 8) as detailed in Supporting Information.  
Collagenase-assisted release of lymphocytes from fresh arterial tissue obtained from SA 
patients with advanced lesions undergoing thrombendarterectomy was performed as 
previously described [47] with some modifications (Supporting Information). After staining 
with anti-TCR Vα24-FITC and anti-TCR Vβ11-biotin/streptavidin-Cy5 cells were collected by 
cytospin and analyzed for TCR Vα24+Vβ11+ cells by confocal microscopy. In some 
experiments the released lymphocytes were resuspended in complete RPMI-1640 medium 
(Supporting Information), split, seeded into individual wells of a 96-well plate and subjected 
to 2 rounds of restimulation with DC obtained as described [48] plus 100 ng/ml αGalCer (kind 
gift of Kirin Breweries) and addition of anti-MHC class I and anti-MHC class II mAb (W6/32 
and L243, both from ATCC) to avoid activation of MHC-restricted alloreactive T cells. The 
expanded plaque tissue-derived cells were assessed for the presence of iNKT cells by 
multicolor FACS (Supporting Information and figure legends) and antigen presentation 
assays.  
 
In vitro study procedures 
Materials and methods for these studies are fully detailed and referenced in the Supporting 
Information. The following human cell lines and clones were used: MOLT-4 expressing 
negligible CD1d (ATCC CRL 1582), C1R-hCD1d and HeLa-hCD1d [49] as antigen 
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presenting cell (APC) lines, human microvascular endothelial cell line HMEC-1 (EC), iNKT 
cell clones from PBMC of healthy donors and iNKT cell lines from plaques. To generate 
conditioned medium (CM), iNKT cells were cultured with APC pulsed with αGalCer or 
vehicle, and supernatant was harvested after 48h. Cytokines in CM were quantified by 
sandwich ELISA, or by Multiplex analysis (BioRad; Human17-Plex Panel 171-A11171) in 
selected experiments. Assays testing angiogenic effects of CM on EC included the EC-
spheroid model of in vitro angiogenesis, proliferation, Boyden-chamber transmigration and 
videomicroscopy of wound closure. 
 
Statistical analysis 
Patient data were compared between groups using the Mann-Whitney U test. Data from in 
vitro experiments were compared using the unpaired Student’s 2-tailed t test and are given 
as mean±SD. All analyses were performed using GraphPad Prism software (version 5.03). 
Differences were considered significant at P<0.05. 
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FIGURE LEGENDS 
 
Figure 1. APC in atherosclerotic lesions. The number of CD68+ macrophages and CD1d+ 
cells per intima area were determined with arterial tissue microarrays [5]. For each arterial 
sector, the intima area was morphometrically measured and the CD1d+ and CD68+ cells in 
the intima counted (expressed as cells/mm2). (A) Macrophage and CD1d+ cell counts in 
arterial sectors affected by atherosclerotic lesions of increasing severity according to the 
AHA classification. (B) Quantitative analysis of macrophage and CD1d+ cell counts in arterial 
sectors according to disease activity (i.e. whether patients suffered CV events during their 
lifetime or not and said to have asymptomatic (ASA) or symptomatic atherosclerosis (SA)). 
Neovessels were detected as vWF-positive microvessels in the arterial intima [5] and 
plaques were scored positive (filled boxes) or negative (open boxes) with respect to this 
anatomical sign. Data in A and B are presented as box plots with median, interquartile range 
and 5-95 percentiles. n.s., not significant *P<0.5, **P<0.01, ***P<0.001, Mann-Whitney U 
test. §, compares all ASA with all SA. 
 
 
Figure 2. iNKT cells in atherosclerotic lesions. (A) Lesional T cells in situ. Cryosections of 
intima of arterial rings from 5 patients with advanced atherosclerotic lesions were examined 
by confocal microscopy for the presence of T cells co-expressing CD3 and TCR Vβ11 (upper 
panels) or CD3 and TCR Vα24 chains (lower panels). Quantitative evaluation of cells positive 
for CD3/TCR Vα24 or CD3/TCR Vβ11 is given in Table 2. (B) Confocal analysis of iNKT cells 
freshly isolated from atherosclerotic plaques. Collagenase-released cells from fresh arterial 
tissue biopsies were collected by cytospin, co-stained with anti-TCR Vα24 and anti-TCR 
Vβ11 and analyzed by confocal microscopy. The data are representative of 4 independent 
experiments. All scale bars represent 2 μm.  
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Figure 3. Identification of iNKT cells in atherosclerotic lesions. Panels from left to right show 
the staining of iNKT cells with anti-TCR Vα24-Jα18, of CD1d+ cells, iNKT cells (in red) 
merged to CD1d+ cells (in green), and of nuclei (Hoechst). Scale bars: 10 μm. Stainings were 
performed on 8 patient tissue specimens and 2 representative stainings are shown. UPN, 
unique patient number. Boxed regions/arrows indicate co-localization of the iNKT TCR with 
CD1d (UPN 259) and iNKT TCR and CD1d polarization towards each other (UPN 189).  
 
Figure 4. iNKT cells from atherosclerotic plaque tissue. (A) A representative (of 6 total) bulk 
T-cell lines isolated from plaques and expanded after stimulation with αGalCer. T cells were 
stained with anti-CD3, anti-CD4, anti-TCR Vα24 and anti-TCR Vβ11 and with αGalCer-
loaded CD1d dimers. The FACS gating strategy is depicted in Supporting Information Fig. 7. 
Left panel shows density plot after gating on CD3+ cells. The right panel shows density plot 
after gating on CD3+Vα24+Vβ11+ cells. (B) Cytokine release from one representative plaque-
derived iNKT cell line after in vitro stimulation with αGalCer. Empty circles show cytokine 
release in the presence of the maximum dose of αGalCer and absence of CD1d-expressing 
APC. Results are expressed as mean ± SD of triplicate determinations. One representative 
experiment out of 3 is shown. Similar results were obtained with the other 5 cell lines in at 
least 2 experiments. (C) Potency of αGalCer on 66 iNKT cell clones established from PBMC 
(open symbols) or with 6 iNKT cell lines isolated from plaque tissue (closed symbols). ED50 
here defines the αGalCer dose inducing half-maximal IFN-γ release. Each point represents 
the ED50 value of one titration experiment, and for each group the median and interquartile 
range is given. ***P>0.001, unpaired Student’s t-test.  
 
Figure 5. Circulating iNKT cells are reduced in atherosclerosis patients. Distribution of iNKT 
cells in PBMC from healthy young donors (N) and from age-matched patients with 
asymptomatic atherosclerosis (ASA) or patients with symptomatic atherosclerosis (SA). iNKT 
cells were detected by FACS with αGalCer-loaded CD1d dimers (A and B) or with anti-TCR 
Vα24 and anti-TCR Vβ11 (C). The FACS gating strategy is depicted in Supporting 
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Information Fig. 7. In order to have a statistically quantifiable number of iNKT cells 
acquisition of at least 5 million CD3+ cells was performed. Data are reported as percentage 
after gating on CD3+ cells (A) or as percentage of total PBMC (B and C). Box plots with 
median, interquartile range and 5-95 percentiles are presented. * P<0.5, **P<0.01, 
***P<0.001, Mann-Whitney U test. 
 
Figure 6. Antigen activation of iNKT cells increases sprout outgrowth from EC spheroids. 
Conditioned media derived from iNKT cell cultures stimulated without (open bars) or with 
αGalCer (filled bars) were examined using the EC-spheroid model of in vitro angiogenesis. 
(A) Representative images of spheroids 24h after exposure to conditioned media. Spheroids 
were morphometrically analysed for total sprout number (B) and total sprout length (C). Bars 
undermarked “no APC” indicate the response to medium from iNKT cells cultured alone. 
Data are mean±SD from 6 experiments, each performed in triplicate. *P<0.05, **P<0.01, 
Student’s t-test. A second iNKT cell clone elicited similar proangiogenic effects (Supporting 
Information Fig. 3).  
 
Figure 7. Antigen activation of iNKT cells promotes EC migration. Confluent monolayers of 
EC were scrape-wounded and the subsequent rate of wound closure monitored over a time 
period of 12h by time lapse videomicroscopy. Acquired images were processed and 
analyzed using CellR software. (A) Representative images illustrating EC migration in the 
presence of CM+ or CM-. White lines indicate the location of the wound front and arrows 
indicate migration path length. (B) Quantitative analysis of the rate of EC migration from the 
initial wound front into the wound area (path length versus time). The data are representative 
of at least 30 experiments, each one performed in duplicate and values are given as 
averaged path length measurements ± SD from triple fixed observation fields/well. CM+ from 
different iNKT clones similarly enhanced motility (Supporting Information Fig. 5). (C) EC 
transmigration toward CM+ and CM- in Boyden chamber chemotaxis assay was quantified 
after a 6h incubation. Data are reported as mean±SD from 3 experiments each performed in 
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duplicate. ***, P < 0.001, Student’s t-test. The CM used in the illustrated experiments were 
obtained using HeLa cells as APC. In other experiments C1R cells were used as APC with 
comparable results (data not shown). 
 
Figure 8. Antigen activated iNKT cells produce IL-8 which promotes EC migration. (A) 
Intracellular IL-8 analyzed by FACS in plaque-derived lines either resting (APC alone) or 
activated with APC + αGalCer or with PMA + ionophore. Cells were stained intracellularly 
with anti-IL-8 and anti-CD3 mAb. Percentages of CD3+ cells producing IL-8 are indicated. 
The FACS gating strategy is depicted in Supporting Information Fig. 7. (B) Effects of 
inclusion of anti-IL-8 blocking mAb (upper panels) and of IL-8 immunodepletion (lower 
panels) of CM on EC migration examined by wound assay. Upper graphs: assays were 
performed in the absence (open circles) and presence of neutralizing anti-IL-8 mAb or 
isotype control IgG (closed or open triangles, respectively). Lower graphs: assays were 
performed with untreated CM (open circles), or CM subjected to immunodepletion protocols 
using neutralizing anti-IL-8 mAb or isotype control IgG (closed or open squares, 
respectively). Data shown are the average path length measurements ± SD from triple fixed 
observation fields/well of duplicate samples. Similar results were obtained in three 
experiments using CM from different iNKT cell clones. The CM used in the illustrated 
experiments were obtained using HeLa cells as APC. In other experiments C1R cells were 
used as APC with comparable results (data not shown). 
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Table 1. Clinical characteristics of the 36 patients. 
 no cardiovascular 
events (n = 21) 
cardiovascular 
events (n = 15) 
P value 
    
UCardiovascular risk factors    
Diabetes mellitus - no. (%)  1 (5) 7 (47) 0.004 
Body mass index (kg/m2) a) 23 ± 6 26 ± 5 0.06 
Hypercholesterolemia - no. (%)  2 (10) 4 (27) 0.17 
Arterial hypertension - no. (%)  4 (19) 6 (40) 0.17 
Smoking - no. (%)  3 (14) 4 (27) 0.35 
Male sex - no. (%)  13 (48) 11 (50) 0.90 
Age (years) a) 74 ± 14 79 ± 9 0.12 
    
UHistory of cardiovascular disease    
Coronary heart disease c) - no. (%)  0 (0) 15 (100)  
Cerebrovascular disease d) - no. (%)  0 (0)  5 (33)  
Arterial occlusive disease e) - no. (%)  0 (0) 6 (40)  
    
Autopsy (hours after death) a) 24 ± 12 24 ± 13 0.94 
Infection at death - no. (%) b) 9 (43) 8 (53) 0.53 
 
a) mean ± standard deviation. b) Infection at death was defined by the presence of two or more 
of the following criteria: body temperature >38°C, C-reactive protein >50mg/L, neutrophils 
(band forms) >10%, positive blood cultures. c) myocardial infarction, angina pectoris with 
myocardial ischemia, revascularization, d) cerebrovascular ischemic stroke, transient 
ischemic attack, revascularization, e) symptomatic peripheral arterial occlusive disease, 
symptomatic aortic aneurysm, revascularization.  
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Table 2. Lesional T cells in situ: confocal estimation of numbers of cells positive for 
CD3 and TCR Vα24 or TCR Vβ11. 
Patient AHA plaque 
type 
TCR Vα24+/total CD3+ cells (%) TCR Vβ11+/total CD3+ cells (%) 
1 IV 5/163 (3.1) 8/143 (5.6) 
2 IV 5/274 (1.8) 3/255 (1.2) 
3 V 5/180 (2.8) 6/192 (3.1) 
4 V 2/152 (1.3) 2/121 (1.6) 
5 VI 8/153 (5.2) 7/185 (3.8) 
  (2.8 ± 1.5) (3.1 ± 1.8) 
 
Values in parentheses express numbers of Vα24+/CD3+ or Vβ11+/CD3+ cells as a percentage 
of total CD3+ cells and are given for each individual patient biopsy and as the mean ± SD for 
all 5 biopsies examined.  
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Invariant natural killer T cells: linking inflammation and neovascularization in 
human atherosclerosis 
(Kyriakakis, Cavallari, Andert, Philippova, Koella, Bochkov, Erne, Wilson, Mori, Biedermann, 
Resink, De Libero) 
 
 
SUPPORTING INFORMATION 
 
 
METHODS 
 
Arterial tissue arrays and immunohistochemistry 
From each patient 3 autoptic arterial ring segments were taken, 1 each from the left common 
carotid, the left renal and the left common iliac artery. In each case the most affected ring sector 
was typed histopathologically according to the AHA consensus report [1], punched out, 
incorporated into tissue array paraffin blocks and processed for immunohistochemical staining 
[2]. The arterial sectors (3x36=108) were quantitatively analyzed for CD1d+ cells and CD68+ 
macrophages in the arterial intima (assessed as cells/mm2), and ectopic plaque 
neovascularization in the arterial intima was by staining for vWF. For the immunohistochemical 
analysis, mAb for CD1d (MCA982, Serotec), CD68 (M-0876, Dako) and polyclonal antiserum 
against von Willebrand Factor (vWF; M-0616, Dako) were used. Antibody was detected by a 
peroxidase-conjugated secondary antibody (Dako Envision), diaminobenzidine (Vector 
Laboratories) as a chromogenic substrate, and hemalaun as counterstain. The CD1d staining 
data are shown in Supporting Information Fig. S1. For each arterial sector, the intima area was 
morphometrically quantified and the numbers of CD1d+ and CD68+ cells in the intima were 
counted. Ectopic neovascularization was defined by the presence of any microvessels in the 
arterial intima [2]. The time between death and autopsy had no effect on the staining intensity of 
any of the epitopes analyzed (data not shown) 
 
Confocal analysis of iNKT cells in atherosclerotic plaque tissue 
Primary antibodies used were mouse anti-TCR Vα24 (clone C15), anti-TCR Vβ11 (clone C21 
[3]), rat anti-CD3 (MCA1477, Serotec), mouse anti-TCR Vα24-Jα18 (clone 6B11, BD) and 
mouse anti-CD1d (clone 51.1, eBioscience). Mouse and rat IgG were used as negative control 
antibodies (Serotec). Secondary antibodies used were biotin-conjugated donkey anti-mouse IgG 
followed by streptavidin-Cy2/-Cy5, Cy3-conjugated donkey anti-rat IgG (Jackson 
ImmunoResearch), goat anti-mouse IgG1 Alexa-555 and goat anti-mouse IgG2b Alexa-647 
(Invitrogen). Sections were counterstained for nuclei with Hoechst 33342 or DAPI. Sections were 
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analyzed on an Olympus BX61 fluorescence microscope and on a Zeiss LSM-510 or LSM-710 
confocal laser scanning microscope. Colocalization of the TCR Vα24 chain and the TCR Vβ11 
chain with CD3 was determined after image merging with Zeiss Image Browser (version 3.2.0). 
All CD3+ cells per intima were detected, counted and checked for double positivity. Images of 
tissue sections stained with anti-TCR Vα24-Jα18 and anti-CD1d were loaded into ImageJ, 
visualized using HiLo LUT for background correction (thresholding), and further processed to 
montages. 
 
Collagenase-assisted isolation of lymphocytes from fresh arterial tissue  
This was performed according to previously described protocols [4] with some modifications. 
Fresh arterial tissue biopsies obtained during thrombendarterectomy were used. Only patients 
with symptomatic disease undergo this clinical procedure. Due to local ethical restrictions bioptic 
tissue was primarily reserved for diagnostic purposes and only a small part was available to us 
for cell isolation. Excised arterial tissue was kept in PBS at room temperature until initiation of 
cell isolation procedures. The biopsy was transferred to a Petri dish containing cold PBS, cells 
were gently scraped off from the inside of the artery with a scalpel and retained. Then the artery 
was cut into small pieces, and after extensive washing transferred to a Falcon tube for digestion. 
Digestion to access tissue penetrating lymphocytes was performed in RPMI-1640 medium 
containing 5% HS (AB human serum Blutspendezentrum beider Basel, Basel Switzerland), 2 
mM L-glutamine, 1 mM sodium pyruvate, 100 μM non-essential aminoacids, 100 µg/ml 
kanamycin (all Invitrogen), and 100 U/ml recombinant IL-2 (defined as complete RPMI-1640 
medium) plus 20 µg/ml gentamycin (Gibco), ciproxin (HBayerH), and 2.5 μg/ml fungizone 
(HGibcoH) including 400 U/ml collagenase Type IV (Sigma) and 500 U/ml benzonase nuclease 
(HSigmaH). Scraped and collagenase-freed cells were pooled and separated from debris by 
Ficoll density gradient centrifugation. 
 
Multicolor FACS analysis of iNKT cells isolated from human atherosclerotic plaque tissue 
This was performed with the following reagents: anti-TCR Vα24-Alexa488, anti-TCR Vβ11-biotin 
followed by streptavidin-allophycocyanin, anti-CD3-Pacific blue or -Cascade yellow (Dako), anti-
CD4-Pacific blue, anti-CD8-PE-Cy5.5 (Caltag), and α-GalCer-loaded human CD1d dimers 
(produced in our laboratory, Cavallari M. et al., manuscript in preparation) followed by goat anti-
mouse IgG2b-PE. Cells were analyzed on a CYAN ADP flow cytometer (Dako), and events were 
gated to exclude nonviable cells on the basis of light scatter and propidium iodide (PI) 
incorporation as well as on pulse-width of the forward scatter signal to include only single living 
cells. 
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Multicolor FACS analysis of iNKT cells in total PBMC 
PBMC were separated from total blood cells with a ficoll gradient and iNKT cells were detected 
by Multicolor FACS analysis using αGalCer-loaded CD1d dimers, anti-TCR Vα24 and anti-TCR 
Vβ11 mAb (as described above) together with anti-CD3ε mAbs (BD). In order to have a 
statistically quantifiable number of iNKT cells acquisition of at least 5 million CD3+ cells was 
performed. Living cells were gated as above. 
 
Cell culture 
The APC lines MOLT-4 (ATCC CRL 1582), which expresses only negligible CD1d, and human 
CD1d-transfected C1R and HeLa (C1R-hCD1d and HeLa-hCD1d, respectively) [5] were 
maintained in RPMI-1640 medium containing 10% FCS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 100 μM non-essential aminoacids, and 100 μg/ml kanamycin.  
Isolation of iNKT cell clones from PBMC of healthy donors has been described before [6]. 
Mainly, four different clones were used in this study: iNKT1, iNKT2, iNKT3, iNKT4. iNKT cells 
were maintained in RPMI-1640 medium containing 5% HS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 100 μM non-essential aminoacids, 100 μg/ml kanamycin, and 100 U/ml recombinant 
IL-2. 
Human microvascular endothelial cell line HMEC-1 (EC) [7] was maintained in 
endothelial cell growth medium (ECGM) consisting of basal endothelial cell medium and 
endothelial cell growth supplement mix (PromoCell GmbH; C-22210) with addition of FCS to a 
final concentration of 10% 1 d before passaging into experimental culture dishes. For all 
experimental protocols, unless otherwise stated, EC were cultured in ECGM supplemented with 
FCS to a final concentration of 4%.  
 
Generation of conditioned medium (CM) 
ECGM with 4% FCS was used in all activation assays to generate conditioned medium (CM). 
APC were plated at 2.5 x 104/well in 96-well plates and incubated during the whole assay at 
37°C with vehicle or 100 ng/ml αGalCer. After 1 h iNKT cells (0.5-1 x 105/well) were added. Cell 
culture supernatants (CM- and CM+ indicate absence and presence of αGalCer during 
incubations, respectively) were harvested after 48 h, filtered (0.22 μm) and stored in aliquots at -
70°C. Unless otherwise specified for all in vitro assays on endothelial cell behavior CM was 
mixed 1:1 with fresh ECGM supplemented with FCS to a final concentration of 4%. 
 
Antigen titration assay and ED50 calculation 
APC were plated at 2.5 x 104/well in 96-well plates and incubated during the whole assay at 
37°C with vehicle or αGalCer at the indicated concentrations. After 1 h iNKT cells (0.5-1 x 
105/well) were added. Supernatants were harvested after 24-48 h and released cytokines were 
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measured by ELISA. The ED50 was calculated using a response curve mathematical fitting as 
the dose giving half maximal activation. 
 
Measurement of cytokines 
IL-4, TNFα, GM-CSF and IFNγ were quantified in cell culture supernatants by sandwich ELISA 
with the following mAb: 8D4-8 and MP4-25D2 (anti-human IL-4, BD), MAb1 and MAb11 (anti-
human TNFα, BD), 6804 and 3209 (anti-human GM-CSF, R&D), HB-8700 and γ69 (anti-human 
IFNγ, ATCC and [8]). Cytokine concentrations were expressed as mean pg/ml ± SD of triplicate 
samples by comparison to standards of human lymphokines. In some experiments CM were 
also analyzed for an array of cytokine/chemokine using the Bioplex Multiplex system (BioRad; 
Human17-Plex Panel 171-A11171) according to the manufacturers’ instructions. Beads specific 
for the following cytokines/chemokines were used: IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, 
IL-13, IL-17, MCP-1, MIP-1β, TNFα, IL-1β, IFNγ, G-CSF and GM-CSF. Data obtained by Bioplex 
assay are given in Supporting Information Fig. S2. 
 
IL-8 depletion of conditioned medium 
CM- and CM+ were incubated overnight at 4°C with 40 μg/ml of either anti-CXCL8/IL-8 (clone 
6217, R&D Systems) or isotype control IgG (Sigma-Aldrich) under rotation. The next day media 
were incubated for 2 h at 4°C and under rotation with 40 μl/ml of protein G Sepharose beads 
(GE Healthcare Bio-Sciences AB). Beads were pelleted by centrifugation (10,000 rpm for 30 min 
at 4°C) and the supernatants used to overlay EC in wound assays.  
 
Spheroid assay of angiogenesis in vitro 
EC spheroid assay in 3-D fibrin gels was performed as described previously [9]. EC spheroids 
were composed of 500 cells/spheroid and fibrin gels containing approximately 30 spheroids/gel 
were overlaid with either 500 μl ECGM, or with CM, with standard inclusion of 100 ng/ml VEGF 
and incubation under normoxic conditions for 24 h. For microscopic visualization of spheroids, in 
gel-fixation and staining with 0.5 μg/ml TRITC-conjugated phalloidin (Sigma-Aldrich) were 
performed. Outgrowth of capillary-like structures from spheroids was evaluated by morphometric 
analysis of the number and total length of sprouts per spheroid using AnalySIS software (Soft 
Imaging System GmbH). At least 20 spheroids from two parallel wells were analyzed for each 
experimental point.  
 
Proliferation assay 
Effects of CM on EC proliferation were evaluated by cell enumeration and BrdU incorporation 
assays. For cell enumeration, EC that had been growth arrested following 18 h culture in basal 
ECGM containing 0.1% FCS and 0.1% BSA were enzymatically detached and re-seeded at 2 x 
103 cell/well into 96-well plates and cultured for 3 d in the presence of CM. Cell numbers were 
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determined after complete adherence (d 0) and thereafter daily by trypsinization and counting in 
a Coulter counter. For BrdU incorporation assay EC were seeded into 96-well dishes (2 x 103 
cells/well), growth arrested for 18 h, then cultured with CM for 24 h followed by use of a BrdU 
colorimetric assay according to manufacturers’ instructions (Roche Diagnostics). Measurements 
were made in triplicate wells for both cell enumeration and BrdU incorporation assays.  
 
Wound assay and time-lapse videomicroscopy 
Confluent monolayer cultures of EC were scrape-wounded (5 mm wide wound) and then normal 
growth medium substituted with CM. In some experiments CM included neutralizing anti-
CXCL8/IL-8 (clone 6217, R&D Systems) or isotype control IgG (Sigma-Aldrich), or was depleted 
of IL-8 prior to wound assay. Wound closure was filmed at a rate of 1 frame/15 min, for at least 
12 h using an Olympus IX-81 inverted time-lapse microscope equipped with a digital camera 
within a humidified incubation chamber with 5% CO2
 
at 37°C (Olympus Optical). Acquired 
images were processed and analyzed using CellR software (Soft Imaging System GmbH). Each 
experiment contained parallel wells for every experimental condition. Three different fields of 
observation at the initial wound front (time 0) were randomly selected and fixed and the distance 
of cell migration into the wound area was measured every 15 min. Every 45 min a data point for 
path length was calculated as the average path length from three consecutive 15 min frames. 
Representative videos of the assay are shown in Supporting Information FigS5video1-CM-.avi 
and FigS5video1-CM+.avi. 
 
Boyden chamber-transmigration assay 
Migration assay was performed in a modified 96-well Boyden micro-chamber (MBA96, Neuro 
Probe) as described previously [9, 10]. Membranes (10 μm pore size) were precoated on the 
underside only with collagen I in PBS (50 µg/ml) and CM was placed into the lower wells of the 
chamber. Upper wells of the chamber contained 5 x 104 EC/well in DMEM containing 0.1% BSA. 
After a 6 h incubation period cells that had migrated through to the underside of the membrane 
were fixed and stained with Diff-Quik® Staining Kit (Dade Behring). The membrane was 
scanned with a desktop scanner, and the intensity of spots (given as AU) analyzed using Aida 
software. 
 
Staining for intracellular IL-8 
APC were first pulsed for 1 h with 100 ng/ml αGalCer or vehicle and then cocultured with iNKT 
cells isolated from plaques or from PBMC. In parallel lymphocytes and iNKT cells were directly 
stimulated with PMA/ionomycin (200 ng/ml and 2 μg/ml) as a positive activation control. After 20 
min, Brefeldin A (10 μg/ml, Sigma-Aldrich) was added and incubation allowed to proceed for an 
additional 16 h. After washing, the cells were fixed with 2% PFA and permeabilized with 0.1% of 
saponin. Immunofluorescence analysis was performed using anti-IL-8 (clone 6217, R&D 
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Systems) followed by goat-anti-mouse IgG1 PE-labeled (SBA) and anti-CD3-biotin (clone S4.1; 
also known as 76D, Caltag) followed by streptavidin-APC (Caltag). Cells were analyzed on a 
CYAN ADP flow cytometer and data analyzed using Summit™ 4.3 software (Dako).  
 
 
REFERENCES 
 
1 Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Jr., 
Rosenfeld, M. E. et al., A definition of advanced types of atherosclerotic lesions and a 
histological classification of atherosclerosis. A report from the Committee on Vascular 
Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995. 
92: 1355-1374. 
2 Fleiner, M., Kummer, M., Mirlacher, M., Sauter, G., Cathomas, G., Krapf, R. and 
Biedermann, B. C., Arterial neovascularization and inflammation in vulnerable patients: 
early and late signs of symptomatic atherosclerosis. Circulation 2004. 110: 2843-2850. 
3 Dellabona, P., Padovan, E., Casorati, G., Brockhaus, M. and Lanzavecchia, A., An 
invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by 
clonally expanded CD4-8- T cells. J Exp Med 1994. 180: 1171-1176. 
4 De Libero, G., Rocci, M. P., Casorati, G., Giachino, C., Oderda, G., Tavassoli, K. and 
Migone, N., T cell receptor heterogeneity in gamma delta T cell clones from intestinal 
biopsies of patients with celiac disease. Eur J Immunol 1993. 23: 499-504. 
5 Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P. and 
Kronenberg, M., CD1d-mediated recognition of an alpha-galactosylceramide by natural 
killer T cells is highly conserved through mammalian evolution. J Exp Med 1998. 188: 
1521-1528. 
6 Franchini, L., Matto, P., Ronchetti, F., Panza, L., Barbieri, L., Costantino, V., 
Mangoni, A. et al., Synthesis and evaluation of human T cell stimulating activity of an 
alpha-sulfatide analogue. Bioorg Med Chem 2007. 15: 5529-5536. 
7 Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C. 
and Lawley, T. J., HMEC-1: establishment of an immortalized human microvascular 
endothelial cell line. J Invest Dermatol 1992. 99: 683-690. 
8 Gallati, H., Pracht, I., Schmidt, J., Haring, P. and Garotta, G., A simple, rapid and 
large capacity ELISA for biologically active native and recombinant human IFN gamma. J 
Biol Regul Homeost Agents 1987. 1: 109-118. 
9 Bochkov, V. N., Philippova, M., Oskolkova, O., Kadl, A., Furnkranz, A., Karabeg, E., 
Afonyushkin, T. et al., Oxidized phospholipids stimulate angiogenesis via autocrine 
mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic 
lesions. Circ Res 2006. 99: 900-908. 
10 Ivanov, D., Philippova, M., Allenspach, R., Erne, P. and Resink, T., T-cadherin 
upregulation correlates with cell-cycle progression and promotes proliferation of vascular 
cells. Cardiovasc Res 2004. 64: 132-143. 
11 Mutschelknauss, M., Kummer, M., Muser, J., Feinstein, S. B., Meyer, P. M. and 
Biedermann, B. C., Individual assessment of arteriosclerosis by empiric clinical profiling. 
PLoS ONE 2007. 2: e1215. 
 
 
72
SUPPORTING DATA 
 
INDEX OF SUPPORTING DATA 
 
Table 1 Clinical data from the patients who donated blood. 
 
Figure 1 shows staining controls for CD1d and a representative arterial tissue sector. 
 
Figure 2 shows that IL-8 is amongst different cytokines released by antigen-activated human 
iNKT cell clones as determined by Bio-Plex cytokine assay. 
 
Figure 3 shows stimulation of sprouting from EC spheroids following antigen-activation of 
different human iNKT cell clones and also illustrates the requirement for APC-
presentation of αGalCer. 
 
Figure 4 shows effects of CM on EC-proliferation. 
 
Figure 5 shows stimulation of endothelial cell motility following antigen-activation of different 
human iNKT cell clones. 
 
Figure 6 shows FACS analysis for expression of intracellular IL-8 by antigen-activated human 
iNKT cell clones. 
 
Figure 7 depicts FACS gating strategies. 
 
Videos show EC motility in the presence of CM- (FigS5video1-CM-.avi) and CM+ (FigS5video2-
CM+.avi).  
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Table 1. Clinical data from the patients who donated blood 
 
UPN gender age (yr) a.h. a) d.m. b) h.c. c) s. d) f.h. e) 
 
Patients with ≥ 2 cardiovascular events in the past (symptomatic arteriosclerosis, SA) 
 
773 f 76 no no yes no yes 
602 m 76 yes yes yes yes no 
756 m 76 no no no yes yes 
655 f 77 yes yes yes no yes 
749 m 77 no yes yes yes yes 
664 m 79 yes no yes yes no 
716 f 82 yes yes no no no 
764 m 84 yes no no yes no 
582 m 89 no no no no no 
698 f 92 yes no no no no 
 
Patients without cardiovascular events in the past (asymptomatic arteriosclerosis, ASA) 
 
622 f 74 no no no no no 
581 f 77 yes no no no no 
601 f 78 no no yes no yes 
771 m 78 yes no no yes yes 
651 m 79 yes no no yes no 
624 f 79 yes yes no no yes 
632 f 81 no no no no yes 
596 m 84 no no no yes no 
741 f 85 yes no no no no 
574 m 88 yes no no no no 
 
UPN, unique patient number. a) arterial hypertension. b) diabetes mellitus. c) hypercholesterolemia. 
d) smoking. e) positive family history for cardiovascular events. For detailed definition of 
cardiovascular events see reference [11].  
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 A B C
 
Figure 1. CD1d staining controls and representative arterial sector. mAb for CD1d 
(MCA982, Serotec) were used. (A) CD1d-transduced C1R cells. (B) Untransduced C1R cells. 
(C) Intramural CD1d positive cells in the common iliac artery. Scale bar, 50 μm. 
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Figure 2. Antigen-activated human iNKT cells release different cytokines. CM from different 
activation conditions were analyzed for the presence of an array of cytokines by MultiplexPlex 
assay.  
ECGM = normal EC growth medium;  
M, H, iNKT = CM from APC (MOLT-4, HeLa-hCD1d) or iNKT cultured alone; 
M/H:αGC = CM from cultures of αGalCer-pulsed APC (MOLT-4 or HeLa-hCD1d); 
iNKT + αGC = CM from iNKT cultured in the presence of αGalCer; 
iNKT + M/H = CM from cultures of iNKT and APC (MOLT-4 or HeLa-hCD1d); 
iNKT + M/H:αGC = CM from cultures of iNKT and αGalCer-pulsed APC (MOLT-4 or HeLa-
hCD1d).  
Data are representative of 2 experiments performed on the same iNKT cell line. 
76
30
20
10
40
S
pr
ou
t N
um
be
r
0
 
Figure 3. Only CM from antigen-activated iNKT cell clones stimulates sprouting from EC 
spheroids. The EC-spheroid in vitro angiogenesis assay was applied to test angiogenic 
potentials of CM collected from the following culture sets: 
ECGM = normal EC growth medium alone or with inclusion of αGalCer (ECGM:αGC);  
no iNKT = APC lines MOLT-4 (expressing negligible CD1d) or HeLa-hCD1d or C1R-hCD1d 
alone (M, H, C) or pulsed with αGalCer (M:αGC, H:αGC, C:αGC); 
no APC = iNKT cell clones alone (iNKT1 and iNKT2) or with inclusion of αGalCer (iNKT1:αGC or 
iNKT2:αGC),  
iNKT and APC expressing negligible CD1d = iNKT1 + M or + M:αGC; 
iNKT and hCD1d-transfected APC = iNKT1/iNKT2 + H/C, or + H:αGC/C:αGC).  
Normal endothelial cell growth medium (ECGM) served as the baseline assay control. 
Morphometric analysis of sprout number and total sprout length was performed after a 24 h 
assay period. Data (mean ± SD) are from at least 3 experiments. **, P<0.001, Student’s t-test.  
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Figure 4. CM from antigen-activated iNKT cells does not stimulate proliferation. Effects of 
CM- and CM+ on EC proliferation were measured by BrdU incorporation (A) and cell 
enumeration (B) assays. EC cultured in normal ECGM served as baseline control and for BrdU 
assays thrombin (4U/ml) was included as a positive activation stimulus. For BrdU incorporation 
assay EC were seeded into 96-well dishes (2 x 103 cells/well), growth arrested for 18 h, then 
cultured with CM for 24 h followed by use of a BrdU colorimetric assay according to 
manufacturers’ instructions (Roche Diagnostics). For cell enumeration, EC that had been growth 
arrested following 18 h culture in basal ECGM containing 0.1% FCS and 0.1% BSA were 
enzymatically detached and re-seeded at 2 x 103 cell/well into 96-well plates and cultured for 3 d 
in the presence of CM. Cell numbers were determined after complete adherence (d 0) and 
thereafter daily by trypsinization and counting in a Coulter counter. Measurements were made in 
triplicate wells for both cell enumeration and BrdU incorporation assays. Data are mean ± SD 
from 3 separate experiments using iNKT cell clone iNKT1. **, P< 0.001, Student’s t-test. 
Experiments in which CM from other iNKT cell clones was tested yielded similar results. 
Whereas EC start to proliferate after 24 h under control conditions or in the presence of CM-, 
and at similar rates, there was no proliferation in the presence of CM+ and cell death began to 
occur after 48 h. The latter is most likely due to the fact that CM+ contains high levels of IFNγ 
and TNFα, which can induce apoptosis in EC (Molostvov, G., A. Morris, P. Rose, and S. Basu. 
2002. Modulation of Bcl-2 family proteins in primary endothelial cells during apoptosis. 
Pathophysiol Haemost Thromb. 32:85-91).  
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Figure 5. CM from antigen-activated iNKT cell clones stimulates endothelial cell motility. 
Wounded EC monolayers were incubated with CM from cultures of APC (HeLa-hCD1d) ± 
αGalCer (A) or cultures of three different iNKT clones cocultured with APC ± αGalCer (B-D). 
Closed and open symbols indicate the presence and absence of αGalCer, respectively. Motility 
of EC was monitored over a 12 h period by time lapse videomicroscopy (see FigS5video1-CM-
.avi and FigS5video2-CM+.avi for representative recordings) and the rate of EC migration from 
the initial wound front into the wound area (path length versus time) was measured by 
morphometric analysis of acquired images. Data (averaged ± SD) shown here are from a single 
experiment in which the different CM were tested in parallel and in duplicate wells. The data are 
representative of at least 30 other motility experiments in which different CM were tested 
individually or in parallel.  
 
FigS5video1-CM-.avi. Wounded EC monolayers were incubated with CM from non-activated 
iNKT cells (iNKT1 cocultured with HeLa-hCD1d) and motility of EC monitored over a 12 h period 
by time lapse videomicroscopy.  
 
FigS5video2-CM+.avi. Wounded EC monolayers were incubated with CM collected from 
activated iNKT cells (iNKT1 cocultured with αGalCer-pulsed HeLa-hCD1d) and motility of EC 
monitored over a 12 h period by time lapse videomicroscopy. 
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Figure 6. Antigen-activated iNKT cells express IL-8. Human iNKT1 and iNKT3 cell clones 
were activated with PMA/ionophore or APC + αGalCer (HeLa-hCD1d:αGC) or were non-
activated (HeLa-hCD1d). Intracellular IL-8 was detected by FACS after staining fixed and 
permeabilized cells with anti-CD3 and anti-IL8 mAb. Similar results were obtained with two other 
iNKT cell clones. 
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Figure 7. FACS gating strategies. (A) Cells were gated for lymphocytes according to forward 
scatter (FSC) and side scatter (SSC) properties (FSSS gate). This gating was used in Fig. 8A 
and Supporting Information Fig. 6. (B) Dead cells (propidium iodide, PI) and multipletts (Pulse 
Width, PW) were excluded from FSSS cells by further gating on the PWPI gate. This gating was 
used in Fig. 5B and 5C. (C) Single living lymphocytes (FSSS and PWPI gated) gated as being 
CD3-positive T cells (CD3 gate). This gating was used in Fig. 4A and Fig. 5A. (D) T cells were 
gated according to their expression of TCR Vα24 and TCR Vβ11 chains as iNKT cells if being 
double-positive (iNKT gate). This gating was used in Fig. 4A. After gating the cells were further 
analyzed for the markers of interest. 
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Project 2 
Molecular mechanisms involved in response to iNKT cell activation during 
neovascularization 
The results of this project have been drafted as a preliminary manuscript. 
IL-8-mediated angiogenic responces of endothelial cells to lipid-antigen activation of 
iNKT cells depend on EGFR transactivation.  
(The manuscript is appended) 
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ABSTRACT  
Invariant  natural  killer  T  (iNKT)2  cells  are  a  unique  T  cell  subset  contributing  to  both  innate  and 
acquired  immunity.  This  T  cell  subset  is  CD1d‐restricted  and  specific  for  glycolipids,  including  the 
marine  sponge  α‐galactosylceramide  (α‐GalCer)  and  unidentified  self‐molecules.  In  advanced 
atherosclerotic  plaques,  focal  collections  of  inflammatory  cells  correlate with  areas  of  intraplaque 
neovascularisation. We  recently  found  that  iNKT  cells  can  promote  plaque  neovascularization  by 
enhancing endothelial cell (EC) migration and sprouting in an interleukin‐8 (IL‐8)‐dependent manner. 
Here  we  investigate  the  participating  signal  transduction  mechanisms.  EC  were  treated  with 
conditioned medium derived from  iNKT cells activated (CM+) or not (CM‐) by αGalCer. CM+‐induced 
migration  in  2D‐wound  assay  and  sprout  outgrowth  in  a  3D‐model  of  angiogenesis  in  vitro  was 
abolished by epidermal growth factor receptor (EGFR)  inhibitors cetuximab, gefitinib or  lapatinib, as 
was  CM+‐induced  acquisition  of  angiogenic  morphology.  Immunoblotting  and  reverse  protein 
microarray  (RPA)  revealed  that  CM+  increased  (vs.  CM‐)  phosphorylation  of  several  signalling 
effectors  including  focal  adhesion  kinase  (FAK),  Src,  extracellular‐signal‐regulated  kinase,  c‐Jun  N‐
terminal kinase, p38‐mitogen activated protein kinase, signal transducer and activator of transcription 
1 and 3. EGFR‐inhibition or  IL‐8‐immunodepletion of CM+ abrogated activation of FAK and Src only. 
RPA also revealed CM+‐induced phosphorylation of EGFR, which was blocked by EGFR‐inhibition or IL‐
8 immunodepletion of CM+. Thus IL‐8‐dependent activation of angiogenic behaviour in EC in response 
to lipid‐antigen activation of iNKT occurs via transactivation of EGFR. The data support EGFR as a non‐
traditional  proangiogenic  receptor  driving  inflammation‐associated  neovascularization  in 
atherosclerotic disease. 
 
 
Short title: EGFR transactivation in iNKT cell driven angiogenesis 
 
 
Keywords:  plaque  neovascularization,  inflammation,  EGFR  transactivation,  EGFR  pharmacological 
inhibition, motility, signal transduction 
 
2Abbreviations  used:  APC,  antigen  presenting  cell;  αGalCer,  α‐galactosylceramide;  iNKT  cells, 
invariant natural killer T cells; CM, conditioned medium; EC, endothelial cells; ECGM, endothelial cell 
growth  medium;  EGFR,  epidermal  growth  factor  receptor;  GSK3β,  glycogen  synthase  kinase  3β; 
GPCRs, G‐protein coupled receptors; HB‐EGF, heparin‐binding EGF‐like growth factor; HCMV, human 
cytomegalovirus; HMEC‐1, human microvascular endothelial cell line; IL‐8, interleukin 8; MMP, matrix 
metalloproteinase;  RPA,  reverse  protein microarray;  FAK,  focal  adhesion  kinase;  Erk,  extracellular‐
signal‐regulated  kinase;  Jnk,  c‐Jun N‐terminal  kinase;  p38MAPK, mitogen  activated  protein  kinase; 
S6rp,  S6  ribosomal  protein,  STAT,  signal  transducer  and  activator  of  transcription.
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INTRODUCTION 
 
Atherosclerosis is now generally accepted as an inflammatory disease, characterized by degenerative 
changes and extracellular accumulation of  lipid and cholesterol. The evolving  inflammatory reaction 
plays  an  important  role  in  the  initiation  of  atherosclerotic  plaques  and  their  destabilization, 
converting a chronic process into an acute disorder with ensuing thromboembolism [1]. The main risk 
factor for the throboembolic complications of atherosclerotic disease is the development of complex 
and  unstable  forms  of  atherosclerotic  plaques  that  are  prone  to  spontaneous  erosion,  fissure  or 
rupture.  Most  clinical  events  result  from  unstable  plaques  which  do  not  appear  severe  on 
angiography, and thus plaque stabilization may be a way to reduce morbidity and mortality. 
Progressive atherosclerotic disease and the development of acute lesion instability are linked 
with  plaque  angiogenesis  (reviewed  in  [2‐6]).  In  early  lesions  local  hypoxic  conditions within  the 
developing  and  expanding  intima  induce  vasa  vasorum  angiogenesis  and medial  infiltration, which 
prevents  cellular  death  and  contributes  to  plaque  growth  and  stabilization.  However,  ectopic 
neovessels are detrimental  to plaque  integrity because  they are  immature and  fragile and promote 
development  of  an  unstable  haemorrhagic  rupture‐prone  environment.  Intraplaque  haemorrhage 
autoamplifies both the angiogenic process and the  intraplaque  inflammatory response, and thereby 
exacerbates plaque vulnerability.  In more advanced plaques,  focal collections of  inflammatory cells 
correlate with areas of  intraplaque neovascularization and haemorrhage, suggesting  that  release of 
growth factors and cytokines by macrophages and leukocytes may have a key role in modulating the 
neovascularization process.  
Although  neovascularization  and  inflammation  are  recognized  as  closely  linked  processes, 
specific  inflammatory  cell  protagonists  and  angiogenic  mediators  underlying  intraplaque 
neovascularization remain poorly understood. Invariant natural killer T (iNKT) cells are a unique T cell 
subset  contributing  to  both  innate  and  acquired  immunity.  This  peculiar  T  cell  subset  is  CD1d‐
restricted and specific for glycolipids, including unidentified self‐molecules and the marine sponge α‐
galactosylceramide  (α‐GalCer)  [7].  We  recently  identified  iNKT  cells  as  novel  cellular  candidates 
promoting  plaque  neovascularization  and  destabilization  in  human  atherosclerosis  [8].  We 
demonstrated a  significant association of CD1d+  cells with neovascularization  in plaques as well as 
intraplaque  infiltration  of  iNKT  cells  in  advanced  human  atherosclerotic  lesions  [8].  Activation  of 
plaque‐derived iNKT cell lines by CD1d‐expressing antigen presenting cells (APC) presenting α‐GalCer 
enhanced endothelial cell  (EC) migration  in vitro and promoted sprout outgrowth  in an EC‐spheroid 
model of in vitro angiogenesis. Proangiogenic activity was ascribed to interleukin‐8 (IL‐8) released by 
the activated iNKT cells.  
The notion of IL‐8 as plaque destabilizing and/or angiogenic factor in human atherosclerosis is 
not new. In 1996 Wang et al, disclosed IL‐8 expression primarily in the macrophage‐abundant zones of 
the plaque by in situ hybridization and immunohistochemical staining of human coronary atheromata 
[9]. IL‐8 was shown to downregulate expression of tissue inhibitor of metalloproteinase‐1 expression 
in  cholesterol‐laden  human macrophages,  thereby  favouring  local  extracellular matrix  degradation 
and  plaque  instability  [10].  Simonini  et  al.,  reported  that  IL‐8  was  expressed  at  higher  levels  in 
homogenates  of  coronary  artherectomy  tissue  than  in  homogenates  of  internal mammary  artery 
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tissue;  however,  localization  of  IL‐8  (immunohistochemistry  and  in  situ  RT‐PCR) was  exclusive  to 
coronary atherectomy tissue sections and correlated with the presence of factor VIII–related antigen 
[11]. Corneal  in  vivo  angiogenesis  induced by  coronary  atherectomy homogenates was  completely 
inhibited by anti‐IL‐8 antibodies, revealing the relevance of atheroma IL‐8 to angiogenesis [11].  
However, signal transduction pathways mediating angiogenic properties of IL‐8 remain poorly 
defined.  IL‐8  has  been  reported  to  affect  different  aspects  of  angiogenic  behaviour  of  EC  and  by 
different  signal  transduction mechanisms.  Li  et  al.,  reported  a  direct  stimulatory  effect  of  IL‐8  on 
proliferation, survival and matrix metalloproteinases (MMP) [12]. Schraufstatter et al., demonstrated 
that  IL‐8  induces a haptotactic response and also Rac‐dependent cytoskeletal reorganization  leading 
to cell retraction and gap  formation between adjacent cells  [13]. Schraufstatter et al., subsequently 
reported that IL‐8‐mediated migration depended on cathepsin B activity and also involved epidermal 
growth factor receptor (EGFR) [14]. While we have demonstrated that lipid‐antigen activation of iNKT 
cells  increases  the  migration  capacity  of  EC  in  an  IL‐8  dependent  manner,  associated  signalling 
pathways  involved were not studied. Here we report that stimulatory effects of activated  iNKT cells 
on  EC  migration,  sprouting  and  actin  reorganization  are  driven  through  EGFR  with  selective 
downstream activation of focal adhesion kinase (FAK) and Src. 
 
EXPERIMENTAL 
 
Lipid antigen activation of iNKT cells and generation of conditioned medium 
The generation of conditioned medium (CM) following activation of CD1d‐restricted iNKT cells (clones 
isolated  from PBMC of healthy donors  [15] by CD1d‐expressing APC  (human CD1d‐transfected HeLa 
[16]) presenting α‐GalCer  lipid antigen was carried out as detailed previously  [8]. Briefly, APC were 
suspended in EC growth medium (ECGM) consisting of basal endothelial cell medium and endothelial 
cell growth supplement mix (C‐22210; PromoCell GmbH; Heidelberg, Germany) with addition of FCS 
to  a  final  concentration  of  4%  FCS  (ECGM‐4%  FCS),  plated  at  2.5  x  104/well  in  96‐well  plates  and 
preincubated for 1 h at 37°C with vehicle or 50‐100 ng/ml α‐GalCer. The iNKT cells (0.5‐1 x 105/well) 
were  added  and  culture  supernatants  (CM‐  and  CM+  indicate  absence  and  presence  of  α‐GalCer 
during APC preincubation,  respectively) were harvested after 48 h,  filtered  (0.22 μm) and stored  in 
aliquots at  ‐70°C. For some experiments the CM were subjected to  IL‐8  immunodepletion protocols 
using  anti‐CXCL8/IL‐8  (clone 6217, R&D  Systems Europe  Ltd., Abingdon, UK) or  isotype  control  IgG 
(Sigma‐Aldrich, Buchs, Switzerland) as detailed before [8].  
 
Endothelial cell culture 
Human microvascular endothelial cell line HMEC‐1 [17] were normally maintained in ECGM‐10% FCS. 
Seeding densities for experiments were as follows: 2 x 104 cells/well into 24‐well plates or onto 0.1% 
gelatin‐coated glass cover slips inserted into 24‐well plates for morphology analysis or confocal 
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microscopy respectively, 8 x 104 cells/well into 24‐well plates for wound assay, 2 x 105 cells/well into 
6‐well plates for immunoblotting and 1 x 104 cells/well into 96‐well plates for reverse phase protein 
array (RPA). Each experiment contained duplicate or triplicate wells for every experimental condition. 
Culture medium was removed after overnight adherence, cell layers were rinsed with PBS and 
stimulation protocols were initiated by addition of either ECGM‐4% FCS (control) or CM mixed 1:1 
with ECGM‐4% FCS. When used, the EGFR tyrosine kinase inhibitors gefitinib (Iressa®, Astra Zeneca 
AG, Zug, Switzerland) and lapatinib (Tykerb®, GlaxoSmithKline, London, UK), or the neutralizing anti‐
EGFR monoclonal antibody cetuximab (Erbitux®, Merck KGaA, Darmstadt, Germany) and isotype 
control IgG (Sigma‐Aldrich) were added to cultures 1 h prior to and again at the start of experiments.  
 
Wound assay and time‐lapse videomicroscopy 
Real  time  analysis  of  cell migration  in wound  assay was performed  as  detailed before  [8]. Briefly, 
closure of scrape‐wounded cultures of HMEC‐1 was filmed over 12 h using an Olympus IX‐81 inverted 
time‐lapse  videomicroscope  (Olympus  Optical  Co.,  Geneva,  Switzerland).  Acquired  images  were 
processed and analyzed using CellR software (Soft Imaging System GmbH, Muenster Germany). Three 
different  fields of observation at  the  initial wound  front  (time 0) were  randomly selected and  fixed 
and the distance of cell migration  into the wound area was measured every 15 min. Every 45 min a 
data point for path  length was calculated as the average path  length from three consecutive 15 min 
frames.  
 
Spheroid assay of angiogenesis in vitro 
The EC  spheroid assay of angiogenesis  in  vitro  in 3‐D  fibrin gels has been detailed previously  [18]. 
After 24 h of experimental  incubation spheroids were fixed  in‐gel and stained with 0.5 μg/ml TRITC‐
conjugated phalloidin (Sigma‐Aldrich). Outgrowth of capillary‐like structures from spheroids (at  least 
20  for  each  experimental  point)  was  evaluated  by morphometric  analysis  of  the  total  length  of 
sprouts per spheroid using AnalySIS software (Soft Imaging System GmbH) [18]. 
 
Immunofluoresence microscopy 
After 24 h of experimental incubation HMEC‐1 were fixed with 4% paraformaldehyde, permeabilized 
with 0.1% Triton X‐100 in PBS and stained with 0.5 μg/ml TRITC‐conjugated phalloidin (Sigma‐Aldrich) 
followed  by  counterstaining  of  nuclei with  Hoechst  (Molecular  Probes,  Leiden,  Netherlands)  [19]. 
After  extensive  washes  with  PBS  samples  were  mounted  in  Mowiol  4.88  reagent  (Calbiochem, 
Darmstadt, Germany)  and  analysed using  an  LSM‐710  Laser  Scanning Microscope  (Zeiss,  Feldbach, 
Switzerland).  
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Immunoblotting 
Whole cell  lysis and  immunoblotting procedures have been detailed  [20, 21]. The  following primary 
antibodies were used: rabbit anti‐phosphothr202/tyr204‐Erk (extracellular‐signal‐regulated kinase), rabbit 
anti‐phosphoser473‐Akt,  phosphoser9‐GSK3β  (glycogen  synthase  kinase  3β)  rabbit  anti‐
phosphoThr180/Tyr182‐p38MAPK (mitogen activated protein kinase) (Cell Signalling, Bioconcept, Allschwil, 
Switzerland) phosphotyr397‐FAK (BD, Allschwil Switzerland), goat anti‐GAPDH (Abcam, Cambridge, UK). 
Secondary HRP‐conjugated  goat  anti‐mouse  IgG,  anti‐rabbit  IgG  (Southern  Biotechnology,  BioReba 
AG, Reinach, Switzerland) or donkey anti‐goat  IgG  (Santa Cruz, Heidelberg, Germany)  together with 
Amersham  ECL  (Amersham  Biosciences,  Little  Chalfont,  UK)  were  used  for  detection  of 
immunoreactive  proteins.  Scanned  images  of  autoradiograms  were  analyzed  using  AIDA  Image 
software. 
 
Reverse protein microarray 
All  experimental  and  analytical  protocols  for  the  platform  of  planar‐waveguide  reverse  (phase) 
protein  microarray  (RPA)  as  developed  by  Zeptosens  (www.zeptosens.com)  have  been  precisely 
detailed  previously  [22,  23]  as  have  the  sources  and  validation  of  the  phospho‐specific  antibodies 
used  (phosphotyr1173‐EGFR, phosphothr202/tyr204‐Erk, phosphoThr180/Tyr182‐p38MAPK, phosphoTyr701‐STAT1 
(signal transducer and activator of transcription 1), phosphotyr705‐STAT3, phosphoThr183/Tyr185‐Jnk (c‐Jun 
N‐terminal kinase), p‐Aktser473, phosphoser235&ser236‐S6rp  (S6  ribosomal protein) phosphoTyr576/577‐FAK, 
phosphoTyr416‐Src) [23].  
 
In situ zymography 
Gelatinolytic activity of the metalloproteinases MMP‐2 (72kDa gelatinase A/type IV collagenase) and 
MMP‐9  (92  kDa  gelatinase  B/type  IV  collagenase)  was measured  by  in  situ  zymography.  Sample 
supernatants collected from EC treated with CM were loaded on 10% polyacrylamide gels containing 
gelatin  (1 mg/ml). The gel was washed  in 2.5%  (v/v) Triton X‐100  followed by  repeated washes  in 
distilled water,  and  then  incubated  overnight  at  37°C  in  a  gelatin  renaturation  buffer  followed  by 
staining with 2% Coomassie Blue. Proteolysis was detected as white zones in a dark field.  
 
Statistical analysis 
Statistical  analysis  was  performed  using  GraphPad  Prism  software  5.0  (GraphPad  Software, 
http://www.graphpad.com) using Student’s  t  test or one‐way ANOVA  followed by Tukey’s multiple 
comparison tests with P<0.05 taken as statistically significant. 
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RESULTS 
 
Angiogenic behavioural responses induced in EC in response to lipid antigen activation of iNKT cells 
are sensitive to EGFR inhibition 
We have demonstrated that activation of iNKT cells by APC presenting the lipid antigen α‐GalCer can 
elicit  angiogenesis  in  vitro  and  identified  IL‐8  released  by  iNKT  cells  as  the  chemokine  involved  in 
endothelial cell migration and sprouting; the migration response of HMEC‐1 to culture supernatants 
derived  from  α‐GalCer‐activated  iNKT  cells  could be  completely  abrogated by  inclusion of  anti‐IL‐8 
blocking antibodies or using culture supernatants which had been subjected to  immunodepletion of 
IL‐8 prior to assay [8]. Here, and since IL‐8 has previously been shown to transactivate EGFR in HMEC‐
1 [14], we  investigate a possible  involvement of EGFR  in the angiogenic response of HMEC‐1 to  lipid 
antigen activation of iNKT cells.  
Conditioned media were  collected  from  iNKT  cell  cultures  either  stimulated with  α‐GalCer 
(CM+)  or  not  (CM‐),  applied  to  scrape‐wounded HMEC‐1 monolayers  or  fibrin‐embedded HMEC‐1 
spheroids  without  (control)  or  with  inclusion  of  either  anti‐EGFR  blocking monoclonal  antibodies 
(cetuximab)  or  EGFR  tyrosine  kinase  inhibitors  (gefitinib  or  lapatinib).  Figure  1  recapitulates  our 
previous findings that migration of HMEC‐1 into the wound area is increased in the presence of CM+ 
(vs. CM‐)  and demonstrates  that  each of  the  EGFR  inhibitory  treatments markedly  attenuated  the 
enhanced  migration  response  to  CM+  (Figure  1  B,  D,  F).  The  migration  of  HMEC‐1  exposed  to 
supernatants from non‐activated iNKT (CM‐) was minimally affected by the treatments (Figure 1 A, C, 
E).  Figure 2  recapitulates our previous  findings of  a  stimulatory effect of CM+  (vs. CM‐) on  sprout 
outgrowth  in the EC‐spheroid model of angiogenesis  in vitro and demonstrates complete abrogation 
of  this  effect  in  the  presence  of  EGFR  tyrosine  kinase  inhibitor  gefitinib.  Sprout  outgrowth  in  the 
presence  of  CM‐  was  not  affected  by  gefitinib.  We  did  not  examine  the  effects  of  lapatinib  or 
cetuximab in this experimental model.  
We next examined the influence of iNKT cell activation on cell morphology following culture of 
HMEC‐1  in  the  presence  of  CM+  or  CM‐  for  24  h.  Phase  contrast microscopy  revealed  that  CM+ 
treated  cells  were  more  elongated  and  exhibited  more  frequent  and  pronounced  lamellipodial 
extensions,  characteristics  of  the  motile  phenotype  (Figure  3A).  Accordingly,  evaluation  of  actin 
cytoskeletal organization by TRITC‐phalloidin staining showed that stress fibers were more prominent 
in CM+ treated HMEC‐1 (Figure 3A). Morphometric analysis of cell  lengths showed that average cell 
length for CM+ treated HMEC‐1 cells was markedly greater than that for CM‐ treated ones (≈ 80 μm 
and ≈ 50 μm, respectively). As shown by presentation of the data as a frequency distribution of cell 
length, HMEC‐1 treated with CM+ exhibited a high frequency (≈ 67.4%) of cells with  lengths of ≥ 61 
μm, whereas the majority (≈ 70.7%) of HMEC‐1 treated with CM‐ exhibited lengths of ≤ 60 μm (Figure 
3B). Average cell  length  in the presence of either gefitinib or  lapatinib remained at ≈ 50 μm for CM‐ 
treated HMEC‐1 but decreased to ≈ 60 μm for CM+ treated HMEC‐1, the latter reflecting a decrease in 
the frequency (from ≈ 67.4% to 40%) of cells ≥ 61 μm in length (Figure 3B). Abrogating effects of EGFR 
tyrosine kinase  inhibition on the CM+‐induced acquisition of a motile phenotype are consistent with 
the abrogation of CM+‐enhanced migration and sprout outgrowth. The differential effects of CM‐ and 
CM+ on EC behaviour were not associated with differences  in metalloproteinases MMP‐2 or MMP‐9 
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as determined by in situ gelatin zymography of culture supernatants collected from HMEC‐1 after 2, 
6 and 24 h incubation with CM‐ or CM+ (Supplementary Figure S1).  
 
Lipid  antigen  stimulation  of  iNKT  cells  activates  multiple  signal  transduction  effectors:  unique 
sensitivity of Src and FAK to inhibitors of EGFR or IL‐8 neutralization. 
In order to reveal the signalling pathways that might be triggered in HMEC‐1 upon activation of iNKT 
cells, we investigated the activation status of a variety of effector molecules known to be involved in 
regulating endothelial cell migration. Whole cell  lysates from HMEC‐1 under control culture medium 
conditions  (ECGM‐4% FCS) or  treated with CM‐ or CM+  for 15 min were  subjected  to  immunoblot 
analysis  for  phosphorylated  Akt,  GSK3β,  p38MAPK,  Erk  and  FAK.  Compared  to  control  culture 
conditions,  CM‐  and  CM+  similarly  increased  phosphorylation  of  Akt  and  GSK3β  phosphorylation, 
whereas only CM+ increased the phosphorylatin of FAK, p38MAPK and Erk (Figure 4A). The presence 
of lapatinib or gefitinib attenuated the CM+‐induced increase in phosphorylation of FAK (Figure 4B).  
Next  we  utilized  the  highly  sensitive  Zeptosens  chip‐based  reverse  protein  array  (RPA) 
platform [22, 23] which allows the generation of high‐fidelity data for protein expression profiling of 
low levels or transient states of protein abundance. This method revealed an increased level of EGFR 
phosphorylation  in  HMEC‐1  treated  with  CM+  or  with  IL‐8,  but  not  with  CM‐  (Figure  5A).  IL‐8‐
immunodepletion of CM completely abrogated the phosphorylation of EGFR induced by CM+ (Figure 
5A).  
RPA was  further  applied  to  validate  the  findings  obtained  by  immunoblot  analysis  and  to 
identify additional candidate signalling effectors. Elevated phosphorylation of FAK, p38MAPK and Erk 
in CM+ treated HMEC‐1 could be confirmed and the RPA revealed that also levels of phosphorylated 
Jnk, STAT1, STAT3, Src and S6rp were higher in CM+ treated HMEC‐1 than in CM‐ treated ones (Figure 
5B). Either  inclusion of  gefitinib or  IL‐8‐immunodepletion of CM  fully  attenuated  the CM+‐induced 
increase in FAK and Src phosphorylation (Figure 5C) whereas the phosphorylation of Akt, Jnk, STAT1, 
STAT3, p38MAPK and S6rp were not affected (Supplementary Figure S2). 
 
 
DISCUSSION 
Antiangiogenic strategies have already shown promising results  in cancer disorders [24] and  in other 
conditions such as macular degeneration [25] and rheumatoid arthritis [26], where angiogenesis plays 
a crucial role in disease progression. The accumulating evidence linking ectopic neovascularization and 
immature microvessels with atherosclerosis, reinforced  inflammation, and plaque destabilization has 
spurred considerable interest in the concept of antiangiogenic therapy for atherosclerotic disease [3‐
5, 27]. This poses a challenge since a multitude of cellular receptors and signalling components can 
contribute  to  angiogenesis.  The  design  of  treatments  that  target  plaque  angiogenesis  requires  a 
detailed knowledge of the critical participating cellular and molecular regulatory pathways.  
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In previous work we  identified  iNKT cells as a novel culprit  leukocyte population  involved  in 
plaque  destabilization.  Plaque‐derived  iNKT  promptly  released  a  spectrum  of  proinflammatory 
cytokines and chemokines upon  lipid antigen activation and the culture supernatants from activated 
iNKT  cells  induced migratory and  tubulogenic  responses  in EC  that  specifically depended upon  IL‐8 
released  by  iNKT  cells  [8].  In  this  study we  provide  evidence  that  these  IL‐8‐mediated  functional 
proangiogenic  activities  are  driven  through  EGFR.  Firstly,  in  functional  analyses  CM+‐induced  EC 
migration  and  angiogenic  sprout  formation were  completely  abolished  by  EGFR  function  blocking 
antibodies or EGFR tyrosine kinase  inhibitors [8]. Secondly,  in morphological studies EGFR  inhibition 
impeded CM+‐induced acquisition of the elongated, motile phenotype. Thirdly, in signal transduction 
analysis  either  IL‐8‐immunodepletion  or  EGFR  inhibition  completely  abolished  CM+‐induced 
phosphorylation of EGFR, Src and FAK.  
VEGFR‐1 and VEGFR‐2 are key cellular receptors on EC that trigger angiogenesis [28]. However, 
there are numerous other receptors that may participate in plaque angiogenesis including hepatocyte 
growth  factor  receptor,  fibroblast  growth  factor  receptor,  platelet‐derived  growth  factor  receptor, 
Tie1/Tie2 as well as G‐protein  coupled  receptors  (GPCRs)  for  ligands  such as  thrombin, bradykinin, 
angiotensin II, endothelin‐1 lysophosphatidic acid and IL‐8 [29]. GPCRs are capable of mediating some 
of their biological effects through the transactivation of the EGFR [30]. Our cumulative findings (this 
study and  [8])  that CM+‐stimulated migration, EGFR phosphorylation and activation of FAK and Src 
could be completely abolished by either  IL‐8 or EGFR  inhibition are consistent with  involvement of 
EGFR  transactivation.  Previous  studies  have  demonstrated  that  the migration  response  of  EC  to 
exogenous  IL‐8  depends  upon  activation  of  the  IL‐8  receptor  CXCR2  [13,  31]  and  involves  EGFR 
transactivation through cathepsin B‐mediated cleavage of EC‐expressed transmembrane pro‐heparin‐
binding EGF‐like growth factor (pro‐HB‐EGF) to soluble HB‐EGF [14], a cognate member of the EGFR 
family of ligands [32]. HB‐EGF directly induces EC migration in vitro and angiogenesis both in vitro and 
in  vivo  [33].  Although  we  did  not  directly  address  whether  HB‐EGF  is  indeed  the  molecule 
transactivating EGFR in our experimental model, our observed inhibition of CM+‐induced migration by 
cetuximab  supports  a  requirement  of  EGFR  ligand‐induced  EGFR  transactivation  rather  than  an 
alternate transactivation via non‐receptor tyrosine kinases (e.g. proline‐rich tyrosine kinase 2 and Src) 
activated  downstream  of  IL‐8  receptor  ligation  [34‐36].  Expression  of  HB‐EGF  is  upregulated  in 
macrophage‐rich areas of human atherosclerotic plaques [37, 38]. Specific associations between the 
presence of HB‐EGF and  iNKT cell‐associated plaque neovascularization have not been  investigated. 
However,  the complete attenuation of CM+‐induced Src and FAK activation  (this study) and  in vitro 
angiogenesis  [8]  by  IL‐8  neutralizing mAbs would  exclude  that  HB‐EGF  derives  from  lipid  antigen 
activated iNKT cells. 
EGFR‐mediated signalling has been linked to pathogenic angiogenesis in tumor growth [28, 39, 
40] and now is a major pharmacological target for inhibiting tumor growth [39‐41]. Accumulating data 
suggest  that  EGFR  signalling may  also  participate  in  vascular  disease  [42]. Numerous  studies  have 
demonstrated  that  EGFR  ligands  promote  dedifferentiation  and  proliferation  of  vascular  smooth 
muscle cells and on chemotaxis and proliferation of monocyte‐derived macrophages, processes which 
actively  drive  atherosclerosis  [42].  Much  less  is  known  about  EGFR‐dependent  control  of  EC 
angiogenic  behaviour  and  signalling  in  atherosclerosis.  The  association  of  human  cytomegalovirus 
(HCMV)  infection  with  atherosclerosis,  transplant  vascular  sclerosis  and  coronary  restenosis  was 
recently  attributed  to  the  ability of HCMV  to  trigger  angiogenesis  via  specific binding of HCMV  to 
EGFR and β1 and β3 integrins and the downstream activation of the phosphatidylinositol 3 kinase and 
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MAPK  pathways  in  EC  [43].  Schraufstatter  et  al.,  demonstrated  that  the  EC migration  induced 
through  IL‐8‐mediated EGFR  transactivation  involved activation of  small GTPase Rac  [13]. Although 
our  study  did  not  directly  examine  small  GTPase  activation,  the  CM+‐induced  alterations  in  EC 
cytoskeletal  organization  (strong  stress  fibres)  and  morphology  (more  frequent  and  pronounced 
lamellipodial  extensions)  suggest  activation  of  at  least Rac  [44].  In  signal  transduction  analysis we 
found that a broad spectrum of signalling pathways (Erk, Jnk, p38MAPK, STAT1, STAT3, Src/FAK) were 
activated  to  a  greater extent  in CM+  treated  EC, which was not  surprising  given  that  lipid‐antigen 
activation  of  iNKT  cells  induces  the  release  of  a  broad  spectrum  of  chemokines  and  cytokines 
(including  tumor necrosis  factor  α,  interferon  γ, granulocyte‐macrophage  colony‐stimulating  factor, 
interleukins ‐2, ‐4, ‐13 and ‐8) [8]. However, only Src and FAK activation were sensitive to inhibition by 
either  IL‐8‐immunodepletion or gefitinib, suggesting an  IL‐8/EGFR transactivation mechanism that  is 
rather  selective  with  respect  to  subsequent  intracellular  signal  pathway  activation  in  EC.  The 
complete attenuation of CM+‐induced EGFR phosphorylation by IL‐8 immunodepletion confirms that 
IL‐8 derived from lipid antigen activated iNKT cells mediates EGFR transactivation in EC.  
The non‐receptor tyrosine kinases Src and FAK are key regulators of cell migration and their 
activities are regulated through alterations in phosphorylation at mutiple sites [45]. EGFR, via SRC‐3Δ4 
as a bridging protein [46],  is known to  induce the autophosphorylation of FAK at tyrosine 397 which 
creates a binding site  for Src through  its SH2 homology domain. Resultant activation of Src through 
autophosphorylation on  tyrosine 416  contributes  to maximal  FAK  activation by phosphorylation of 
FAK  at  several  sites  including  tyrosine  576  and  tyrosine  577  [47]. Our  immunoblot  and  RPA  data 
showing  phosphorylation  at  these  sites  are  consistent  with  the  abovementioned  EGFR‐induced 
cascade of FAK/Src activation.  
In  conclusion,  our  study  supports  EGFR  as  a  non‐traditional  proangiogenic  receptor  driving 
inflammation‐associated neovascularization  in atherosclerotic disease. Figure 6 presents a model for 
events involved in the angiogenic response of EC to lipid antigen activation of iNKT cells, and different 
modalities  for  inhibiting  this  response. The model, depicting  IL‐8‐mediated  transactivation of EGFR, 
incorporates  also  the  observations  of  Schraufstatter  et  al.,  with  respect  to  Rac  activation  [13] 
cathepsin B generation of EGFR ligand HB‐EGF [14]. While the model presents HB‐EGF as an autocrine 
ligand  for EC,  this  ligand can be elaborated by several other cell  types  (monocytes, smooth muscle 
cells,  T‐cells)  resident  and  activated within  atherosclerotic  lesions  in  vivo  [42],  thereby  facilitating 
paracrine activation of EGFR on EC and exacerbation of angiogenesis. Thus EGFR inhibition represents 
a  novel  therapeutic  modality  for  control  of  neovascularisation  within  developing  atherosclerotic 
plaques. 
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FIGURE LEGENDS 
 
Figure  1.  The  enhanced  migration  response  of  endothelial  cells  to  conditioned  medium  from 
activated iNKT cells is sensitive to EGFR inhibition. 
Confluent monolayers  of  EC  were  scrape‐wounded  and  cultured  in  the  presence  of  conditioned 
culture media derived  from non‐activated  (CM‐, A, C, E) or  α‐GalCer‐activated  (CM+, B, D, F)  iNKT 
cells, and without  (A‐F  ‐open  circles) or with  inclusion of 1  μg/ml anti‐EGFR blocking mAbs  (A, B  ‐ 
closed  triangles), 1  μg/ml  isotype  control  IgG  (A, B  ‐open  triangles), 0.5  μM  gefitinib  (C, D  ‐closed 
circles) or 0.1 μM lapatinib (E, F ‐ closed squares). Wound closure was monitored over a time period 
of 12 h by time lapse videomicroscopy. The rate of EC migration from the initial wound front into the 
wound  area  (path  length  versus  time) was  determined  by  analysis  of  acquired  images  using  CellR 
software.  The  data  are  representative  of  1  of  3  independent  experiments,  each  performed  in 
duplicate  and  values  are  given  as  averaged  path  length  measurements  ±  SD  from  triple  fixed 
observation fields/well. 
 
Figure 2. Increased sprout outgrowth induced by conditioned medium from antigen activated iNKT 
cells is attenuated upon EGFR inhibition.  
EC‐spheroids were  incubated  for 24 h  in  the presence of conditioned media derived  from  iNKT cell 
cultures stimulated without (CM‐, white bars) or with (CM+, grey bars) αGalCer, and without (control) 
or with inclusion of gefitinib (0.5 μM). Representative images of whole spheroids at the end of the 24 
h culture period are shown  (scale bar = 200 μm). The total  length of sprouts growing out  from any 
given  spheroid  was  morphometrically  analyzed;  at  least  40  spheroids  from  duplicate  wells  per 
condition were analyzed. Results  are mean ±  SD  for 3  independent experiments  and express  total 
sprout length relative to that under control (no inhibitor) CM‐ conditions. ***P<0.001. 
 
Figure 3. Cytoskeletal  rearrangement and phenotype alterations  induced by conditioned medium 
from antigen activated iNKT cells is sensitive to pharmacological inhibition of EGFR. 
(A) HMEC‐1 at ≈ 70% confluency were cultured with CM‐ or CM+ for 24 h and cell morphology was 
examined by phase contrast microscopy  (upper panels, at 10x and 20x magnification) and confocal 
microscopy  (lower panels, at 40x and 60x magnification) after  staining  for actin with TRITC‐labeled 
phalloidin. (B) Culture with CM‐ (white bars) or CM+ (grey bars) was performed without (control) or 
with  inclusion of gefitinib (0.5 μM) or  lapatinib (0.1 μM). Cell  lengths were measured using AnalySIS 
software. At  least 100 cells  from each of at  least  three  fields  in duplicate wells per condition were 
analyzed. The histogram presents a  relative  frequency distribution analysis of data acquired and  is 
representative of 1 of 3 independent experiments.  
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Figure  4.  Effect  of  antigen  activated  iNKT  cells  on  some  signalling  effectors  involved  in  EC 
migration and angiogenesis; immunoblot analysis.  
(A) Whole cell  lysates  (10‐15 µg per  lane)  from HMEC‐1  incubated  for 15 min with control medium 
(ECGM‐4% FCS; Ctrl), CM‐ or CM+ were  immunoblotted  for phospho  (p)‐FAK, p‐Erk, p‐p38MAPK, p‐
Akt,  p‐GSK3β  and  GAPDH  (as  internal  control).  Qualitatively  similar  data  were  obtained  in  4 
independent experiments, each using CM derived from a different  iNKT cell clone. (B) HMEC‐1 were 
incubated for 15 min with CM‐ or CM+ without or with inclusion of gefitinib (0.5 μM, gef) or lapatinib 
(0.1  μM,  lap)  and  whole  cell  lysates  immunoblotted  for  p‐FAK,  p‐Erk,  p‐p38MAPK  and  GAPDH. 
Phosphorylation  levels  in CM+ treated HEMC‐1 (filled bars) are expressed relative to that  in HMEC‐1 
treated with CM‐ (open bars), and results are mean ± SD for 3 independent experiments. Blots from 
one experiment are presented.  
 
Figure 5. Analysis of signalling responses of HMEC‐1 to antigen activation of iNKT cells using reverse 
protein array.  
EC were variously  incubated for 15 min as depicted within the figure panels A, B and C with control 
medium (ECGM‐4% FCS; Ctrl) without or with inclusion of IL‐8 (10ng/ml), CM+ or CM‐ without or with 
inclusion of gefitinib  (0.5 μM), CM+ or CM‐ subjected  to  immunodepletion protocols using anti‐IL‐8 
mAb  or  non‐immune  (n.i.)  IgG. Whole  cell  lysates were  analysed  by  reverse  protein  array  for  the 
phosphorylation status of  the  indicated molecules, expressed  relative  to  the status  in EC  incubated 
with control medium (Ctrl). Data in B are the average of 2 experiments. Results in A and C are mean ± 
SD  from  3  independent  experiments.  **P<0.01,  ***P<0.001.  (a)  compares  native  CM‐  or  n.i.  IgG‐
immunoprecipitated  CM‐  with  native  CM+  or  n.i.  IgG‐immunoprecipitated  CM+,  respectively  (b) 
compares  anti‐IL‐8 mAb  immunoprecipitated CM+ with native CM+ or n.i.  IgG‐immunoprecipitated 
CM+. 
 
Figure 6. A simple model for events involved in the angiogenic behavioural response of endothelial 
cells to lipid antigen activation of iNKT cells, and different modalities for inhibiting this response. 
Activation of CD1d‐restricted  iNKT  cells  through  the presentation of  lipid antigen  α‐GalCer  to  iNKT 
cells  by  CD1d‐expressing  APC  induces  release  of  IL‐8  from  iNKT  cells  which  induces  angiogenic 
behaviour  in  EC.  Angiogenic  responses  of  EC  can  be  fully  attenuated  by  either  IL‐8  neutralizing 
antibodies  or  IL‐8  immunodepletion  [8],  anti‐EGFR  blocking monoclonal  antibodies  (cetuximab)  or 
EGFR tyrosine kinase inhibitors (gefitinib or lapatinib), implicating a mechanism of IL‐8 mediated EGFR 
transactivation.  This  is  supported  by  blockade  of  EGFR  phosphorylation  following  IL‐8 
immunodepletion  of  the  secretome  released  by  iNKT  cells.  IL‐8  (CRCX2)  mediated  EGFR 
transactivation has been proposed to depend on cathepsin B induced cleavage of pro‐HB‐EGF to HB‐
EGF  [14],  a  cognate  ligand  for  EGFR  [32].  FAK  and  Src  are  major  downstream  migration  signal 
transduction  effectors which  can  target many  proteins,  including  Rac  [13],  that  participate  in  the 
dynamic regulation of cortical actin organization and cell locomotion.  
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Figure S1. Conditioned medium from lipid antigen activated iNKT 
cells does not affect secretion of metalloproteinases by endothelial 
cells.
Human microvascular
 
endothelial cell monolayers
 
at 80% confluency
 
were 
cultured for the indicated periods in the presence of conditioned culture 
media derived from non-activated (CM-) or α-GalCer-activated
 
(CM+)  
iNKT
 
cells. Gelatinolytic
 
activity of the metalloproteinases
 
MMP-2 and 
MMP-9 in HMEC-1 culture supernatants was measured by in situ 
zymography.
 
The Coomassie
 
blue-stained gel  shown here is 
representative of at least 3 other independent experiments.
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antigen activation of iNKT cells depend on EGFR transactivation
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Figure S2. Lipid antigen activation of iNKT cells also activates numerous signal 
pathways in endothelial cells independently of endothelial cell EGFR tyrosine 
kinase activity and IL-8 released by the iNKT cells. Human microvascular
 
endothelial 
cells  were incubated for 15 min with CM-
 
or CM+ without or with inclusion of gefitinib
 
(0.5 μM) (A) , or with CM+ or CM-
 
that had been subjected to immunodepletion
 
protocols using anti-IL-8 mAb
 
or non-immune (n.i.) IgG
 
(B). Whole cell lysates
 
were 
analysed by reverse protein array for the phosphorylation
 
status of the indicated 
molecules, expressed relative to the status in EC incubated with
 
control medium 
(ECGM-4% FCS). The data in A and B are the average of 2 experiments each 
performed in triplicate.
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Project 3 
The role of T-cadherin during endoplasmic reticulum stress 
 
The results of this project have been published. 
 
T-cadherin attenuates the PERK branch of the unfolded protein response and protects 
vascular endothelial cells from endoplasmic reticulum stress-induced apoptosis.  
Cellular Signalling. September 2010, volume 22, Issue 9, Pages 1308-1316 
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Unfolded protein responseEndoplasmic reticulum (ER) stress activated by perturbations in ER homeostasis induces the unfolded
protein response (UPR) with chaperon Grp78 as the key activator of UPR signalling. The aim of UPR is to
restore normal ER function; however prolonged or severe ER stress triggers apoptosis of damaged cells to
ensure protection of the whole organism. Recent findings support an association of ER stress-induced
apoptosis of vascular cells with cardiovascular pathologies. T-cadherin (T-cad), an atypical glycosylpho-
sphatidylinositol-anchored member of the cadherin superfamily is upregulated in atherosclerotic lesions.
Here we investigate the ability of T-cad to influence UPR signalling and endothelial cell (EC) survival during
ER stress. EC were treated with a variety of ER stress-inducing compounds (thapsigargin, dithiothereitol,
brefeldin A, tunicamycin, A23187 or homocysteine) and induction of ER stress validated by increases in
levels of UPR signalling molecules Grp78 (glucose-regulated protein of 78 kDa), phospho-eIF2α
(phosphorylated eukaryotic initiation factor 2α) and CHOP (C/EBP homologous protein). All compounds
also increased T-cad mRNA and protein levels. Overexpression or silencing of T-cad in EC respectively
attenuated or amplified the ER stress-induced increase in phospho-eIF2α, Grp78, CHOP and active caspases.
Effects of T-cad-overexpression or T-cad-silencing on ER stress responses in EC were not affected
by inclusion of either N-acetylcysteine (reactive oxygen species scavenger), LY294002 (phosphatidylino-
sitol-3-kinase inhibitor) or SP6000125 (Jun N-terminal kinase inhibitor). The data suggest that upregulation
of T-cad on EC during ER stress attenuates the activation of the proapoptotic PERK (PKR (double-stranded
RNA-activated protein kinase)-like ER kinase) branch of the UPR cascade and thereby protects EC from ER
stress-induced apoptosis.osis signal-regulated kinase 1;
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Endothelial dysfunction (ED) plays a key role in the pathogenesis
of atherosclerosis [1]. ED is characterized by impairment of endothe-
lium-dependent vasorelaxation and by a specific state of endothelial
“activation” which manifests itself in increased endothelial cell (EC)
production of proinflammatory and proliferative mediators, adhesion
molecules and procoagulants. Thus injured EC significantly impair
vascular function and trigger thrombogenic and atherogenic reaction
cascades.
Important pathophysiological roles have been attributed to
different types of stress in the development of ED and the progression
of atherosclerosis. Luminal endothelium which is in direct contact
with plasma and blood components is the first target of pathogens
and damaging toxic compounds including risk factors for atheroscle-
rosis. Acute and chronic oxidative stress associated with lipoprotein
oxidation, activation of the inflammatory response and generation of
1309E. Kyriakakis et al. / Cellular Signalling 22 (2010) 1308–1316reactive oxygen species (ROS) is well recognized as an early event
which plays an initiating role in cardiovascular disorders, while the
ability of EC to resist stressors determines the progression and
outcome of the disease [2,3]. Endoplasmic reticulum (ER) stress
caused by perturbations in ER function including accumulation of
misfolded proteins, changes in redox status or intraluminal calcium
concentration, nutrient deprivation, altered glycosylation and path-
ogen infections contributes to pathogenesis of many human pathol-
ogies including neurodegenerative disorders, diabetes, obesity and
cancer [4–10]. ER stress triggers the unfolded protein response (UPR),
an adaptive signalling cascade aimed at restoring normal ER folding
capacity and promoting cell survival, or, if ER stress is severe or
prolonged, at promoting death of damaged cells to ensure protection
of the whole organism [4–10].
UPR has recently been demonstrated to be involved in ED and
related cardiovascular pathologies. Accumulation of free cholesterol
in macrophages was shown to trigger ER stress and C/EBP-
homologous protein (CHOP)-induced apoptosis [11]. Upregulation
of ER chaperone glucose-regulated protein of 78 kDa (Grp78),
apoptosis signal-regulated kinase 1 (ASK1) and other ER stress-
related genes were detected in hypoxic cultured myocytes and in a
murine model of myocardial infarction [12,13]. Both cytoprotective
and apoptotic components of ER stress signalling are upregulated in
myocardial ischemia and heart failure [14,15]. High levels of apoptosis
and expression of Grp78 and pro-apoptotic transcription factor CHOP
were found in smooth muscle cells and macrophages within the
fibrous caps of thin-cap atheroma and ruptured plaques of both
autoptic human coronary specimens and atherectomy specimens
from patients with unstable angina pectoris [16]. Studies in
apolipoprotein E knock-out (apoE−/−) mice showed that UPR
activation occurred at all stages of atherosclerosis, and evidence was
provided to support the relevance of ER stress to macrophage
apoptosis and enlargement of the necrotic core in advanced
atherosclerotic plaques [17,18]. ER stress markers are also upregu-
lated in atherosclerotic lesions of apoE−/− mice fed a hyperhomo-
cysteinemic diet [19]. Homocysteine, a well known inducer of ER
stress, induces apoptosis in vitro in a number of cell types including EC
[20–23] and is believed to adversely affect stability and thrombo-
genicity of atherosclerotic lesions. In EC ER stress is activated by shear
stress in vitro [24] and in vivo at atherosclerosis-susceptible arterial
sites [25]. Pharmacological inducers of ER stress including tunicamy-
cin, thapsigargin, Sin-1 and A23187 have variously been demonstrat-
ed to activate apoptosis in EC via induction of UPR-related
proapoptotic factors CHOP and T-cell death-associated gene 51
[22,26]. Taken together, these findings support an association of ER
stress and induction of UPR induced-apoptosis of EC, smooth muscle
cells and macrophages with progression of atherosclerosis and
development of plaque vulnerability.
T-cadherin (T-cad), an unusual glycosylphosphatidylinositol–
anchored member of the cadherin superfamily of adhesionmolecules,
is upregulated in vascular cells under pathological conditions
associated with abnormal vascular tissue remodeling and stress
including atherosclerosis [27] and restenosis [28]. We have previously
demonstrated that T-cad is involved in regulation of EC survival under
conditions of oxidative stress. T-cad is markedly upregulated in EC by
ROS, and its overexpression decreases oxidative stress-induced
apoptosis [29]. Both overexpression and ligation of T-cad on the EC
surface activate signalling pathways (phosphatidylinositol-3-kinase
(PI3-kinase), Akt, glycogen synthase kinase 3 beta (GSK3β)) impor-
tant for cell survival and proliferation [29,30]. There is considerable
interplay between ER stress and oxidative stress. Oxidative stress,
which occurs when the production of ROS overwhelms the antiox-
idant defenses, may cause alterations in ER homeostasis and activate
UPR-related signalling, while conversely ER stress may result in
accumulation of ROS and initiate expression and activation of
oxidation-related signalling mediators [7]. Together these data112suggest that T-cad upregulation represents a protective mechanism
aiming at resisting stress conditions and might be involved in
endothelial ER stress response. Moreover, our recent data on physical
colocalization of T-cad and ER chaperon Grp78 in EC [31] further point
to a possible role for T-cad in UPR signalling. In this study we
investigate the ability of T-cad to influence UPR activation and EC
survival during ER stress.
2. Experimental
2.1. Cell culture
Human umbilical vein EC (HUVEC), purchased from PromoCell
GmbH (Heidelberg, Germany), were cultured on plates precoated
with 0.1% gelatine in EC growth medium containing EC growth
supplement (PromoCell). Human microvascular EC line (HMEC-1)
was cultured in the same medium supplemented with 10% fetal calf
serum (FCS). Cells were seeded either at 2×105 cells/well into 6-well
plates (for immunoblotting) or at 2×104cells/well into 96-well plates
(for Homogenous Caspases ELISA) and allowed to adhere overnight.
Culture medium was refreshed and cells were treated for selected
intervals with a variety of ER stress-inducing agents including
thapsigargin (500 nM), dithiothreitol (DTT, 1 mM), brefeldin A
(5 μg/ml), tunicamycin (3 μg/ml), calcium ionophore A23187 (2 μM)
and homocysteine (5 mM). Some experiments included ROS scaven-
ger N-acetylcysteine (NAC, 15 mM), PI3-kinase inhibitor LY-294002
(10 μM) or Jun N-terminal kinase (JNK) inhibitor SP600125 (20 μM),
which were added to cultures 1 h before stimulation protocols. All
compounds were purchased from Sigma-Aldrich (Buchs, Switzerland)
with the exception of SP600125 which was purchased from VWR/
Merck (Dietikon, Switzerland). Agent vehicles at the appropriate final
concentrations were tested in pilot studies and found not to affect any
of the parameters measured in this study.
2.2. Overexpression and silencing of T-cad
Overexpression of T-cad in HMEC-1 was achieved by using Adeno-
X Expression System (Clontech, Palo Alto, USA) as detailed previously
[32]. Briefly, HMEC-1 in normal growth media were infected
overnight with empty, LacZ or T-cad containing adenoviral particles
at a final approximate concentration of 4 pfu/cell; expression of T-cad
was monitored by immunoblotting (representative blots shown in
Fig. 3). T-cad silencing in HMEC-1 was performed using MISSION®
Lentiviral transduction system (Sigma-Aldrich Chemie, Buchs,
Switzerland). Lentiviral particles expressing T-cad short hairpin RNA
(product number TRCN0000055546) and non-target control trans-
duction particles (product number SHC002V) were used at a
multiplicity of infection of 4 lentiviral particles per cell according to
manufacturer's recommendations. Infected cells were selected against
puromycin for about 10 days. Efficiency of T-cad silencing was in the
order of 80–90% as controlled by immunoblotting (representative
blots shown in Fig. 4).
2.3. Homogenous caspases assay
Following exposure to ER stress-inducing agents caspase activity
in treated cells was evaluated using Homogeneous Caspases ELISA
that detects activated caspases 2, 3, 6, 7, 8, 9, and 10 (Roche
Diagnostics GmbH, Mannheim, Germany) as described previously
[29]. Substrate solution was added to wells without prior removal of
any detached cells or medium change.
2.4. Immunoblotting
Immunoblotting was performed on whole cell lysates prepared by
lysis with PBS containing 1% SDS and protease inhibitor cocktail
1310 E. Kyriakakis et al. / Cellular Signalling 22 (2010) 1308–1316(Sigma), with inclusion of 1 mM orthovanadate and 5 mM NaF in
samples analysed for protein phosphorylation status. In some
experiments immunoblotting for CHOP protein was additionally
performed on nuclear extracts prepared using the CHEMICON®
Nuclear Extraction Kit according to the manufacturers' protocol
(Millipore, Billerica MA, USA). Protein concentrations were deter-
mined using the Lowry method. Samples were loaded at 5–10 µg per
lane and electrophoresed in 8% SDS-polyacrylamide gels under
reducing conditions. The following antibodies were used for immu-
noblotting: goat anti-T-cad (R&D Systems Europe Ltd., Abingdon, UK),
goat anti-GAPDH (Abcam, Cambridge, UK), mouse anti-Grp78 (BD
Biosciences, Basel, Switzerland), rabbit anti-cleaved caspase 3 and
rabbit anti-phospho-eIF2α (Cell Signalling, New England Biolabs,
Frankfurt, Germany), rabbit anti-CHOP (sc7351, Santa Cruz from Lab
Force AG, Nunningen, Switzerland), mouse anti-lamin A/C (LaZ-1)
(kind gift of Prof. Harald Herrmann, Department of Molecular
Genetics, German Cancer Research Center, Heidelberg, Germany).
Secondary HRP-conjugated goat anti-mouse IgG or anti-rabbit IgG
(Southern Biotechnology (BioReba AG, Reinach, Switzerland) or
donkey anti-goat IgG (Santa Cruz) together with Amersham ECL
(Amersham Biosciences, Little Chalfont, UK) were used for detection
of immunoreactive proteins. Scanned images of autoradiograms were
analyzed using AIDA Image or Scion (NIH) Image software.Fig. 1. Induction of ER stress in HMEC-1. HMEC-1 cultures were exposed for the indicated pe
(Bref.A), tunicamycin (Tunica), A23187 and homocysteine (Hcys). Cells were processed for
with GAPDH to control for equivalence of protein loading. Changes in levels of phospho-eIF
(0h). Total caspases activity in HMEC-1 cultures was measured using homogenous caspases
level in untreated control cells. Activity of caspase-3 in HMEC-1 lysates were analysed b
independent experiments. Blots are representative of 3–4 separate experiments.
112.5. RT-PCR
Isolation of RNA, reverse transcription, and real-time PCR analysis
were performed as described previously [33]. The expression of target
molecules was normalized to the expression of ß2-microglobulin or to
GAPDH. Primer sequences are available on request.
2.6. Statistical analysis
All experiments were performed on at least three separate
occasions. Results are given as mean±SD unless otherwise stated.
Differences were variously determined with 1-way or 2-way repeated
measures ANOVA with Tukey's or Bonferroni's multiple comparison
test, respectively, using GraphPad Prism 5.0 software (GraphPad
Software, San Diego, CA, USA). A P value of b0.05 was considered
significant.
3. Results
3.1. Activation of the UPR and apoptosis in EC by ER stress inducers
In order to establish the experimental model we examined the
kinetics of responses of HMEC-1 to a variety of pharmacologicalriods of time to the different ER stress inducers: thapsigargin (Thapsi), DTT, brefeldin A
immunoblot analysis of phospho-eIF2α (A), Grp78 (B) or CHOP (C). Blots were probed
2α, Grp78 and CHOP are expressed relative to their respective levels in untreated cells
assay kit (D). Data (mean±SD, n=3) are expressed relative to the baseline fluorimetic
y immunobloting (E). The histograms show data (mean±SD) obtained from 3 to 4
3
1311E. Kyriakakis et al. / Cellular Signalling 22 (2010) 1308–1316compounds that are known to induce ER stress by different
mechanisms, namely disturbance of calcium homeostasis (ER calcium
pump inhibitor thapsigargin, calcium ionophore A23187), inhibition
of N-glycosylation in the ER (tunicamycin), inhibition of ER/Golgi
transport (brefeldin A) and reduction of disulfide bonds (dithiothrei-
tol, homocysteine). Cells were treated with the compounds for up to
12 h. As read-outs for UPR activation we determined the phosphor-
ylation status of the α-subunit of eukaryotic translational initiation
factor 2 (eIF2α) as an index of translational attenuation and the level
of Grp78 protein as an index of transcriptional induction of ER
chaperone genes. All the chemicals tested induced an increase in
phosphorylation of eIF2α within 3h that remained generally steady
during treatment for up to 12h (Fig. 1A). Levels of Grp78 increased
between 3 and 6h of exposure to the chemicals and thereafter
continued to rise steadily during treatment for up to 12h (Fig. 1B).
Similar responses were elicited in HUVEC (Supplemental Fig. S1).
Since excessive or prolonged ER stress is linked to the triggering of
programmed cell death [4–10] the effects of the ER stressors on
indices of apoptosis in HMEC-1 were investigated. CEBP homology
protein (CHOP), a major ER stress-inducible pro-apoptotic transcrip-
tion factor which operates as a downstream component of ER-stress
pathways, at the convergence of the inositol-requiring kinase 1
(IRE1), protein kinase RNA (PKR)-like ER kinase (PERK) and activating
transcription factor 6 (ATF6) [34] was induced by all the ER stressors
(Fig. 1C). The specificity of the anti-CHOP antibodies used in this study
(Sc-7351 from Santa Cruz) and our use of whole cell lysates for
immunoblotting [35] were validated by comparison of immunoreac-
tivity in whole cell lysates and nuclear extracts prepared in parallelFig. 2. Induction of T-cad expression in HMEC-1 in response to ER stress. HMEC-1 culture
thapsigargin (Thapsi), DTT, brefeldin A (Bref.A), tunicamycin (Tunica), A23187 and homocy
for immunoblot analysis of T-cad protein (B). The immunoblot shows samples from cells tr
their respective levels in untreated cells. The histograms present data (mean±SD) obtaine
114following treatment of parental HMEC-1 with thapsigargin, brefeldin
A or homocysteine (Supplemental Fig. S2). Analysis for caspases
activity with the Homogeneous Caspases ELISA revealed a ∼5-fold
increase in cells treated with homocysteine and a lesser ∼2-fold
increase in cells treated with thapsigargin, brefeldin A, A23187,
tunicamycin and DTT (Fig. 1D). Immunoblot analysis for active
caspase-3 revealed its presence only in cells treated with homo-
cysteine (Fig. 1E). This, taken together with the ∼2–3-fold greater
induction of caspases activity by homocysteine as compared with the
other stressors (Fig. 1D), might reflect that, under our experimental
conditions, homocysteine elicited the most potent proapoptotic
response in EC.
3.2. Induction of the UPR in EC is associated with upregulation of T-cad
Next we investigated the effects of the ER stressors on induction of
T-cad mRNA and protein. All ER stressors induced a 1.5 to 3-fold
upregulation of T-cad transcripts within 2h that remained elevated
for up to at least 6h (Fig. 2A). Likewise all compounds induced a 1.5 to
3-fold increase in T-cad protein expression within 3h, which
generally remained stable for up to at least 9h (Fig. 2B). HUVEC
responded similarly to conditions of ER stress (Supplemental Fig. S1).
3.3. T-cad expression modulates ER stress responses of EC
To determine whether T-cad plays a role in ER stress response in
EC we examined the consequences of overexpression and silencing of
T-cad on UPR activation. These gain-of-function and loss-of-functions were exposed for the indicated periods of time to the different ER stress inducers:
steine (Hcys). Cells were processed for RT-PCR analysis of T-cad transcript levels (A) or
eated for 6h. Changes in T-cad mRNA and protein expression are expressed relative to
d from 3 to 4 independent experiments.
1312 E. Kyriakakis et al. / Cellular Signalling 22 (2010) 1308–1316experiments were performed using HMEC-1. Homocysteine, thapsi-
gargin and brefeldin A were selected as the test ER-stress and UPR
activation agents. Compared with the responses in control empty
vector- or LacZ-transduced cells, T-cad overexpression significantly
attenuated the elevation in levels of phospho-eIF2α, Grp78 and pro-
apoptotic C/EBP homologous protein CHOP induced by the ER
stressors (Fig. 3). In contrast, and compared with control shRNA-
transduced cells, T-cad silencing significantly augmented the stimu-
latory effects of the ER stressors on phospho-eIF2α, Grp78 and CHOP
levels (Fig. 4).
3.4. T-cad promotes EC survival during ER stress
In order to determine if modulation of UPR signalling by T-cad
translates into a functional response and influences apoptosis rates
during ER stress we studied effects of T-cad overexpression and
silencing on caspase activation. T-cad overexpression blunted the
induction of total caspases activity by thapsigargin, brefeldin A and
homocysteine (Fig. 5A) and upregulation of cleaved caspase-3 level by
homocysteine (Fig. 5B). In T-cad silenced cells these proapoptotic
responses to the ER stressors were amplified (Fig. 5C, D).Fig. 3. T-cad overexpression attenuates ER stress response. Empty- (E, open bars), LacZ- (L,
thapsigargin, brefeldin A or homocysteine for the indicated times. Whole cell lysates were pr
CHOP proteins. Changes are expressed relative to levels in untreated E-transduced HMEC-1
Representative blots, including the controls for T-cad overexpression, are shown. Asterisks
113.5. T-cad effects on UPR signalling in EC do not depend on PI3-kinase
pathway, JNK activity or protection against oxidative stress
We have previously demonstrated that T-cad-dependent activa-
tion of prosurvival signalling protects EC from oxidative stress. Since
generation of ROS can be a cause of disturbances in ER function we
investigated whether T-cad may prevent ER stress-induced apoptosis
by acting not on UPR pathways directly but rather by limiting the
impact of oxidative stress. As described above, upregulation of
proapoptotic factor CHOP by thapsigargin and homocysteine was
much more prominent in EC transduced with T-cad shRNA as
compared to control shRNA-expressing cells. ROS scavenger N-
acetylcysteine did not prevent the stress-induced increase in CHOP
or Grp78 levels in T-cad-silenced cells (Fig. 6A), suggesting that the
ability of T-cad to attenuate ER stress is distinct from its ability to
protect EC from oxidative stress [29]. ER stress attenuation in T-cad
overexpressing cells could not be prevented by PI3-kinase inhibitor
LY-294002 suggesting that activation of PI3-kinase pathway by T-cad
[29] does not contribute to protection of cells from excessive UPR
(Fig. 6B). Inclusion of anthrapyrazolone SP600125 to inhibit JNK,
which is a target of ASK1 and plays an important role in ER stress-grey bars) and T-cad- (T, black bars) lentivector transduced HMEC-1 were treated with
epared for immunoblot analysis of eIF2α phosphorylation and expression of Grp78 and
. The histograms present data (mean±SD) obtained from 3 independent experiments.
indicate a significantly decreased response in T vs. E or L (P at least b0.05).
5
Fig. 4. Silencing of T-cad expression augments ER stress response. HMEC-1 transduced with lentiviral vectors expressing T-cad-specific (shT, grey bars) or control (shC, open bars)
shRNAs were treated with thapsigargin, brefeldin A or homocysteine for the indicated times. Whole cell lysates were prepared for immunoblot analysis of T-cad,
eIF2α phosphorylation and expression of Grp78 and CHOP proteins. Changes are expressed relative to levels in the control shRNA-transduced HMEC-1. The histograms present
data (mean±SD) obtained from 3 independent experiments. Representative blots, including the controls for T-cad silencing, are shown. Asterisks indicate a significantly increased
response in shT vs. shC (*Pb0.05, ** P at least b0.01).
1313E. Kyriakakis et al. / Cellular Signalling 22 (2010) 1308–1316induced apoptosis, also did not prevent the stress-induced increase in
CHOP or Grp78 levels in T-cad-silenced cells (Fig. 6C).
4. Discussion
We have previously reported that upregulation of T-cad in EC
occurs in vivo [27,28] and in vitro under conditions associated with
oxidative stress [29] and functions as a protection mechanism
promoting EC survival through activation of the PI3K/Akt/mTOR
survival signal pathway and concomitant suppression of the p38
MAPK proapoptotic pathway [29]. The present study has demonstrat-
ed that upregulation of T-cad in EC also takes place during ER stress. T-
cad overexpression and silencing studies collectively suggest that
upregulation of T-cad attenuates ER stress by restricting activation of
the proapoptotic PERK branch of the UPR cascade and thereby limits
ER stress-induced apoptosis.
The cellular ER stress/UPR signalling cascade falls into several
phases with different effector functions (reviewed in [4–9]). It is
triggered by an accumulation of misfolded proteins in the ER which
bind to ER chaperone Grp78, causing dissociation of Grp78 from the116three major ER stress sensors PERK, ATF6 and IRE1 and a resultant
launching of the UPR [4–9]. The first response aims at re-establishing
homeostasis and normal ER function. PERK-dependent phosphoryla-
tion of eIF2α results in translational attenuation reducing the load of
new protein synthesis on the ER. IRE1 induces expression of X-box
binding protein XBP-1, while ATF6 is translocated to the Golgi and
activated by proteolysis. XBP-1 and ATF6 act together with eIF2α-
downstream target ATF4 as transcription factors activating expression
of ER chaperones and components of ER associated degradation system
(ERAD) eliminating misfolded proteins. In a later phase, immune and
anti-apoptotic responses are activated via the NFκB pathway.When the
adaptive mechanisms fail to compensate in the face of protracted or
excessive ER stress apoptotic cell death is induced to protect the
organismby eliminating the damaged cells. Several apoptosis pathways
are known to be involved, the central role being played by the
proapoptotic transcription factor CHOP which blocks expression of
antiapoptotic protein Bcl-2. Transcriptional induction of CHOP mostly
depends upon activation of PERK/eIF2α; however, IRE1 and ATF6
pathways also stimulate CHOP transcription, meaning that CHOP
operates at the convergence of all UPR branches. ER stress-induced
Fig. 5. Effects of T-cad overexpression and silencing on ER stress-induced apoptosis. Apoptosis was measured by homogenous total caspase activity assay (A, C) or by
immunoblotting with anti-cleaved caspase-3 antibody (B, D) in empty- (E, open bars), LacZ- (L, grey bars) and T-cad- (T, black bars) lentivector transduced HMEC-1 (A, B) or in
HMEC-1 transduced with lentiviral vectors expressing T-cad-specific (shT, grey bars) or control (shC, open bars) shRNAs (C, D) after treatment with thapsigargin (Thapsi), brefeldin
A (Bref.A) or homocysteine (Hcys) for 15h. Changes in caspase activity or level of caspase 3 are expressed relative to baseline levels (untreated) in respective control-transduced
HMEC-1. The histograms present data (mean±SD) obtained from 3 independent experiments. Asterisks in A and B indicate a significantly decreased response in T vs. E or L
(*, Pb0.05; ** P at least b0.01). Asterisks in C and D indicate a significantly increased response in shT vs. shC (*Pb0.05, ** P at least b0.01).
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JNK cascade and via Ca2+-dependent activation of caspase-12.
Experimental evidence suggests that all stress sensors activate both
protective and proapoptotic signalling. The final outcome of UPR will
depend on a complex interplay of various factors such as balance
between activity of different pathways and persistence of stress
conditions, so any influence that can shift the phase of UPR between
adaptation and apoptosis is likely to affect the cell fate decision
between survival and death (reviewed in [4–9]). In terms of
cardiovascular disease this phenomenon of “the double-edged sword”
is illustrated by several studies demonstrating that UPR can be either
beneficial or damaging for vascular and cardiac cells. Upregulation of
Grp78 by endothelin-1 or salvianolic acid protects hypoxic cardiomyo-
cytes and HUVEC from ER-stress [36]. Overexpression of Grp78 inhibits
homocysteine-induced ER stress [37] associatedwith endothelial injury
and increased risk of thrombosis. On the other hand, downregulation of
UPR markers including Grp78 by darbepoetin and kaempferol exerts
cardioprotective effect in autoimmune cardiomyopathy [5,38]. Increas-
ing eIF2α phosphorylation status by pharmacological inhibition of its
dephosphorylation may either protect cells [4] or potentiate ER stress-
induced apoptosis caused by fatty acids [39]. Many studies suggest that
prevention of UPR-induced apoptosis is an attractive target for
minimizing tissue damage under stress conditions. In an experimental
model of myocardial infarction ASK1−/− mice show reduced cardio-
myocyte apoptosis rates and myocardial injury. Inactivation of CHOP
gene exerted a survival benefit during diabetes [40] and prevented
plaque growth, apoptosis and necrosis in apoE−/− and LDLR−/−mouse
models of atherosclerosis [41].
In this study we have demonstrated that T-cad overexpression-
dependent attenuation of UPR signalling is beneficial and results in11the shift of the balance between UPR signalling branches in favour of
prosurvival signalling, while T-cad silencing promotes apoptotic cell
death. We have previously demonstrated that T-cad upregulation
improves survival of EC during oxidative stress via concomitant
activation of PI3-kinase/Akt signalling and inhibition of p38 MAPK
signalling [29]. There is bi-directional cross-talk between oxidative
and ER stress: protein folding and generation of ROS as a by-product
of protein oxidation in the ER are closely linked events, and activation
of the UPR upon exposure to oxidative stress is an adaptive
mechanism to preserve cell function and survival [7]. Therefore, it
was logical to consider that protective effects of T-cad against ER
stress might be related to its ability to minimize ROS-induced damage
[29]. However, we were unable to prevent the amplified ER stress-
induced apoptosis of T-cad-silenced EC by treatment with ROS
scavenger N-acetylcysteine. Inhibition of PI3-kinase did not eliminate
the attenuating effects of T-cad overexpression on Grp78 and CHOP
expression, supporting that T-cad limits ER stress in EC by mechan-
isms distinct from those (i.e. PI3-kinase/Akt signalling axis) mediat-
ing T-cad-dependent protection of EC from oxidative stress.
Furthermore, JNK inhibitor failed to prevent the amplified ER
stress-induced apoptosis of T-cad-silenced EC, indicating that anti-
apoptotic effects of T-cad upregulation under conditions of ER stress
are also unlikely to involve inactivation of ASK1 signalling (and by
inference p38 MAPK [5,10]). On the other hand, we have clearly
demonstrated T-cad-dependent modulation of phospho-eIF2α and
CHOP which represent the proapoptotic PERK branch of the UPR
cascade [4–10]. Thus, the protection afforded by T-cad against ER
stress-induced apoptosis likely involves main ER stress pathways
directly rather than modulation of related anti-stress signalling
which converge with UPR.7
Fig. 6. T-cad dependent effects on ER stress response do not involve oxidative stress, PI3-kinase and JNK. HMEC-1 transduced with lentiviral vectors expressing T-cad-specific (shT,
grey bars) or control (shC, open bars) shRNAs (A, C) or Empty- (E, open bars) and T-cad- (T, black bars) lentivector transduced HMEC-1 (B) were treated with thapsigargin (Thapsi)
or homocysteine (Hcys) for 6h in the absence or presence of ROS scavenger N-acetylcysteine (NAC; 15 mM), PI3-kinase inhibitor LY-294002 (LY; 10 μM) or JNK inhibitor SP6000125
(SP; 20 μM). Levels of Grp78 and CHOP protein were determined by immunoblot analysis of whole cell lysates. Changes are expressed relative to baseline levels (untreated) in the
respective control-transduced HMEC-1. The histograms present data (mean±SD) obtained from 3 independent experiments. Asterisks indicate significant differences between shC
and shT or between E and T (*Pb0.05, ** P at least b0.01).
Fig. 7. Schematic diagram illustrating different mechanisms whereby upregulation of T-cad induced in response to cellular stress protects EC from apoptosis. In EC GPI-anchored T-cad is
upregulated in response to ER stress and oxidative stress. The diagram shows the threemajor ER stress sensors (PERK, IRE1 and ATF6) which, for the sake of simplicity, are all depicted in
associationwith Grp78. Our results suggest that T-cad protects against ER-stress-induced apoptosis by restricting the PERK arm of the UPR response, and in amanner that is insensitive to
PI3-kinase inhibitor LY-294002 or ROS scavenger N-acetylcysteine. This is distinct from the PI3-kinase/Akt-dependent mechanism whereby T-cad protects EC from oxidative stress-
induced apoptosis. How T-cad communicates signals to the ER stress machinery is not yet known.
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be elucidated. Of interest in view of the present data is our recent
finding that T-cad associates with Grp78 in EC [31]. However, we
detected colocalization not with ER-localized Grp78, which is a well-
recognized trigger of UPR, but with its cell surface pool [31]. Surface
Grp78 has been demonstrated to be present on the plasmamembrane
of several cell types including vascular endothelium [42,43]. Increased
levels of surface Grp78 have been detected in different pathological
conditions, for example on highly metastatic cancer cells [44], on
endothelial and monocyte/macrophage-like cells in atherosclerotic
lesions [42], and on procoagulantmicroparticles shed from the plasma
membrane of activated EC [45]. When expressed on the cell surface,
Grp78 is able to initiate various functional responses including
inhibition of tissue factor procoagulant activity [42], mediation of
signal transduction from activated α2-macroglobulin in peritoneal
macrophages [44] and 1-LN prostate cancer cells [44,46,47], binding
of dengue virus [48] and coxsackievirus [49], regulation of EC
apoptosis induced by K5 kringle domain of plasminogen [43] and
association with MHC class I molecules [50] and with Ro-52 antigen
on mouse splenocytes presumably contributing to autoimmunity
during rheumatoid arthritis [51]. There is also some evidence for
participation of surface Grp78 in ER stress responses; in 1-LN cells
ligation of activated α2-macroglobulin by cell-surface expressed
Grp78 was associated with induction of UPR signalling [47]. Our study
did not address the contribution of surface Grp78 to the protective
effects of T-cad against adverse effects of ER stress. One might
speculate that association of T-cad with surface Grp78 may either
regulate downstream signalling ormodulate localization or trafficking
of Grp78 in the cell thus affecting intracellular levels of Grp78, which
is the main sensor and trigger of the UPR.
5. Conclusions
The study reveals a novel regulatory mechanism for modulation of
ER stress responses in the context of cardiovascular disease. We have
demonstrated that upregulation of T-cad in EC occurs early following
induction of ER stress, and that it functions to protect EC from adverse
outcomes (e.g. apoptosis) caused by excess and chronic UPR. The
mechanism of protection primarily involves an attenuation of
signalling through the PERK arm of the UPR and is distinct from the
mechanism whereby T-cad protects EC from oxidative stress-induced
apoptosis [29] (Fig. 7). Upregulation of T-cad on the surface of
vascular cells in atherosclerotic lesions may represent a protective
mechanism for limiting tissue damage during cardiovascular disease
progression.
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Supplemental Figure S1. HUVEC were variously treated with thapsigargin (500 nM), DTT (1 
mM), brefeldin A (5 μg/ml), tunicamycin (3 μg/ml), A23187 (2 μM), homocysteine (5 mM), or 
were incubated under serum-free conditions (SF). At the indicated time points HUVEC were 
processed for immunoblot analysis of Grp78 (A) or T-cad (B, C) with GAPDH as loading control 
(A-C), or for RT-PCR analysis of T-cad transcript levels (D). Ca and Cb specify control, untreated 
HUVEC processed at 0 h or 12 h, respectively. Data in A, B and C are from independently 
performed experiments. Data in D are given as the mean of triplicates in a single experiment.  
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Supplemental Figure S2. HMEC-1 were incubated for 6 hours in the absence (control) or 
presence of thapsigargin (500 nM), brefeldin A (5 μg/ml) or homocysteine (5mM). Whole cell 
lysates (from cells in 6-well plates) or nuclear extracts (from cells in T-75 flasks) were subjected 
to immunoblot analysis for CHOP (using Santa Cruz monoclonal anti-CHOP antibodies; Sc-735). 
Blots were probed with anti-GAPDH or lamin A/C to control for equivalence of protein loading.  
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3. CONCLUSIONS AND FUTURE PERSPECTIVES 
Endothelial activation and dysfunction play key roles in the pathogenesis of atherosclerosis. 
Inflammation and different types of stress may cause endothelial cells to become activated or to 
dysfunction. The present dissertation has addressed a number of issues related to 
atherosclerosis and endothelial dysfunction including: 
A. The role of iNKT cells during the development of atherosclerosis and more 
specifically  
i.whether iNKT cells infiltrate atherosclerotic plaques 
ii.whether iNKT cell activation induces EC activation or/and dysfunction 
B. The signalling mechanisms generated in EC in response to iNKT activation 
i.which molecules expressed upon iNKT activation elicit EC activation 
ii.which signalling cascade is responsible for EC migration and sprout outgrowth 
iii.whether pharmacological interventions may influence neovascularization  
C. The role of T-cadherin during endoplasmic reticulum stress 
i.whether T-cadherin is modulated under endoplasmic reticulum stress 
ii.whether T-cadherin protects endothelial cells from apoptosis during ER stress  
iii.which signalling pathways are involved for T-cadherin induced survival during ER stress 
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The vulnerable atherosclerotic plaque. iNKT cells are recruited in the atherosclerotic lesion. Their 
activation induces EC to form intraplaque neovessels. Prolonged ER stress may cause EC death. 
Both actions may result a very unstable atherosclerotic plaque. T-cadherin protects endothelial cells 
from ER-stress-induced apoptosis.  
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Key findings 
In the present study we provide evidence for the presence of iNKT cells in atherosclerotic 
plaques and that plaque-isolated iNKT cells are more sensitive to antigen stimulation. In addition 
CD1d-expressing APCs are present in advanced, vascularized plaques from patients with active 
disease. Our in vitro data identified IL-8 as the main molecule, amongst the many cytokines and 
chemokines that are released upon activation of iNKT cells, mediating pro-migratory and pro-
angiogenic responses in EC. A possible mechanism underlying intraplaque activation and 
angiogenic behaviour of EC in response to iNKT cell activation was then investigated. We were 
able to demonstrate that IL-8 released by antigen-loaded iNKT cells, activates the EGF receptor 
in EC. IL-8 is able to induce the activity of various matrix metalloproteinases, cathepsins or 
members of the ADAM proteases which cause shedding of EGFR ligands. We found that 
subsequent EGFR transactivation further activates FAK and Src, key regulators of cell migration 
and actin cytoskeleton re-organization. Thus the data support the notion that the angiogenic 
behaviour observed in EC in response to lipid-antigen activation of iNKT cells occurs via EGFR 
transactivation and therefore it represents a non-traditional proangiogenic receptor driving iNKT 
cell-associated neovascularization in atherosclerotic disease. The proposed hypothetical 
pathway is shown in the figure below.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothetical mechanism involved in EC activation. Upon activation of iNKT cells by lipids, IL-8 is released 
among other chemical stimuli. EGF ligands are released and ECs are activated through EGFR, which in return 
transmits signals to the interior of the cell activating FAK and Src, important regulatory components for actin 
cytoskeleton reorganization and migration. EC obtain a more motile type of phenotype, migrate faster and 
eventually get organized to form sprouts. 
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The second study reveals a novel regulatory mechanism for modulation of ER stress responses 
in the context of cardiovascular disease. ER stress has attracted the attention of several studies 
the last years because of its association with cardiovascular diseases and the progression of 
atherosclerosis. We have demonstrated that upregulation of T-cad in EC occurs early following 
induction of ER stress, and that it functions to protect EC from adverse outcomes (e.g. 
apoptosis) caused by excess and chronic UPR. The mechanism of protection primarily involves 
an attenuation of signalling through the PERK arm of the UPR and is distinct from the 
mechanism whereby T-cad protects EC from oxidative stress-induced apoptosis. Upregulation of 
T-cad on the surface of vascular cells in atherosclerotic lesions may represent a protective 
mechanism for limiting tissue damage during cardiovascular disease progression. Below the 
schematic diagram illustrates the T-cadherin-associated mechanisms involved during ER stress 
and their distinction from the T-cadherin associated pathway operative during oxidative stress.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signalling mechanism involved for the protection of vascular endothelial cells from 
endoplasmic reticulum stress-induced apoptosis by T-cad. The PERK branch of the UPR 
response is restricted by T-cad.  
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Future perspectives 
Although we successfully elucidated the involvement of CD1d expressing APCs and CD1d-
restricted iNKT cells in the progression of atherosclerosis and the importance of T-cadherin in 
EC survival during ER stress there are still a lot of issues to delineate. 
 
The role of other stimuli released by iNKT cells while activated and their participation in 
signalling pathways. 
Analysis of an array of cytokines and chemokines using the Bioplex Multiplex system or by 
ELISA revealed that several cytokines and chemokines are found in the CM derived from 
activated iNKT cells apart from IL-8. It was found that IL-2, IL-4, IL-6, IL-13, INF-γ and TNF-α are 
present at quite high levels. All these molecules are either pro-inflammatory or/and potential 
angiogenic modulators. We already demonstrated that IL-8 is mainly responsible for the 
enhanced migration of EC and eventually for the sprout formation. However, we cannot rule out 
the possibility that there is an interplay or crosstalk between the other factors or that further 
signalling pathways are activated. Microarray technology could be a good approach for 
addressing the different pathways involved and the effect of the CM on EC under physiological 
conditions or under conditions of different disease stages.  
 
Role of the VE-cadherin and N-cadherin on EC treated with CM.  
Morphological responses also include changes of adherens junctions, the primary sites of 
mechanical coupling between ECs. VE-cadherin, which is restricted to the EC and is located at 
intercellular junctions, is responsible for controlling cell contacts. For example in epithelial cells 
E-cadherin is important for cell contact integrity. Delocalization of VE-cadherin from cell 
junctions, facilitates a mesencymal type of phenotype (Arciniegas et al., 2007).  VE-cadherin 
downregulation is required for endothelial-to-mesenchymal transition and in analogy to 
epithelial-mesenchymal transition (EMT), N-cadherin upregulation serves as a marker of 
ongoing mesenchymal transition of EC. In the following table the most well studied markers for 
epithelial-mesenchymal transition markers are shown and can potentially serve as endothelial-
mesenchymal transition markers.  
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Epithelial-mesenchymal transition markers (Lee et al., 2006) 
Increased 
proteins levels 
Decreased 
proteins levels 
Increased 
protein 
activity 
Nuclear protein 
accumulation 
Functional 
markers 
N-cadherin 
E-cadherin 
(VE-cadherin  for 
endothelial cells) 
ILK β-catenin 
Increased 
migration 
Vimentin Desmoplakin GSK-3β Smad-2/3 
Increased 
invasion 
Fibronectin Cytokeratin Rho Snail1 and 2 
Increased 
scattering 
Snail1 and 2 Occludin  Twist 
Elongation of 
cell shape 
Sox10   NF-κβ 
Resistance to 
anoikis 
Integrin αvβ6     
 
EC in the presence of CM became elongated, resembling mesenchymal cells. Our data showed 
a downregulation of VE-cadherin in migrating cells and N-cadherin upregulation (Western blot 
analysis is shown below) suggesting a transition to a more mesenchymal phenotype when EC 
are exposed to CM+. T-cadherin was not altered under the specific experimental conditions. 
Endothelial-to-mesenchymal transition may contribute to neovascularisation and vascular 
remodelling.  
 
 
 
 
 
 
 
 
 
 
Further investigation would shed more light for the pathways involved.  
C
M
+
C
M
-
C
on
tro
l
24 hrs0
GAPDH
N-cadherin
VE-cadherin
T-cadherin
 
Western blot analysis. VE-cadherin downregulation and 
concominant N-cadherin upregulation while treated with CM+ is 
shown. T-cad remained unaltered. 
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 Conditional knockdown of CD1d in atherosclerotic mice model. 
We revealed the significance of CD1d and CD1d-restricted iNKT cells in respect to 
atherosclerosis and neovascularization in humans and in vitro. There are no known studies in 
vivo about the importance of iNKT cells on angiogenesis. Mice that are deficient in 
apolipoprotein E (apoE) develop atherosclerotic lesions resembling those observed in humans. 
The effect of iNKT cells in atherosclerosis has been studied in αGalCer treated apoE−/− and 
apoE−/−CD1d−/− mice (Tupin et al., 2004). They demonstrated that activation of iNKT cells 
induces atherosclerosis. Aortic sections of those mouse models were made available to us, but 
the quality of the sections were not ideal for investigating any correlation, between 
neovascularization and progression of atherosclerosis. 
 
The exact mechanism linking T-cadherin to UPR sensors has to be elucidated 
T-cadherin colocalizes and associates functionally with surface expressed Grp78 (Philippova et 
al., 2008). Since dissociation of Grp78 from the UPR sensors is needed to initiate the UPR and 
recover protein homeostasis it would be of interest to examine whether T-cadherin may 
modulate localization and trafficking of Grp78, thus regulating the initiation and progression of 
UPR. One approach to address these questions is to use RNAi for directed silencing of Grp78. A 
second approach would be the use of pharmacological inhibition of Grp78, by which we can 
distinguish between surface and endoplasmic reticulum localization of Grp78. Both of these 
approaches would be applied to our gain- and loss-of function models. 
 
Conditional knock-out and knock-in on T-cadherin in endothelium in mice. 
The mouse is the most commonly used mammal for genetic manipulation. A conditional knock-
out or knock-in mouse on T-cadherin in endothelium could be a valuable tool for investigating 
the T-cadherin effects in vivo. It is known that T-cadherin may get activated by homophilic 
ligation, but whether homophilic ligation occurs in vivo and what is the biological function 
remains elusive. A double knock-out mouse model for T-cadherin and apoE would be of great 
interest for investigating the pro-angiogenic and pro-survival properties of T-cadherin during 
atherosclerosis. Endothelial specific T-cadherin transgenic mice could be exploited to address 
issues regarding ER stress in human diseases. Mouse models for monitoring ER stress exist 
(Iwawaki et al., 2004) and can be used to cross it with the T-cadherin transgenic mouse, thus 
creating a powerful in vivo system.  
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